WO1996030393A1 - A method for the synthesis of mixtures of compounds - Google Patents
A method for the synthesis of mixtures of compounds Download PDFInfo
- Publication number
- WO1996030393A1 WO1996030393A1 PCT/US1995/016332 US9516332W WO9630393A1 WO 1996030393 A1 WO1996030393 A1 WO 1996030393A1 US 9516332 W US9516332 W US 9516332W WO 9630393 A1 WO9630393 A1 WO 9630393A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reaction
- set forth
- compounds
- mixtures
- wells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 125
- 150000001875 compounds Chemical class 0.000 title claims abstract description 100
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 230000015572 biosynthetic process Effects 0.000 title description 71
- 238000003786 synthesis reaction Methods 0.000 title description 71
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 45
- 238000012360 testing method Methods 0.000 claims abstract description 37
- 238000003491 array Methods 0.000 claims abstract description 12
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 5
- 238000005580 one pot reaction Methods 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 510
- 239000000047 product Substances 0.000 claims description 57
- 230000000694 effects Effects 0.000 claims description 25
- 150000001469 hydantoins Chemical class 0.000 claims description 18
- 238000004458 analytical method Methods 0.000 claims description 14
- 229940049706 benzodiazepine Drugs 0.000 claims description 14
- 150000001557 benzodiazepines Chemical class 0.000 claims description 13
- 238000004949 mass spectrometry Methods 0.000 claims description 11
- 108010016626 Dipeptides Proteins 0.000 claims description 10
- 238000005481 NMR spectroscopy Methods 0.000 claims description 9
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- KANAPVJGZDNSCZ-UHFFFAOYSA-N 1,2-benzothiazole 1-oxide Chemical class C1=CC=C2S(=O)N=CC2=C1 KANAPVJGZDNSCZ-UHFFFAOYSA-N 0.000 claims description 4
- 150000007660 quinolones Chemical class 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical class C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 claims description 4
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical class C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims description 3
- 238000004445 quantitative analysis Methods 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- XTBAPWCYTNCZTO-UHFFFAOYSA-N 1H-isoindolone Natural products C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 claims 2
- RHKWAICCWZUOJW-SNVBAGLBSA-N (4r)-4-benzamido-5-oxopentanoic acid Chemical class OC(=O)CC[C@H](C=O)NC(=O)C1=CC=CC=C1 RHKWAICCWZUOJW-SNVBAGLBSA-N 0.000 claims 1
- IAACZXDFIDGTNY-UHFFFAOYSA-N N1C2=CC=NN2C(=O)C2=C1C(=O)NC2 Chemical class N1C2=CC=NN2C(=O)C2=C1C(=O)NC2 IAACZXDFIDGTNY-UHFFFAOYSA-N 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 180
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 154
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 145
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- 239000000243 solution Substances 0.000 description 108
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 81
- 229910052757 nitrogen Inorganic materials 0.000 description 77
- 229960005419 nitrogen Drugs 0.000 description 77
- 229920005989 resin Polymers 0.000 description 69
- 239000011347 resin Substances 0.000 description 69
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 39
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- 239000000706 filtrate Substances 0.000 description 36
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 31
- 239000007787 solid Substances 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- -1 polypropylene Polymers 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 22
- 239000007789 gas Substances 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 238000011068 loading method Methods 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 239000000376 reactant Substances 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- LQERIDTXQFOHKA-UHFFFAOYSA-N nonadecane Chemical compound CCCCCCCCCCCCCCCCCCC LQERIDTXQFOHKA-UHFFFAOYSA-N 0.000 description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 14
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 14
- 238000003776 cleavage reaction Methods 0.000 description 14
- 239000006185 dispersion Substances 0.000 description 14
- 229920005990 polystyrene resin Polymers 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 239000006227 byproduct Substances 0.000 description 12
- 230000005484 gravity Effects 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 239000012043 crude product Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000003760 magnetic stirring Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 8
- 235000004279 alanine Nutrition 0.000 description 8
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 8
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 8
- 239000012467 final product Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 239000004474 valine Substances 0.000 description 8
- 0 *NC(Cc1cnc[n]1)*I Chemical compound *NC(Cc1cnc[n]1)*I 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 238000013019 agitation Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 150000002466 imines Chemical class 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 229960000310 isoleucine Drugs 0.000 description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000003808 methanol extraction Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002924 anti-infective effect Effects 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 3
- WBJWXIQDBDZMAW-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carbonyl chloride Chemical compound C1=CC=CC2=C(C(Cl)=O)C(O)=CC=C21 WBJWXIQDBDZMAW-UHFFFAOYSA-N 0.000 description 3
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 3
- ZYASLTYCYTYKFC-UHFFFAOYSA-N 9-methylidenefluorene Chemical compound C1=CC=C2C(=C)C3=CC=CC=C3C2=C1 ZYASLTYCYTYKFC-UHFFFAOYSA-N 0.000 description 3
- TYMIFYJJOPYXBG-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl piperidine-1-carboxylate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N1CCCCC1 TYMIFYJJOPYXBG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920001367 Merrifield resin Polymers 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000003875 Wang resin Substances 0.000 description 3
- PYHXGXCGESYPCW-UHFFFAOYSA-N alpha-phenylbenzeneacetic acid Natural products C=1C=CC=CC=1C(C(=O)O)C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-N 0.000 description 3
- 230000000767 anti-ulcer Effects 0.000 description 3
- 229940030999 antipsoriatics Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000010936 aqueous wash Methods 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- YIOCIFXUGBYCJR-UHFFFAOYSA-N bis(4-chlorophenyl)acetic acid Chemical compound C=1C=C(Cl)C=CC=1C(C(=O)O)C1=CC=C(Cl)C=C1 YIOCIFXUGBYCJR-UHFFFAOYSA-N 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 229960000604 valproic acid Drugs 0.000 description 3
- MEFKFJOEVLUFAY-UHFFFAOYSA-N (2,2,2-trichloroacetyl) 2,2,2-trichloroacetate Chemical compound ClC(Cl)(Cl)C(=O)OC(=O)C(Cl)(Cl)Cl MEFKFJOEVLUFAY-UHFFFAOYSA-N 0.000 description 2
- MAOBFOXLCJIFLV-UHFFFAOYSA-N (2-aminophenyl)-phenylmethanone Chemical compound NC1=CC=CC=C1C(=O)C1=CC=CC=C1 MAOBFOXLCJIFLV-UHFFFAOYSA-N 0.000 description 2
- HLFNCIYTWSKKSC-HNNXBMFYSA-N (2s)-2-[(2-bromophenyl)methoxycarbonylamino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC=1C(=CC=CC=1)Br)C1=CC=C(O)C=C1 HLFNCIYTWSKKSC-HNNXBMFYSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 2
- FMDGXCSMDZMDHZ-UHFFFAOYSA-N 1-isocyanato-4-methoxybenzene Chemical compound COC1=CC=C(N=C=O)C=C1 FMDGXCSMDZMDHZ-UHFFFAOYSA-N 0.000 description 2
- SLGDFLCMPRPETL-UHFFFAOYSA-N 2-amino-3-[(2-methylpropan-2-yl)oxycarbonyl]benzoic acid Chemical class CC(C)(C)OC(=O)C1=CC=CC(C(O)=O)=C1N SLGDFLCMPRPETL-UHFFFAOYSA-N 0.000 description 2
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 2
- MMBYJYAFFGKUDC-UHFFFAOYSA-N 3-aminoisoindol-1-one Chemical compound C1=CC=C2C(N)=NC(=O)C2=C1 MMBYJYAFFGKUDC-UHFFFAOYSA-N 0.000 description 2
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 2
- OEBIVOHKFYSBPE-UHFFFAOYSA-N 4-Benzyloxybenzyl alcohol Chemical compound C1=CC(CO)=CC=C1OCC1=CC=CC=C1 OEBIVOHKFYSBPE-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- VMAQYKGITHDWKL-UHFFFAOYSA-N 5-methylimidazolidine-2,4-dione Chemical compound CC1NC(=O)NC1=O VMAQYKGITHDWKL-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 102000004300 GABA-A Receptors Human genes 0.000 description 2
- 108090000839 GABA-A Receptors Proteins 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 238000004617 QSAR study Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000006136 alcoholysis reaction Methods 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- HXBPYFMVGFDZFT-UHFFFAOYSA-N allyl isocyanate Chemical compound C=CCN=C=O HXBPYFMVGFDZFT-UHFFFAOYSA-N 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000002973 anti-dopamine Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000003420 antiserotonin agent Substances 0.000 description 2
- 150000001562 benzopyrans Chemical class 0.000 description 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000005289 controlled pore glass Substances 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- NIZHERJWXFHGGU-UHFFFAOYSA-N isocyanato(trimethyl)silane Chemical compound C[Si](C)(C)N=C=O NIZHERJWXFHGGU-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 2
- 229940012189 methyl orange Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- LPGUNQVBZHUBMA-UHFFFAOYSA-N n-(3,3-dimethoxypropyl)formamide Chemical compound COC(OC)CCNC=O LPGUNQVBZHUBMA-UHFFFAOYSA-N 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 238000012418 validation experiment Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- GRESIOVQACOVTD-YYLIZZNMSA-N (1r,3s)-1-(aminomethyl)-3-cyclohexyl-3,4-dihydro-1h-isochromene-5,6-diol;hydrochloride Chemical compound Cl.C1([C@H]2O[C@H](C3=CC=C(O)C(O)=C3C2)CN)CCCCC1 GRESIOVQACOVTD-YYLIZZNMSA-N 0.000 description 1
- PQPGUUQPTSMLKU-YYLIZZNMSA-N (1r,3s)-1-(aminomethyl)-3-phenyl-3,4-dihydro-1h-isochromene-5,6-diol;hydrochloride Chemical compound Cl.C1([C@H]2O[C@H](C3=CC=C(O)C(O)=C3C2)CN)=CC=CC=C1 PQPGUUQPTSMLKU-YYLIZZNMSA-N 0.000 description 1
- ZWAJLVLEBYIOTI-OLQVQODUSA-N (1s,6r)-7-oxabicyclo[4.1.0]heptane Chemical group C1CCC[C@@H]2O[C@@H]21 ZWAJLVLEBYIOTI-OLQVQODUSA-N 0.000 description 1
- JAUFWTSSYRTLLB-UHFFFAOYSA-N (2-phenylacetyl) 2-phenylacetate Chemical compound C=1C=CC=CC=1CC(=O)OC(=O)CC1=CC=CC=C1 JAUFWTSSYRTLLB-UHFFFAOYSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 1
- SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 1
- BENKAPCDIOILGV-MLWJPKLSSA-N (2s)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC(O)C[C@H]1C(O)=O BENKAPCDIOILGV-MLWJPKLSSA-N 0.000 description 1
- FQHCPFMTXFJZJS-UHFFFAOYSA-N (4-methoxyphenyl)hydrazine;hydrochloride Chemical compound Cl.COC1=CC=C(NN)C=C1 FQHCPFMTXFJZJS-UHFFFAOYSA-N 0.000 description 1
- HMHWNJGOHUYVMD-UHFFFAOYSA-N (4-methylanilino)azanium;chloride Chemical compound Cl.CC1=CC=C(NN)C=C1 HMHWNJGOHUYVMD-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- ASEJDTDWRXVAHE-UHFFFAOYSA-N 1,3-dimethyl-7-nitro-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound C12=CC([N+]([O-])=O)=CC=C2N(C)C(=O)C(C)N=C1C1=CC=CC=C1 ASEJDTDWRXVAHE-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- ZPCJPJQUVRIILS-UHFFFAOYSA-N 1-bromo-3-(bromomethyl)benzene Chemical compound BrCC1=CC=CC(Br)=C1 ZPCJPJQUVRIILS-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- ANOOTOPTCJRUPK-UHFFFAOYSA-N 1-iodohexane Chemical compound CCCCCCI ANOOTOPTCJRUPK-UHFFFAOYSA-N 0.000 description 1
- GZWGTVZRRFPVAS-UHFFFAOYSA-N 1-isocyanato-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1N=C=O GZWGTVZRRFPVAS-UHFFFAOYSA-N 0.000 description 1
- PMTQHYJBDAESAC-UHFFFAOYSA-N 1-methyl-7-nitro-5-phenyl-3-propan-2-yl-3h-1,4-benzodiazepin-2-one Chemical compound C12=CC([N+]([O-])=O)=CC=C2N(C)C(=O)C(C(C)C)N=C1C1=CC=CC=C1 PMTQHYJBDAESAC-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- CEPCPXLLFXPZGW-UHFFFAOYSA-N 2,4-difluoroaniline Chemical compound NC1=CC=C(F)C=C1F CEPCPXLLFXPZGW-UHFFFAOYSA-N 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N 2-(2-aminopropanamido)-3-(1h-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- DLGOLDCIEHQIMN-UHFFFAOYSA-N 2-(benzenecarboximidoyl)aniline Chemical class NC1=CC=CC=C1C(=N)C1=CC=CC=C1 DLGOLDCIEHQIMN-UHFFFAOYSA-N 0.000 description 1
- KFLKTDAONDZLAN-UHFFFAOYSA-N 2-(n-phenylanilino)acetic acid Chemical compound C=1C=CC=CC=1N(CC(=O)O)C1=CC=CC=C1 KFLKTDAONDZLAN-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- BCVIOZZGJNOEQS-UHFFFAOYSA-N 2-[(2-Amino-1-hydroxy-3-methylpentylidene)amino]-3-methylpentanoic acid Chemical compound CCC(C)C(N)C(=O)NC(C(O)=O)C(C)CC BCVIOZZGJNOEQS-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- QVHJQCGUWFKTSE-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)C(C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-UHFFFAOYSA-N 0.000 description 1
- YBONNYNNFBAKLI-UHFFFAOYSA-N 2-amino-2,2-diphenylacetic acid Chemical compound C=1C=CC=CC=1C(C(O)=O)(N)C1=CC=CC=C1 YBONNYNNFBAKLI-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- WYKHFQKONWMWQM-UHFFFAOYSA-N 2-sulfanylidene-1h-pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1S WYKHFQKONWMWQM-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical class O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- SDRTYMRZGSHGFG-UHFFFAOYSA-N 3,6-dimethyl-1-propan-2-yl-3h-1,4-benzodiazepin-2-one Chemical compound C1=NC(C)C(=O)N(C(C)C)C2=CC=CC(C)=C21 SDRTYMRZGSHGFG-UHFFFAOYSA-N 0.000 description 1
- HIAPCVLQSLYBSM-UHFFFAOYSA-N 3-(1h-indol-2-ylmethyl)-1-methyl-7-nitro-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound N=1C(CC=2NC3=CC=CC=C3C=2)C(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 HIAPCVLQSLYBSM-UHFFFAOYSA-N 0.000 description 1
- YRSULDCDQDHWFL-UHFFFAOYSA-N 3-(1h-indol-2-ylmethyl)-5-(4-methoxyphenyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(OC)=CC=C1C(C1=CC=CC=C1NC1=O)=NC1CC1=CC2=CC=CC=C2N1 YRSULDCDQDHWFL-UHFFFAOYSA-N 0.000 description 1
- MSTNUKOFOREBPS-UHFFFAOYSA-N 3-(1h-indol-2-ylmethyl)-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N=1C(CC=2NC3=CC=CC=C3C=2)C(=O)NC2=CC=CC=C2C=1C1=CC=CC=C1 MSTNUKOFOREBPS-UHFFFAOYSA-N 0.000 description 1
- XKUDFHRCVYLSGL-UHFFFAOYSA-N 3-(1h-indol-2-ylmethyl)-5-thiophen-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N=1C(CC=2NC3=CC=CC=C3C=2)C(=O)NC2=CC=CC=C2C=1C1=CC=CS1 XKUDFHRCVYLSGL-UHFFFAOYSA-N 0.000 description 1
- KMCZAAUTUJJSBZ-UHFFFAOYSA-N 3-(1h-indol-2-ylmethyl)-6-methyl-1-propan-2-yl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(C(C)C)C2=CC=CC(C)=C2C=NC1CC1=CC2=CC=CC=C2N1 KMCZAAUTUJJSBZ-UHFFFAOYSA-N 0.000 description 1
- ZCBGUQSMLXEMLK-UHFFFAOYSA-N 3-(1h-indol-2-ylmethyl)-7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)C(CC=2NC3=CC=CC=C3C=2)N=C1C1=CC=CC=C1 ZCBGUQSMLXEMLK-UHFFFAOYSA-N 0.000 description 1
- XJPWJKYPZBYYJL-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-1-methyl-7-nitro-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(C)C2=CC=C([N+]([O-])=O)C=C2C(C=2C=CC=CC=2)=NC1C1=CC=C(O)C=C1 XJPWJKYPZBYYJL-UHFFFAOYSA-N 0.000 description 1
- KDPVIOFTVLJBOP-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-5-(4-methoxyphenyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(OC)=CC=C1C(C1=CC=CC=C1NC1=O)=NC1C1=CC=C(O)C=C1 KDPVIOFTVLJBOP-UHFFFAOYSA-N 0.000 description 1
- XZTMHGRCXHWVRR-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(O)=CC=C1C1C(=O)NC2=CC=CC=C2C(C=2C=CC=CC=2)=N1 XZTMHGRCXHWVRR-UHFFFAOYSA-N 0.000 description 1
- CZNWPHGUBCYTIE-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-5-thiophen-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(O)=CC=C1C1C(=O)NC2=CC=CC=C2C(C=2SC=CC=2)=N1 CZNWPHGUBCYTIE-UHFFFAOYSA-N 0.000 description 1
- BWYGLCGJAWEUPV-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-6-methyl-1-propan-2-yl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(C(C)C)C2=CC=CC(C)=C2C=NC1C1=CC=C(O)C=C1 BWYGLCGJAWEUPV-UHFFFAOYSA-N 0.000 description 1
- MORGHNSBZVEPQG-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(O)=CC=C1C1C(=O)NC2=CC=C([N+]([O-])=O)C=C2C(C=2C=CC=CC=2)=N1 MORGHNSBZVEPQG-UHFFFAOYSA-N 0.000 description 1
- JPUVHVWFUYVXCI-UHFFFAOYSA-N 3-(4-methoxyphenyl)-5,5-diphenylimidazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)NC1=O JPUVHVWFUYVXCI-UHFFFAOYSA-N 0.000 description 1
- GMFJKHAPKKMGEY-UHFFFAOYSA-N 3-(4-methoxyphenyl)-5-(2-methylpropyl)imidazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(CC(C)C)NC1=O GMFJKHAPKKMGEY-UHFFFAOYSA-N 0.000 description 1
- YLQURHYPTIDWEU-UHFFFAOYSA-N 3-(4-methoxyphenyl)-5-methylimidazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(C)NC1=O YLQURHYPTIDWEU-UHFFFAOYSA-N 0.000 description 1
- OIPYRWYJHGWZEG-UHFFFAOYSA-N 3-(4-methoxyphenyl)imidazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1N1C(=O)NCC1=O OIPYRWYJHGWZEG-UHFFFAOYSA-N 0.000 description 1
- FFLXYAXFSWVZLZ-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxy]-3-oxo-2-(n-phenylanilino)propanoic acid Chemical compound C=1C=CC=CC=1N(C(C(=O)OC(C)(C)C)C(O)=O)C1=CC=CC=C1 FFLXYAXFSWVZLZ-UHFFFAOYSA-N 0.000 description 1
- ORCKVDUVXRALGR-UHFFFAOYSA-N 3-[2-(trifluoromethyl)phenyl]imidazolidine-2,4-dione Chemical compound FC(F)(F)C1=CC=CC=C1N1C(=O)NCC1=O ORCKVDUVXRALGR-UHFFFAOYSA-N 0.000 description 1
- DMGFVJVLVZOSOE-UHFFFAOYSA-N 3-amino-4-chlorobenzoic acid Chemical compound NC1=CC(C(O)=O)=CC=C1Cl DMGFVJVLVZOSOE-UHFFFAOYSA-N 0.000 description 1
- KLICXIFDRLZSGO-UHFFFAOYSA-N 3-amino-6-chloroisoindol-1-one Chemical compound ClC1=CC=C2C(N)=NC(=O)C2=C1 KLICXIFDRLZSGO-UHFFFAOYSA-N 0.000 description 1
- NSAQJIOXNYXOKM-UHFFFAOYSA-N 3-butyl-5,5-diphenylimidazolidine-2,4-dione Chemical compound O=C1N(CCCC)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 NSAQJIOXNYXOKM-UHFFFAOYSA-N 0.000 description 1
- PFBJMAUZDAASAI-UHFFFAOYSA-N 3-butyl-5-(1h-indol-2-ylmethyl)imidazolidine-2,4-dione Chemical compound O=C1N(CCCC)C(=O)NC1CC1=CC2=CC=CC=C2N1 PFBJMAUZDAASAI-UHFFFAOYSA-N 0.000 description 1
- GQLMSNPCBSEFQY-UHFFFAOYSA-N 3-butyl-5-(2-methylpropyl)imidazolidine-2,4-dione Chemical compound CCCCN1C(=O)NC(CC(C)C)C1=O GQLMSNPCBSEFQY-UHFFFAOYSA-N 0.000 description 1
- QCPGQNBZAJICIL-UHFFFAOYSA-N 3-butyl-5-methylimidazolidine-2,4-dione Chemical compound CCCCN1C(=O)NC(C)C1=O QCPGQNBZAJICIL-UHFFFAOYSA-N 0.000 description 1
- CHOCIUGONPEGNX-UHFFFAOYSA-N 3-butyl-5-propan-2-ylimidazolidine-2,4-dione Chemical compound CCCCN1C(=O)NC(C(C)C)C1=O CHOCIUGONPEGNX-UHFFFAOYSA-N 0.000 description 1
- POOCDTKATJYNHL-UHFFFAOYSA-N 3-butylimidazolidine-2,4-dione Chemical compound CCCCN1C(=O)CNC1=O POOCDTKATJYNHL-UHFFFAOYSA-N 0.000 description 1
- QEYMMOKECZBKAC-UHFFFAOYSA-N 3-chloropropanoic acid Chemical compound OC(=O)CCCl QEYMMOKECZBKAC-UHFFFAOYSA-N 0.000 description 1
- RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 1
- QFCQGJLUYWNOAC-UHFFFAOYSA-N 3-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC=CC=C2NC(=O)C(C)N=C1C1=CC=CC=C1 QFCQGJLUYWNOAC-UHFFFAOYSA-N 0.000 description 1
- KFFCTGDBIRZRMB-UHFFFAOYSA-N 3-methyl-5-thiophen-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC=CC=C2NC(=O)C(C)N=C1C1=CC=CS1 KFFCTGDBIRZRMB-UHFFFAOYSA-N 0.000 description 1
- PRMIWZTXQDCXCT-UHFFFAOYSA-N 3-methyl-7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC([N+]([O-])=O)=CC=C2NC(=O)C(C)N=C1C1=CC=CC=C1 PRMIWZTXQDCXCT-UHFFFAOYSA-N 0.000 description 1
- NXTNASSYJUXJDV-UHFFFAOYSA-N 3-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(C(Cl)=O)=C1 NXTNASSYJUXJDV-UHFFFAOYSA-N 0.000 description 1
- XCTXHWBTYGOGBK-UHFFFAOYSA-N 3-oxo-3-(2,3,4,5-tetrafluorophenyl)propanoic acid Chemical compound OC(=O)CC(=O)C1=CC(F)=C(F)C(F)=C1F XCTXHWBTYGOGBK-UHFFFAOYSA-N 0.000 description 1
- QFOVQRZDLIWFLD-UHFFFAOYSA-N 3-oxo-3-(2,4,5-trifluorophenyl)propanoic acid Chemical compound OC(=O)CC(=O)C1=CC(F)=C(F)C=C1F QFOVQRZDLIWFLD-UHFFFAOYSA-N 0.000 description 1
- QHWUAGOQTZKGMF-UHFFFAOYSA-N 3-prop-2-enylimidazolidine-2,4-dione Chemical compound C=CCN1C(=O)CNC1=O QHWUAGOQTZKGMF-UHFFFAOYSA-N 0.000 description 1
- XKBWTBWRUKPQIR-UHFFFAOYSA-N 3-propan-2-yl-5-thiophen-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC=CC=C2NC(=O)C(C(C)C)N=C1C1=CC=CS1 XKBWTBWRUKPQIR-UHFFFAOYSA-N 0.000 description 1
- RYHMWKGXNUBZPO-UHFFFAOYSA-N 4,6-dioxo-6-phenylhexanoic acid Chemical compound OC(=O)CCC(=O)CC(=O)C1=CC=CC=C1 RYHMWKGXNUBZPO-UHFFFAOYSA-N 0.000 description 1
- HEODCNVWJVNTHS-UHFFFAOYSA-N 4-(benzoylmethyl)-6-cyclohexyl-6,7-dihydro-2-phenyl-4h-pyrazolo[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione Chemical compound C=1C=CC=CC=1C(=O)CN(C1=C2)C=3C(=O)N(C4CCCCC4)CC=3C(=O)N1N=C2C1=CC=CC=C1 HEODCNVWJVNTHS-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- IPLKGJHGWCVSOG-UHFFFAOYSA-N 4-chlorobutanoic acid Chemical compound OC(=O)CCCCl IPLKGJHGWCVSOG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- QJNLUNBGDFUULX-UHFFFAOYSA-N 4-n,4-n'-dimethyl-3h-pyridine-4,4-diamine Chemical compound CNC1(NC)CC=NC=C1 QJNLUNBGDFUULX-UHFFFAOYSA-N 0.000 description 1
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
- JPVUWCPKMYXOKW-UHFFFAOYSA-N 4-phenylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1C1=CC=CC=C1 JPVUWCPKMYXOKW-UHFFFAOYSA-N 0.000 description 1
- OJLXHZZCNYRQOG-UHFFFAOYSA-N 5,5-diphenyl-3-[2-(trifluoromethyl)phenyl]imidazolidine-2,4-dione Chemical compound FC(F)(F)C1=CC=CC=C1N1C(=O)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)NC1=O OJLXHZZCNYRQOG-UHFFFAOYSA-N 0.000 description 1
- UDKIJJQKVFCMDX-UHFFFAOYSA-N 5,5-diphenyl-3-prop-2-enylimidazolidine-2,4-dione Chemical compound O=C1N(C[CH][CH2])C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 UDKIJJQKVFCMDX-UHFFFAOYSA-N 0.000 description 1
- OCHFWQGBCUNZRO-UHFFFAOYSA-N 5-(1h-indol-2-ylmethyl)-3-(4-methoxyphenyl)imidazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(CC=2NC3=CC=CC=C3C=2)NC1=O OCHFWQGBCUNZRO-UHFFFAOYSA-N 0.000 description 1
- BIHJIFWAAWNUNQ-UHFFFAOYSA-N 5-(1h-indol-2-ylmethyl)-3-[2-(trifluoromethyl)phenyl]imidazolidine-2,4-dione Chemical compound FC(F)(F)C1=CC=CC=C1N1C(=O)C(CC=2NC3=CC=CC=C3C=2)NC1=O BIHJIFWAAWNUNQ-UHFFFAOYSA-N 0.000 description 1
- KXYVGEKOOMDDOA-UHFFFAOYSA-N 5-(1h-indol-2-ylmethyl)-3-prop-2-enylimidazolidine-2,4-dione Chemical compound O=C1N(CC=C)C(=O)NC1CC1=CC2=CC=CC=C2N1 KXYVGEKOOMDDOA-UHFFFAOYSA-N 0.000 description 1
- QYASYXWODYQOFU-UHFFFAOYSA-N 5-(1h-indol-2-ylmethyl)imidazolidine-2,4-dione Chemical compound O=C1NC(=O)NC1CC1=CC2=CC=CC=C2N1 QYASYXWODYQOFU-UHFFFAOYSA-N 0.000 description 1
- OZGGZOHXGSRFNK-UHFFFAOYSA-N 5-(2-methylpropyl)-3-[2-(trifluoromethyl)phenyl]imidazolidine-2,4-dione Chemical compound O=C1C(CC(C)C)NC(=O)N1C1=CC=CC=C1C(F)(F)F OZGGZOHXGSRFNK-UHFFFAOYSA-N 0.000 description 1
- BKWBUNMIDXNXLV-UHFFFAOYSA-N 5-(2-methylpropyl)-3-prop-2-enylimidazolidine-2,4-dione Chemical compound CC(C)CC1NC(=O)N(CC=C)C1=O BKWBUNMIDXNXLV-UHFFFAOYSA-N 0.000 description 1
- WLRZLHCGXUHRIG-UHFFFAOYSA-N 5-(2-methylpropyl)imidazolidine-2,4-dione Chemical compound CC(C)CC1NC(=O)NC1=O WLRZLHCGXUHRIG-UHFFFAOYSA-N 0.000 description 1
- XQPBZIITFQHIDI-UHFFFAOYSA-N 5-(4-chlorophenyl)-1h-pyrazol-3-amine Chemical compound N1N=C(N)C=C1C1=CC=C(Cl)C=C1 XQPBZIITFQHIDI-UHFFFAOYSA-N 0.000 description 1
- VADXNBYJNYGWLH-UHFFFAOYSA-N 5-(4-methoxyphenyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(OC)=CC=C1C1=NCC(=O)NC2=CC=CC=C12 VADXNBYJNYGWLH-UHFFFAOYSA-N 0.000 description 1
- IHXONSDUKGLQOL-UHFFFAOYSA-N 5-(4-methoxyphenyl)-3-methyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(OC)=CC=C1C1=NC(C)C(=O)NC2=CC=CC=C12 IHXONSDUKGLQOL-UHFFFAOYSA-N 0.000 description 1
- PPRYVOBAURLNMK-UHFFFAOYSA-N 5-(4-methoxyphenyl)-3-propan-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(OC)=CC=C1C1=NC(C(C)C)C(=O)NC2=CC=CC=C12 PPRYVOBAURLNMK-UHFFFAOYSA-N 0.000 description 1
- LHCXVSVGJKGHCA-UHFFFAOYSA-N 5-benzyl-3-(4-methoxyphenyl)imidazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(CC=2C=CC=CC=2)NC1=O LHCXVSVGJKGHCA-UHFFFAOYSA-N 0.000 description 1
- ZJXMYPKQEFXLDK-UHFFFAOYSA-N 5-benzyl-3-[2-(trifluoromethyl)phenyl]imidazolidine-2,4-dione Chemical compound FC(F)(F)C1=CC=CC=C1N1C(=O)C(CC=2C=CC=CC=2)NC1=O ZJXMYPKQEFXLDK-UHFFFAOYSA-N 0.000 description 1
- ZOTOLRCNCFQPTN-UHFFFAOYSA-N 5-benzyl-3-butylimidazolidine-2,4-dione Chemical compound O=C1N(CCCC)C(=O)NC1CC1=CC=CC=C1 ZOTOLRCNCFQPTN-UHFFFAOYSA-N 0.000 description 1
- LCKIVIVFZMRDSX-UHFFFAOYSA-N 5-benzyl-3-prop-2-enylimidazolidine-2,4-dione Chemical compound O=C1N(CC=C)C(=O)NC1CC1=CC=CC=C1 LCKIVIVFZMRDSX-UHFFFAOYSA-N 0.000 description 1
- DBOMTIHROGSFTI-UHFFFAOYSA-N 5-benzylimidazolidine-2,4-dione Chemical compound O=C1NC(=O)NC1CC1=CC=CC=C1 DBOMTIHROGSFTI-UHFFFAOYSA-N 0.000 description 1
- LDLCLOMMSRIWSJ-UHFFFAOYSA-N 5-butan-2-yl-3-(4-methoxyphenyl)imidazolidine-2,4-dione Chemical compound O=C1C(C(C)CC)NC(=O)N1C1=CC=C(OC)C=C1 LDLCLOMMSRIWSJ-UHFFFAOYSA-N 0.000 description 1
- XSIIUQILRMKQRS-UHFFFAOYSA-N 5-butan-2-yl-3-[2-(trifluoromethyl)phenyl]imidazolidine-2,4-dione Chemical compound O=C1C(C(C)CC)NC(=O)N1C1=CC=CC=C1C(F)(F)F XSIIUQILRMKQRS-UHFFFAOYSA-N 0.000 description 1
- CXQYACVJNABQTL-UHFFFAOYSA-N 5-butan-2-yl-3-butylimidazolidine-2,4-dione Chemical compound CCCCN1C(=O)NC(C(C)CC)C1=O CXQYACVJNABQTL-UHFFFAOYSA-N 0.000 description 1
- IDYRZTIWGVZZQF-UHFFFAOYSA-N 5-butan-2-yl-3-prop-2-enylimidazolidine-2,4-dione Chemical compound CCC(C)C1NC(=O)N(CC=C)C1=O IDYRZTIWGVZZQF-UHFFFAOYSA-N 0.000 description 1
- ZUYPRBNQYTZYIK-UHFFFAOYSA-N 5-butan-2-ylimidazolidine-2,4-dione Chemical compound CCC(C)C1NC(=O)NC1=O ZUYPRBNQYTZYIK-UHFFFAOYSA-N 0.000 description 1
- BRJPZCDOLGSYPS-UHFFFAOYSA-N 5-chloro-2-sulfanylbenzoic acid Chemical compound OC(=O)C1=CC(Cl)=CC=C1S BRJPZCDOLGSYPS-UHFFFAOYSA-N 0.000 description 1
- IHQPPUHOUDNMEL-UHFFFAOYSA-N 5-cyclohexyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC=CC=C2NC(=O)CN=C1C1CCCCC1 IHQPPUHOUDNMEL-UHFFFAOYSA-N 0.000 description 1
- LBDGXUSKZCJLBY-UHFFFAOYSA-N 5-cyclohexyl-3-(1H-indol-2-ylmethyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound O=C1Nc2ccccc2C(=NC1Cc1cc2ccccc2[nH]1)C1CCCCC1 LBDGXUSKZCJLBY-UHFFFAOYSA-N 0.000 description 1
- PMDRGCASLJTKBF-UHFFFAOYSA-N 5-cyclohexyl-3-(4-hydroxyphenyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound Oc1ccc(cc1)C1N=C(C2CCCCC2)c2ccccc2NC1=O PMDRGCASLJTKBF-UHFFFAOYSA-N 0.000 description 1
- JSZMAUJOPIPUSL-UHFFFAOYSA-N 5-cyclohexyl-3-methyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound CC1N=C(C2CCCCC2)c2ccccc2NC1=O JSZMAUJOPIPUSL-UHFFFAOYSA-N 0.000 description 1
- ONKKKEUQTQTHEP-UHFFFAOYSA-N 5-cyclohexyl-3-propan-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound CC(C)C1N=C(C2CCCCC2)c2ccccc2NC1=O ONKKKEUQTQTHEP-UHFFFAOYSA-N 0.000 description 1
- HDIMVSBDROVTPM-UHFFFAOYSA-N 5-methyl-3-[2-(trifluoromethyl)phenyl]imidazolidine-2,4-dione Chemical compound O=C1C(C)NC(=O)N1C1=CC=CC=C1C(F)(F)F HDIMVSBDROVTPM-UHFFFAOYSA-N 0.000 description 1
- PEXZDRCZJDRFJC-UHFFFAOYSA-N 5-methyl-3-prop-2-enylimidazolidine-2,4-dione Chemical compound CC1NC(=O)N(CC=C)C1=O PEXZDRCZJDRFJC-UHFFFAOYSA-N 0.000 description 1
- IVUAAOBNUNMJQC-UHFFFAOYSA-N 5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC=CC=C2NC(=O)CN=C1C1=CC=CC=C1 IVUAAOBNUNMJQC-UHFFFAOYSA-N 0.000 description 1
- PWSZRRFDVPMZGM-UHFFFAOYSA-N 5-phenyl-1h-pyrazol-3-amine Chemical compound N1N=C(N)C=C1C1=CC=CC=C1 PWSZRRFDVPMZGM-UHFFFAOYSA-N 0.000 description 1
- GAAPUAMCTXWBPL-UHFFFAOYSA-N 5-phenyl-3-propan-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC=CC=C2NC(=O)C(C(C)C)N=C1C1=CC=CC=C1 GAAPUAMCTXWBPL-UHFFFAOYSA-N 0.000 description 1
- SJBLHDRWFUCIHF-UHFFFAOYSA-N 5-propan-2-yl-3-[2-(trifluoromethyl)phenyl]imidazolidine-2,4-dione Chemical compound O=C1C(C(C)C)NC(=O)N1C1=CC=CC=C1C(F)(F)F SJBLHDRWFUCIHF-UHFFFAOYSA-N 0.000 description 1
- UJEFFLFKMYKHJD-UHFFFAOYSA-N 5-propan-2-yl-3-prop-2-enylimidazolidine-2,4-dione Chemical compound CC(C)C1NC(=O)N(CC=C)C1=O UJEFFLFKMYKHJD-UHFFFAOYSA-N 0.000 description 1
- PBNUQCWZHRMSMS-UHFFFAOYSA-N 5-propan-2-ylimidazolidine-2,4-dione Chemical compound CC(C)C1NC(=O)NC1=O PBNUQCWZHRMSMS-UHFFFAOYSA-N 0.000 description 1
- KMQQEKNPKAMBOU-UHFFFAOYSA-N 5-thiophen-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC=CC=C2NC(=O)CN=C1C1=CC=CS1 KMQQEKNPKAMBOU-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- PXNQAEKERWTPQO-UHFFFAOYSA-N 6-(4-chlorophenyl)-4,6-dioxohexanoic acid Chemical compound OC(=O)CCC(=O)CC(=O)C1=CC=C(Cl)C=C1 PXNQAEKERWTPQO-UHFFFAOYSA-N 0.000 description 1
- RIMXEJYJXDBLIE-UHFFFAOYSA-N 6-bromohex-1-ene Chemical compound BrCCCCC=C RIMXEJYJXDBLIE-UHFFFAOYSA-N 0.000 description 1
- QEJHMHDPCMFHCO-UHFFFAOYSA-N 6-cyclohexyl-6,7-dihydro-4-(2-oxo-2-phenylethyl)-2-(4-chlorophenyl)-4h-pyrazolo[1,5-a]pyrrolo[3,4-d]-pyrimidine-5,8-dione Chemical compound C1=CC(Cl)=CC=C1C1=NN2C(=O)C(CN(C3=O)C4CCCCC4)=C3N(CC(=O)C=3C=CC=CC=3)C2=C1 QEJHMHDPCMFHCO-UHFFFAOYSA-N 0.000 description 1
- UVDJPJZTYXIAPY-UHFFFAOYSA-N 6-cyclohexyl-6,7-dihydro-4-(phenylmethyl)-2-(4-chlorophenyl)-4h-pyrazolo[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione Chemical compound C1=CC(Cl)=CC=C1C1=NN2C(=O)C(CN(C3=O)C4CCCCC4)=C3N(CC=3C=CC=CC=3)C2=C1 UVDJPJZTYXIAPY-UHFFFAOYSA-N 0.000 description 1
- JRKQSQSFAJCTBQ-UHFFFAOYSA-N 6-hexyl-6,7-dihydro-4-(2-oxo-2-phenylethyl)-2-(4-chlorophenyl)-4h-pyrazolo[1,5-a]pyrrolo[3,4-d]-pyrimidine-5,8-dione Chemical compound O=C1N(CCCCCC)CC(C(N2N=C(C=C22)C=3C=CC(Cl)=CC=3)=O)=C1N2CC(=O)C1=CC=CC=C1 JRKQSQSFAJCTBQ-UHFFFAOYSA-N 0.000 description 1
- UCYFBZLXXSECOY-UHFFFAOYSA-N 6-hexyl-6,7-dihydro-4-(2-oxo-2-phenylethyl)-2-phenyl-4h-pyrazolo [1,5-a]-pyrrolo [3,4-d]-pyrimidine-5,8-dione Chemical compound O=C1N(CCCCCC)CC(C(N2N=C(C=C22)C=3C=CC=CC=3)=O)=C1N2CC(=O)C1=CC=CC=C1 UCYFBZLXXSECOY-UHFFFAOYSA-N 0.000 description 1
- NQNZLXULGPYQFW-UHFFFAOYSA-N 6-hexyl-6,7-dihydro-4-(phenylmethyl)-2-(4-chlorophenyl)-4h-pyrazolo[1,5-a]pyrrolo[3,4-d]-pyrimidine-5,8-dione Chemical compound O=C1N(CCCCCC)CC(C(N2N=C(C=C22)C=3C=CC(Cl)=CC=3)=O)=C1N2CC1=CC=CC=C1 NQNZLXULGPYQFW-UHFFFAOYSA-N 0.000 description 1
- PRGHPKVUWQQOMJ-UHFFFAOYSA-N 6-hexyl-6,7-dihydro-4-(phenylmethyl)-2-phenyl-4h- pyrazolo[1,5-a]pyrrolo[3,4-d]-pyrimidine-5,8-dione Chemical compound O=C1N(CCCCCC)CC(C(N2N=C(C=C22)C=3C=CC=CC=3)=O)=C1N2CC1=CC=CC=C1 PRGHPKVUWQQOMJ-UHFFFAOYSA-N 0.000 description 1
- ARVGUKVASZCOIB-UHFFFAOYSA-N 6-methyl-1,3-di(propan-2-yl)-3h-1,4-benzodiazepin-2-one Chemical compound CC(C)N1C(=O)C(C(C)C)N=CC2=C(C)C=CC=C21 ARVGUKVASZCOIB-UHFFFAOYSA-N 0.000 description 1
- OQOCWRCPORRURO-UHFFFAOYSA-N 6-methyl-1-propan-2-yl-3h-1,4-benzodiazepin-2-one Chemical compound C1=NCC(=O)N(C(C)C)C2=CC=CC(C)=C21 OQOCWRCPORRURO-UHFFFAOYSA-N 0.000 description 1
- QTENOXFSNBDPMO-UHFFFAOYSA-N 6-phenyl-2,3-dihydroisoindol-1-one Chemical compound C1=C2C(=O)NCC2=CC=C1C1=CC=CC=C1 QTENOXFSNBDPMO-UHFFFAOYSA-N 0.000 description 1
- MJHYKYRIASLYPN-UHFFFAOYSA-N 7-chloro-3-(1h-indol-2-ylmethyl)-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(CC=2NC3=CC=CC=C3C=2)N=C1C1=CC=CC=C1 MJHYKYRIASLYPN-UHFFFAOYSA-N 0.000 description 1
- ZLOHGZQKOWPLAQ-UHFFFAOYSA-N 7-chloro-3-(4-hydroxyphenyl)-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(O)=CC=C1C1C(=O)NC2=CC=C(Cl)C=C2C(C=2C=CC=CC=2)=N1 ZLOHGZQKOWPLAQ-UHFFFAOYSA-N 0.000 description 1
- SATGIBNNISQKBG-UHFFFAOYSA-N 7-chloro-3-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C)N=C1C1=CC=CC=C1 SATGIBNNISQKBG-UHFFFAOYSA-N 0.000 description 1
- GIUZMTLJQCHDOJ-UHFFFAOYSA-N 7-chloro-5-phenyl-3-propan-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(C)C)N=C1C1=CC=CC=C1 GIUZMTLJQCHDOJ-UHFFFAOYSA-N 0.000 description 1
- TXKCPZUVTMDZTD-UHFFFAOYSA-N 7-nitro-5-phenyl-3-propan-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC([N+]([O-])=O)=CC=C2NC(=O)C(C(C)C)N=C1C1=CC=CC=C1 TXKCPZUVTMDZTD-UHFFFAOYSA-N 0.000 description 1
- GGZZISOUXJHYOY-UHFFFAOYSA-N 8-amino-4-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C(N)=CC=CC2=C1O GGZZISOUXJHYOY-UHFFFAOYSA-N 0.000 description 1
- ZSOICJZJSRWNHX-ACZMJKKPSA-N Ala-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)[C@H](C)[NH3+] ZSOICJZJSRWNHX-ACZMJKKPSA-N 0.000 description 1
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 description 1
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 1
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 1
- LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BBIXOODYWPFNDT-CIUDSAMLSA-N Ile-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O BBIXOODYWPFNDT-CIUDSAMLSA-N 0.000 description 1
- BCXBIONYYJCSDF-CIUDSAMLSA-N Ile-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O BCXBIONYYJCSDF-CIUDSAMLSA-N 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- AWMVMTVKBNGEAK-UHFFFAOYSA-N Styrene oxide Chemical compound C1OC1C1=CC=CC=C1 AWMVMTVKBNGEAK-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000005644 Wolff-Kishner reduction reaction Methods 0.000 description 1
- PFUUEZRQEPXGQU-UHFFFAOYSA-N [4-methyl-2-(propan-2-ylamino)phenyl]-phenylmethanone Chemical compound CC(C)NC1=CC(C)=CC=C1C(=O)C1=CC=CC=C1 PFUUEZRQEPXGQU-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- CXISPYVYMQWFLE-UHFFFAOYSA-N alanylglycine Chemical compound CC(N)C(=O)NCC(O)=O CXISPYVYMQWFLE-UHFFFAOYSA-N 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 150000001334 alicyclic compounds Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000794 anti-serotonin Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- AXMNGEUJXLXFRY-UHFFFAOYSA-N azaspirodecane Chemical compound C1CCCC21CCNCC2 AXMNGEUJXLXFRY-UHFFFAOYSA-N 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 150000008038 benzoazepines Chemical class 0.000 description 1
- AQIHMSVIAGNIDM-UHFFFAOYSA-N benzoyl bromide Chemical compound BrC(=O)C1=CC=CC=C1 AQIHMSVIAGNIDM-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- RCUIWQWWDLZNMS-UHFFFAOYSA-N benzyl 2-cyanoacetate Chemical compound N#CCC(=O)OCC1=CC=CC=C1 RCUIWQWWDLZNMS-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001717 carbocyclic compounds Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- ORSDQUOMVWYHAE-UHFFFAOYSA-M cesium;prop-2-enoate Chemical compound [Cs+].[O-]C(=O)C=C ORSDQUOMVWYHAE-UHFFFAOYSA-M 0.000 description 1
- 150000005829 chemical entities Chemical group 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- VXVVUHQULXCUPF-UHFFFAOYSA-N cycloheptanamine Chemical compound NC1CCCCCC1 VXVVUHQULXCUPF-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- FESAXEDIWWXCNG-UHFFFAOYSA-N diethyl(methoxy)borane Chemical compound CCB(CC)OC FESAXEDIWWXCNG-UHFFFAOYSA-N 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000001330 gastroprokinetic effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- RGZRSLKIOCHTSI-UHFFFAOYSA-N hydron;n-methylhydroxylamine;chloride Chemical compound Cl.CNO RGZRSLKIOCHTSI-UHFFFAOYSA-N 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical class N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 150000002473 indoazoles Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N isoleucyl-alanine Chemical compound CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- UCGDDTHMMVWVMV-UHFFFAOYSA-N isoleucyl-glycine Chemical compound CCC(C)C(N)C(=O)NCC(O)=O UCGDDTHMMVWVMV-UHFFFAOYSA-N 0.000 description 1
- JWBXCSQZLLIOCI-UHFFFAOYSA-N isoleucyl-leucine Chemical compound CCC(C)C(N)C(=O)NC(C(O)=O)CC(C)C JWBXCSQZLLIOCI-UHFFFAOYSA-N 0.000 description 1
- WMDZARSFSMZOQO-UHFFFAOYSA-N isoleucyl-phenylalanine Chemical compound CCC(C)C(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 WMDZARSFSMZOQO-UHFFFAOYSA-N 0.000 description 1
- BVRPESWOSNFUCJ-UHFFFAOYSA-N isoleucyl-tryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C(N)C(C)CC)C(O)=O)=CNC2=C1 BVRPESWOSNFUCJ-UHFFFAOYSA-N 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- NIXOIRLDFIPNLJ-UHFFFAOYSA-M magnesium;benzene;bromide Chemical compound [Mg+2].[Br-].C1=CC=[C-]C=C1 NIXOIRLDFIPNLJ-UHFFFAOYSA-M 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- JQRHFLQDPJMVAZ-UHFFFAOYSA-N methyl 6-(2-methyl-3,4,5-triphenylpyrrol-1-yl)-3,6-dioxohexanoate Chemical compound COC(=O)CC(=O)CCC(=O)N1C(C)=C(C=2C=CC=CC=2)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 JQRHFLQDPJMVAZ-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- BUQMHUKZYMREQT-UHFFFAOYSA-N n-(pyrrolidin-3-ylmethyl)ethanamine Chemical compound CCNCC1CCNC1 BUQMHUKZYMREQT-UHFFFAOYSA-N 0.000 description 1
- RCHKEJKUUXXBSM-UHFFFAOYSA-N n-benzyl-2-(3-formylindol-1-yl)acetamide Chemical compound C12=CC=CC=C2C(C=O)=CN1CC(=O)NCC1=CC=CC=C1 RCHKEJKUUXXBSM-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNHVTXYLRVGMHD-UHFFFAOYSA-N n-butyl isocyanate Chemical compound CCCCN=C=O HNHVTXYLRVGMHD-UHFFFAOYSA-N 0.000 description 1
- JACMPVXHEARCBO-UHFFFAOYSA-N n-pentylpentan-1-amine Chemical compound CCCCCNCCCCC JACMPVXHEARCBO-UHFFFAOYSA-N 0.000 description 1
- NSNPSJGHTQIXDO-UHFFFAOYSA-N naphthalene-1-carbonyl chloride Chemical compound C1=CC=C2C(C(=O)Cl)=CC=CC2=C1 NSNPSJGHTQIXDO-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 230000006959 non-competitive inhibition Effects 0.000 description 1
- AKPLHCDWDRPJGD-UHFFFAOYSA-N nordazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1 AKPLHCDWDRPJGD-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 150000004880 oxines Chemical class 0.000 description 1
- 125000005522 oxopentanoic acid group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical compound CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- GZRKXKUVVPSREJ-UHFFFAOYSA-N pyridinylpiperazine Chemical compound C1CNCCN1C1=CC=CC=N1 GZRKXKUVVPSREJ-UHFFFAOYSA-N 0.000 description 1
- 150000008512 pyrimidinediones Chemical class 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- ADRDEXBBJTUCND-UHFFFAOYSA-N pyrrolizidine Chemical class C1CCN2CCCC21 ADRDEXBBJTUCND-UHFFFAOYSA-N 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- ZMGRMOMYXWGAAE-UHFFFAOYSA-N sodium;ethyl 3-oxobutanoate Chemical compound [Na+].CCOC(=O)[CH-]C(C)=O ZMGRMOMYXWGAAE-UHFFFAOYSA-N 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 229950009638 tepoxalin Drugs 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
- 229940103494 thiosalicylic acid Drugs 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- PNQBEPDZQUOCNY-UHFFFAOYSA-N trifluoroacetyl chloride Chemical compound FC(F)(F)C(Cl)=O PNQBEPDZQUOCNY-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001478887 unidentified soil bacteria Species 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00279—Features relating to reactor vessels
- B01J2219/00281—Individual reactor vessels
- B01J2219/00283—Reactor vessels with top opening
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00279—Features relating to reactor vessels
- B01J2219/00281—Individual reactor vessels
- B01J2219/00286—Reactor vessels with top and bottom openings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00279—Features relating to reactor vessels
- B01J2219/00306—Reactor vessels in a multiple arrangement
- B01J2219/00308—Reactor vessels in a multiple arrangement interchangeably mounted in racks or blocks
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00279—Features relating to reactor vessels
- B01J2219/00306—Reactor vessels in a multiple arrangement
- B01J2219/00313—Reactor vessels in a multiple arrangement the reactor vessels being formed by arrays of wells in blocks
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00279—Features relating to reactor vessels
- B01J2219/00306—Reactor vessels in a multiple arrangement
- B01J2219/00313—Reactor vessels in a multiple arrangement the reactor vessels being formed by arrays of wells in blocks
- B01J2219/00315—Microtiter plates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00479—Means for mixing reactants or products in the reaction vessels
- B01J2219/00484—Means for mixing reactants or products in the reaction vessels by shaking, vibrating or oscillating of the reaction vessels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00479—Means for mixing reactants or products in the reaction vessels
- B01J2219/00488—Means for mixing reactants or products in the reaction vessels by rotation of the reaction vessels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00495—Means for heating or cooling the reaction vessels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/005—Beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00585—Parallel processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/0059—Sequential processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00592—Split-and-pool, mix-and-divide processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00596—Solid-phase processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/0068—Means for controlling the apparatus of the process
- B01J2219/00698—Measurement and control of process parameters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00725—Peptides
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
- C40B60/14—Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
Definitions
- the invention relates to a method for the synthesis of mixtures of compounds and, in particular, the multiple simultaneous synthesis of compounds.
- peptides or oligonucleotides may be multiply and simultaneously synthesized.
- amino acids are sequentially coupled in solution or on a functionalized solid support.
- Several methods have been developed by which peptides or oligonucleotides may be multiply synthesized.
- One such methodology for peptide synthesis was disclosed in Geysen et al., International Publication No.g WO 90/09395.
- Geysen's method involves functionalizing the termini of polymeric rods and sequentially immersing the termini in solutions of individual amino acids.
- a second method of peptide or oligonucleotide synthesis was developed by Affymax Technologies N.V. and disclosed in U.S. Patent No. 5,143,854.
- the Affymax method involves sequentially using light for illuminating a plurality of polymer sequences on a substrate and delivering reaction fluids to said substrate.
- Houghton' s apparatus is a polypropylene mesh container, similar to a tea-bag, which encloses reactive particles.
- U.S. Patent No. 5,281,540 teaches a test array for performing assays.
- a semi-automated biological sample analyzer is described for simultaneously performing a plurality of enzyme immunoassays for human IgE class antibodies specific to a panel of preselected allergens in each of a plurality of biological samples.
- the technique while having multiple biological samples in a well, uses a coating of an elongated cellulosic body such as a strip of paper which will contact the multiple samples to ascertain which antibodies are specific for the coated allergens and which will then, in turn, bind to the appropriate bands or islands. The bands or islands are then analyzed for the presence of labeled antibodies.
- the technique describes testing done in a seriatim basis, namely, a number of samples, one after the other, even though multiple samples are present in a reaction vessel.
- the use of antibodies which bind to a specific sample is required for the system to be effective.
- the samples may be detected by use of optical reading capabilities.
- PROTEIN RESEARCH 37, 1991, 487-493 entitled "General Method for Rapid Synthesis of Multicomponent Peptide Mixtures", A. Furka et al., a method is suggested for the synthesis of multicomponent peptide mixtures.
- the method is a solid phase synthesis modified in order to give a closely equimolar mixture of peptides with predetermined sequences.
- the main point of modification is that before every coupling cycle, the resin is divided into equal parts and each portion is coupled with a different amino acid. Then, the portions are mixed and before the next coupling cycle, the resin is again distributed into equal portions.
- Solid-Phase Synthesis of Large Numbers of Peptides Specificity of Antigen-Antibody Interaction at the Level of Individual Amino Acids.
- the paper indicates that 248 different 1,3-residue peptides representing single amino acid variance of a segment of the hemoglobulin hemaglutinin (HAI) protein were prepared and characterized in approximately 4 weeks. Through examination of the binding of these analogs to monoclonal antibodies raised against residues of HA1, it was found that a single amino acid, aspartic acid at position 101, is of unique importance to the interaction.
- HAI hemoglobulin hemaglutinin
- the apparatus includes plural reaction vessels in which subunit coupling to biopolymers in a particle suspension is carried out.
- the vessels are connected to common valving structure for use in mixing the suspension and removing suspension liquid.
- WO 9408711 A 1 (Warner Lambert Company) discloses an apparatus and method for multiple simultaneous synthesis.
- the patent indicates at column 14 that the final product solutions are combined, taking care to avoid cross-mixing.
- the individual solutions/extracts are then manipulated as needed to isolate the final compounds which compounds are individually tested for biologic activity.
- the problem that has arisen in the previous prior art techniques generally requires that the materials be physically separated or resynthesized for subsequent testing. Frequently, to ascertain the identification of active ingredients of testing requires a resynthesis of the original mixture.
- Described is a method of synthesizing and analyzing a plurality of compounds in a plurality of wells comprising the steps of: (a) providing a plurality of test wells in a plurality of arrays of the wells, (b) reacting in at least a one step reaction a first reagent with a plurality of reagents called building blocks in the test well to obtain a unique product designed to uniquely occur in each array, (c) continuing to react the same or different reagents such that there are multiple reagents resulting in multiple different products in each well.
- the synthesis is by solid phase or traditional solution phase methods.
- FIGURE 1 shows the combinatorial statistics for 4, 5 or 6 building blocks (reagents) and the number of compounds that may be synthesized per well. Description OfPreferred Embodiments
- the present invention is directed to a method which will provide a means to synthesize, analyze, and ascertain the individual components of the mixtures of organic compounds as they are synthesized. Additionally, the synthesis of inorganic compounds, organo metallic compounds, as well as other compounds, are within the scope of this invention.
- Typical solid supports include cross-linked divinylbenzene-styrene (polystyrene), controlled pore glass (CPG), polyacrylamides, poly (ethylene glycol) monomethyl ether and poly (ethylene glycol) (PEG), silica gel, cellulose, acrylic acid grafted polypropylene, and the like. Additionally, the solid support contains a reactive moiety.
- a functionalized solid support is an insoluble material containing an accessible reactive moiety such as, for example, a carboxylic acid, alcohol, amine, halomethyl, and the like which is used to covalently attach an incoming building block.
- the steps utilized to synthesize mixtures of compounds are: 1) development of a synthetic route that will be feasible in solution or on a solid support, 2) utilize the "mixed resin" or subequimolar reagent approach to generate mixtures of products or intermediates, and 3) construct orthogonally overlapped compound mixtures such that each unique product within a mixture of compounds is synthesized in n unique mixtures, where n represents the number of reaction steps in a synthetic route.
- the steps possible to analyze mixtures of compounds are: 1) construction of a compound mixture which contain products each with unique molecular weights, 2) qualitative analysis of each mixture by mass spectrometry technique to confirm the presence of each unique product, 3) analysis of each mixture by 1H NMR (nuclear magnetic resonance) or other analytical methods and comparison of spectra of different mixtures of compounds (computationally by addition or subtraction of spectra) to identify and confirm the presence of each desired product, and 4) quantitate the concentration of each unique product in the compound mixture utilizing a standard in combination with the 1H NMR.
- the method involves the sequential coupling of building blocks to form soluble or resin-bound intermediates.
- a number of reaction tubes equal to the total number of compounds to be synthesized by the array method are loaded with 1 to 1000 mg, preferably 100 mg, of the appropriate functionalized solid support, preferably 1 to 3% cross-linked polystyrene.
- the individual reaction tubes are inserted into a holder block.
- reaction tubes in combination with the holder block and a manifold, are inserted into the reservoir block so that each reaction tube is submerged in a volume, preferably 3 to 5 mL, of a solvent capable of swelling the polystyrene resin (such as, but not limited to, dichloromethane, chloroform, dimethylformamide (DMF), dioxane, toluene, tetrahydrofuran (THF), ethanol and the like).
- a solvent capable of swelling the polystyrene resin such as, but not limited to, dichloromethane, chloroform, dimethylformamide (DMF), dioxane, toluene, tetrahydrofuran (THF), ethanol and the like.
- the polystyrene resin within the reaction tubes is preferably agitated for 15 to 30 minutes to affect swelling. Swelling times of 5 to 600 minutes, with or without agitation are also within the scope of the invention.
- reaction tubes in combination with the holder block and manifold, are removed from the reservoir block and the excess solvent within the reaction tubes is allowed to drain, preferably by gravity, although gas pressure applied to the manifold inlet (while closing the outlet) can be used to expel the solvent, if desired.
- reaction wells are emptied of solvent and the proper reactant solutions are dispensed into the new or clean reaction wells at appropriate locations in the reservoir block.
- the quantity of reactant is usually 1 to 100 equivalents based on the milliequivalents per gram (meq/g) loading of functionalized solid support (typically 0.1 to 1.0 meq/g for polystyrene resins) originally weighed into the reaction tube. Additional equivalents of reactants can be used if required to drive the reaction to completion in a reasonable time.
- the reaction tubes, in combination with the holder block and manifold, are reinserted into the reservoir block and the apparatus is fastened together.
- Gas flow through the manifold is initiated to provide a controlled environment, for example, nitrogen, argon, air, and the like.
- the gas flow may also be heated or chilled prior to flow through the manifold.
- Heating or cooling of the reaction wells is achieved by immersing the reservoir block in water baths, oil baths, isopropanol/dry ice baths, sand baths, and the like to perform synthetic reactions. Agitation is achieved by shaking, sonication (preferred), or magnetic stirring (within the reaction well or within the reaction tube).
- Reflux is achieved by circulating chilled gas through the manifold while heating the reaction wells in the reservoir block. Reactants may be injected directly into the reaction tubes through an injectable gasket on the top of the manifold.
- the reaction is allowed to proceed for an amount of time deemed necessary from the preliminary validation experiments or monitored by removal and quantitative analysis of filtrate aliquots from selected wells by methods such as GC/ISTD (internal standard) or HPLC/ISTD. If necessary, the complete assembly is allowed to return to ambient temperature, then the holder block and manifold, in combination with the reaction tubes, are detached from and raised above the reservoir block and the excess reagent solution is drained by gravity followed by gas pressure applied to the manifold inlet (while closing the outlet) to expel the excess reagents, solvents, and by-products.
- GC/ISTD internal standard
- HPLC/ISTD HPLC/ISTD
- the resin-bound intermediate within each reaction tube is washed clean of excess retained reagents, solvents, and by-products by repetitive exposure to clean solvent (s) by one of two methods: 1) the reaction wells are filled with solvent (preferably 1-5 mL), the reaction tubes, in combination with the holder block and manifold, are immersed and agitated for 5 to 300 minutes, preferably 15 minutes, and drained by gravity followed by gas pressure applied through the manifold inlet (while closing the outlet) to expel the solvent; 2) the manifold is removed from the holder block, aliquots of solvent (preferably 5 mL) are dispensed through the top of the reaction tubes and drained by gravity through the filter into a receiving vessel such as a test tube or vial. Both of the above washing procedures are repeated 1 to 50 times (preferably 10 times), monitoring the efficiency of reagent, solvent, and byproduct removal by methods such as TLC, GC, or visualization of the wash filtrates.
- Detachment of the final product from the solid support is achieved by immersion of the reaction tubes, in combination with the holder block and manifold, in reaction wells containing a solution of the cleavage reagent (preferably 3-5 mL). Gas flow, temperature control, agitation, and reaction monitoring are implemented as above and as desired to affect the detachment reaction.
- the reaction tubes, in combination with the holder block and manifold, are disassembled from the reservoir block and raised above the solution level but below the upper lip of the reaction wells and gas pressure is applied through the manifold inlet (while closing the outlet) to efficiently expel the final product solution into the reservoir wells.
- the spent resin in the reaction tubes is then washed 2 to 5 times as above with 3 to 5 mL of an appropriate solvent to extract (wash out) as much of the detached product as possible.
- the final product solutions are combined, taking care to avoid cross-mixing.
- the individual solutions/extracts are then manipulated as needed to isolate the final compounds. Typical manipulations include, but are not limited to, evaporation, concentration, liquid/liquid extraction, acidification, basification, neutralization or additional reactions in solution.
- the final compounds are individually tested for biological activity once they are isolated.
- This type of assay can be done using the compounds isolated from the array synthesis for any receptor binding screen or assay (screening for receptor agonists or antagonists), enzyme functional assays (measuring competitive or noncompetitive inhibition of the catalyzed reaction), and the like.
- This strategy may be used to screen for pharmaceutical agents, veterinary agents, agricultural agents, diagnostic reagents, and the like.
- Typical compounds and pharmaceutical applications include: (l) nitrogen containing heterocyclic compounds; imidazopyridines having antiulcer or anxioly- tic activities, dihydropyridines having calcium antagonist activity, nucleoside and nucleoside analogs having antiviral activity, indazoles having 5HT 3 antagonist activity, piperidines having antidopamine, antiserotonin, antidepressant, or antihistamine activities, benzazepines having antiparkinsonism and antidopamine activities, indoles and condensed indoles with 5HT antagonist activities, quinolines and isoquinolines having anti-infective and antiulcer activities, pyrrolidines having anti-infective and antihypertensive activities, aminopyrimidines having antihypertensive activities, pyrrolizidines having antiarrhythmic activities, guanidines having anticancer activities, tetrazoles having antiallergenic; (2) oxygen containing heterocycles; benzopyrans having potassium agonist and antagonist
- the apparatus and methods may be implemented without using a solid support, for example, standard solution techniques.
- An additional alternative use of the apparatus is for the optimization of chemical reactions, for example, reaction yields or reaction times, on solid supports or in solution. This use is accomplished by performing the same reaction in all reaction well locations but systematically determining and varying dependent reaction variables across the array. For example, the reagent concentration and/or reagent equivalency (mole percentage) can be varied from near zero to the maximum achievable with an undiluted reagent. Typically, one varies this variable from 0.001 to 25 mol.
- Reaction times can be varied within the array by withdrawal of the contents of the reaction well, followed by for example workup, and/or isolation, and/or purification, and/or quantitation of the final solution.
- Statistical experimental design strategies or quantitative structure activity relationship (QSAR) strategies may also be implemented to select a subset of locations within the original array which will provide the necessary information for final analysis and conclusions, therefore reducing the number of reactions necessary in the final array.
- TFA trifluoroacetic acid
- MS mass spectroscopy
- 1 H NMR proton nuclear magnetic resonance spectroscopy
- the synthesis of 40 hydantoins in an array illustrates a standard protocol for a typical parallel array synthesis.
- a robotic sample processor (Tecan ® 5032) is used for every liquid sample handling step.
- Some of the key features which demonstrate the strengths, flexibility and scope of the method and apparatus are highlighted below.
- Forty BOC or FMOC protected resin-bound amino acids are weighed into the reaction tubes, assembled in the apparatus, and simultaneously deprotected employing GC/ISTD calibration methods to determine the completion of the FMOC deprotection reactions.
- the ability to simultaneously perform different reactions with vastly different reagents for example, piperidine, DMF and TFA further demonstrates the flexibility of the apparatus.
- Residual solvents, reactants, or byproducts are removed by wash cycles which include submersion and sonication of the reaction tubes in a series of solvents, followed by robotic spotting of the filtrates on a TLC plate and observation of the results under ultraviolet (UV) light to insure the thoroughness of the wash cycles.
- the resin-bound amines are reacted with the desired isocyanates in DMF.
- GC/ISTD calibration methods are used to quantitatively monitor the uptake of the isocyanates.
- the resin-bound ureas are cyclized by heating in aqueous 6N HCl to produce the desired hydantoins.
- the spent resins in the reaction tubes are washed with methanol to completely extract the hydantoins from the resins. All filtrates are combined, concentrated on a commercial centrifugal vacuum system
- the resin bound imines are heated in TFA for a time sufficient to ensure cyclization of the slowest examples (imines of N-methyl 2-amino-5-nitro-benzophenone), while minimizing decomposition of the tryptophan derived benzodiazepines.
- the spent resins in the reaction tubes are washed and the combined filtrates concentrated to dryness.
- an aqueous bicarbonate work-up is implemented (utilizing the Tecan ® 5032 robotic sample processor) to remove residual TFA.
- the corresponding organic extracts are combined, dried, and concentrated to yield the expected benzodiazepines in all but one example (see Table 3).
- the 40 (39 desired) products are characterized by TLC, 1 H-NMR, and MS. The crude yields range from 7 to >100% and the estimated purities from NMR and TLC are greater than 60% in most cases.
- the crude benzodiazepines are tested for activity in a benzodiazepine receptor binding assay without further purification.
- the assay was performed using the commercially available NovaScreen ® assay system contracted by Scios-Nova Pharmaceutical Corp., Baltimore, MD, whereby bovine cortical membrane preparations were used as the source of receptor and the radioligand employed was [ 3 H] Flunitrazipam while the positive control was Clonazepam.
- the calculated IC 50 's from three concentrations (average of two determinations) for the individual compounds are shown in Table 3.
- the array of reaction tubes was fitted into a matching array of reaction wells in an appropriate reservoir block, in this case a test tube rack, and 3 mL of DMF was dispensed through the aperture at the top of the reaction tubes to wash any residual resin to the bottom of the glass frit.
- the manifold was fitted over the holder block and a nitrogen atmosphere was initiated through the ports on the manifold.
- the apparatus was then agitated in a sonic bath for 15 minutes to swell the resin support in preparation for the first reaction. Following swelling of the resin, the holder block and the manifold, in combination with the reaction tubes, were raised above the reservoir block and the reaction tubes were allowed to drain by gravity.
- reaction tubes were submerged in reaction wells containing 2 mL of a solution of 22% piperidine in DMF
- the apparatus was fastened together with clamps and agitated in a sonic bath for 2 hours, while maintaining a positive nitrogen flow through the manifold.
- the reaction progress was monitored by removing a sample of the filtrate (10-100 ⁇ l ) and analyzing for the FMOC-piperidine adduct and dibenzofulvene by GC/ISTD calibration methods.
- the holder block and the manifold, in combination with the reaction tubes were raised above the reservoir block and the reaction tubes were allowed to drain by gravity, then sparged with nitrogen.
- the reaction tubes were sparged by introducing nitrogen into one port of the manifold and closing off the second port.
- reaction tubes were subjected to a series of wash cycles to remove residual solvents, reagents, and byproducts.
- a standard protocol included sequentially submerging the reaction tubes in 2 to 5 mL each of 2 x DMF, 2 ⁇ methanol, 2 ⁇ water, 2 x water:dioxane
- the following DMF solutions were sequentially admixed in two 8-unit reservoir blocks, to generate the activated esters: 1.0 mL of 0.46 M FMOC alanine or FMOC isoleucine , 0 .5 mL of 1. 02 M Benzotriazol - 1 -yloxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP), 1.0 mL of 1.02 M N-Hydroxybenzotriazole (HOBT), and 0.5 mL of 1.84 M N-methylmorpholine.
- BOP Benzotriazol - 1 -yloxy-tris-(dimethylamino)-phosphonium hexafluorophosphate
- BOP Benzotriazol - 1 -yloxy-tris-(dimethylamino)-phosphonium hexafluorophosphate
- HOBT N-Hydroxybenzotriazole
- the apparatus was assembled as above and agitated on a rotational platform shaker for 18 hours, while maintaining a positive nitrogen flow through the manifold.
- the reaction progress was monitored by removing a sample of the resin following the wash cycles and colorometrically analyzing for primary amines (Bromophenol blue or Kaiser/Ninhydrin).
- primary amines Bromophenol blue or Kaiser/Ninhydrin.
- the holder block and the manifold, in combination with the reaction tubes were raised above the reservoir block and the reaction tubes were allowed to drain by gravity then sparged with nitrogen.
- reaction tubes were subjected to the same series of wash cycles as previously set forth.
- deprotection of the above formed FMOC protected dipeptides was repeated following the same procedure as previously set forth.
- reaction tubes were again subjected to the same series of wash cycles as previously set forth.
- the reaction tubes were submerged in reaction wells containing 3 mL of a solution of anisole:TFA
- the apparatus was sealed with clamps and agitated in a sonic bath, while maintaining a positive nitrogen flow through the manifold. After 3 hours, the holder block and the manifold, in combination with the reaction tubes, were raised above the reservoir block and the reaction tubes were allowed to drain by gravity then sparged with nitrogen. To isolate and purify the products, a holder block was fitted with disposable glass pipets which were submerged in the TFA filtrates. The filtrates were concentrated in a well-ventilated hood or glove box fitted with a scrubber by initiating and maintaining a positive, subsurface nitrogen flow through the manifold. The TFA salt was dissolved in 2 mL of water and extracted with 2 mL of ethyl acetate.
- reaction reservoirs were vortexed to affect efficient extraction and the upper organic layer was withdrawn via syringe.
- the extraction cycle was repeated until the organic layer contained no residues as determined by TLC or GC/ISTD (3 times).
- the aqueous layers were concentrated on a Speed-Vac ® in tared vials.
- the dipeptides generated in the apparatus including, alanylphenylalanine; alanylglycine; alanylisoleucine; alanylleucine; alanylalanine; alanylproline; alanylvaline; alanyltryptophan; isoleucylphenylalanine; isoleucylglycine; isoleucylisoleucine; isoleucylleucine; isoleucylalanine; isoleucylproline; isoleucylvaline; and isoleucyltryptophan, are set forth in Table 1.
- Example 1 DMF (v/v) with an internal standard (anthracene at 1.74 mg/mL).
- an internal standard anthracene at 1.74 mg/mL.
- the apparatus was assembled as set forth in Example 1 and agitated in a sonic bath while maintaining a positive nitrogen flow through the manifold. The reaction progress was monitored by removing a sample of the filtrate (e.g. 10-100 ⁇ l) and analyzing for the FMOC-piperidine adduct and dibenzofulvene by GC/ISTD calibration methods. The reaction was complete after 6 hours in a sonic bath. At the end of the reaction, the reaction tube array was drained and sparged as set forth in Example 1.
- reaction tubes were subjected to the standard wash cycle set forth in Example 1.
- reaction tubes were submerged in reaction wells containing 3 mL of a solution of 0.19 to 0.23 M isocyanate (trimethylsilyl isocyanate, butyl isocyanate, allyl isocyanate, trifluoro-o-tolyl isocyanate, and 4-methoxyphenyl isocyanate) in DMF, containing an internal standard (e.g., anthracene at 1.89-2.00 mg/mL).
- an internal standard e.g., anthracene at 1.89-2.00 mg/mL
- reaction progress was monitored by removing a sample of the filtrate (10-100 ⁇ l ) , derivatization with an appropriate amine or alcohol, and analysis by GC/ISTD calibration methods.
- the reaction tube array was drained and sparged as set forth in Example 1.
- the reaction tubes were subjected to the standard wash cycle set forth in Example 1.
- the reaction tubes, in combination with the holder block and manifold were submerged in reaction wells containing 3 mL each of 6N HCl.
- the apparatus was sealed with clamps and submerged in an oil bath (at 105°C) and heated at 85 to 100°C while maintaining a positive chilled nitrogen flow through the manifold. (The chilled nitrogen flow through the manifold was affected by submersion of the nitrogen inlet tubing in an isopropanol/dry ice bath.)
- the reaction tube array was cooled, drained and sparged as set forth in Example 1.
- reaction tubes in combination with the holder block and manifold, were submerged in reaction wells containing 3 mL each of methanol .
- the apparatus was agitated in a sonic bath for 10 to 15 minutes to extract the hydantoins from the resins then drained by gravity and nitrogen sparge.
- the methanol extraction protocol was repeated until the filtrates were free of any organic components as determined by TLC (4 times).
- the HCl and methanol filtrates were concentrated on a Speed-Vac ® in tared vials to afford 39 of the 40 desired hydantoins.
- the hydantoins generated in the apparatus including: 5-methyl-2,4-imidazolidinedione; 5-(phenylmethyl)-2,4-imidazolidinedione; 2,4-imidazolidinedione; 5- (1-methylpropyl)-2,4-imidazolidinedione; 5- (2-methylpropyl) -2,4-imidazolidinedione; 5-(1-methylethyl)-2,4-imidazolidinedione; 5-(1H-indol-2-ylmethyl)-2,4-imidazolidinedione; 5,5-diphenyl-2,4-imidazolidinedione; 3-butyl-5-methyl-2,4-imidazolidinedione; 3-butyl-5-(phenylmethyl)-2,4-imidazolidinedione; 3-butyl-2,4-imidazolidinedione, 3-butyl-5-(1-methylpropyl)-2,4
- each amino acid resin prepared above, as its TFA salt was loaded into 40 reaction tubes.
- the apparatus was assembled, swelled with 3 mL of CH 2 Cl 2 , and drained as set forth in Example 1.
- the appropriate reaction tubes are submerged in reaction wells containing a solution of the appropriate 2-aminobenzophenoneimines (3-6 eq) in 3 mL of dichloroethane (see Scheme 2).
- the apparatus was sealed as set forth in Example 1 and heated at 60°C (oil bath temp.), while maintaining a positive chilled nitrogen flow through the manifold.
- reaction tube array was allowed to cool and then drained and sparged as set forth in Example 1.
- reaction tubes were washed by adding 4 mL portions of CH 2 Cl 2 through the top of each reaction tube repeatedly (12 times) until the washes were no longer colored (indicating the absence of 2 -amino benzophenone imine or its corresponding ketone from hydrolysis).
- the reaction tube array was then sparged as set forth in Example 1 and the reaction tubes are submerged in reaction wells containing 3 mL of 100% TFA.
- the apparatus is sealed as set forth in Example 1 and heated at 60°C (oil bath temp.) for 20 hours, while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. Again, the reactions were not monitored, but were allowed to react for a time sufficient to ensure conversion of the slowest reactions (N-methyl2-amino-5-nitro benzophenone imine), while minimizing decomposition of the tryptophan derived benzodiazepines.
- the reaction tube array was allowed to cool and then drained as set forth in Example 1.
- reaction tubes are then washed as above with 3 ⁇ 2 mL portions of CH 2 Cl 2.
- Example 2 The appropriate washes are then combined and evaporated under a stream of nitrogen as set forth in Example 1, except in this case the pipet tips were maintained above the surface of the liquid.
- a simple extraction procedure was implemented using the Tecan ® robot. The residues from evaporation were dissolved in 3 mL CH 2 Cl 2 and mixed with 3 mL saturated sodium bicarbonate. The organic phase was withdrawn and the aqueous layer was extracted twice more with 1.5 mL of CH 2 Cl 2 . The combined organic extracts were dried with MgSO 4 , filtered, and concentrated as before to yield the expected benzodiazepines in all but one example (see Table 3). The 40 (39 desired) products were characterized by TLC, 1 H-NMR, and MS. The crude yields range from 4 to >100% and the estimated purities from
- NMR and TLC are greater than 60% in most cases.
- the desired products including: 1, 3-dihydro-3-methyl- 5-phenyl-2H-1,4-benzodiazepin-2-one; 7-chloro- 1,3-dihydro-3-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-5-(4-methoxyphenyl)-3-methyl-2H- 1,4-benzodiazepin-2-one; 1,3-dihydro-3-methyl-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-dihydro- 1-isopropyl-3,6-dimethyl-2H-1,4-benzodiazepin-2-one; 7-nitro-1,3-dihydro-1,3-dimethyl-5-phenyl-2H-1,4-benzodiazepin-2-one; 5-cyclohexyl-1,3-dihydro- 3-methyl-2H-1,4-benzodiazepin-2-one
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath for 12 hours, while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2.
- the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tube array is then washed using CH 2 Cl 2 (10 times) as set forth in Example 3.
- Example 1 Into every well of the array is added 3 mL of a solution of acetic anhydride/triethyl orthoformate (1:1 v/v) and the apparatus is sealed as set forth in Example 1. The apparatus is then heated at 150°C (oil bath temp.) for 3 hours, while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using CH 2 Cl 2 (10 times, 3 mL.)
- Example 1 To three sets of 12 reaction wells within the array is added 3 mL of a t-butanol solution 0.13 M in both ethyl amine and t-butoxide, or cyclopropyl amine and t-butoxide, or 2,4-difluoroaniline and t-butoxide.
- the apparatus is reassembled as set forth in Example 1, immersed in an oil bath (60°C) and heated for 12 hours as set forth in Example 3.
- the reaction tube array At the end of the reaction, the reaction tube array is allowed to cool and then drained and sparged as set forth in Example 1.
- reaction tubes are then washed as set forth in Example 3, using CH 2 Cl 2 (12 times, 3 mL.)
- CH 2 Cl 2 (12 times, 3 mL.
- To four sets of nine reaction wells within the array is added 3 mL of a 0.26 M acetonitrile solution of either piperazine, piperidine, N-methyl piperazine, or 3- (ethylaminomethyl) pyrrolidine.
- the apparatus is assembled as set forth in Example 1, and heated in an oil bath (80°C) for 4 hours as set forth in Example 3.
- the reaction tube array is allowed to cool and then drained and sparged as set forth in Example 1.
- reaction tubes are then washed as set forth in Example 3, using CH 2 Cl 2 (12 times, 3 mL.)
- the reaction tubes are submerged in reaction wells containing 3 mL of 2N NaOH in 1:1 dioxane :water.
- the apparatus is assembled as set forth in Example 1, and allowed to stand at room temperature for 6 hours to affect ester hydrolysis.
- the reaction tube array is drained and sparged as set forth in Example 1.
- Example 5 The reaction tubes are then washed as set forth in Example 3, using 3 x 3 mL of 0.1N NaOH in dioxane:water (1:1). The filtrates are then combined and the dioxane is removed by evaporation as set forth in Example 3. The resulting aqueous solutions are acidified with 5 N HCl solution and evaporated to give the 36 individual expected crude quinolones.
- Example 5
- the dried aldehyde resin is then reacted with O-methylhydroxylamine hydrochloride (7.5 eq) and pyridine (7.8 eq) in refluxing ethanol to form the resin-bound oxime, which is washed with excess MeOH and CH 2 Cl 2 , and then directly reduced with sodium cyanoborohydride (10 eq) in EtOH saturated with HCl at room temperature for 3 hours using methyl orange as an indicator and adjusting the pH to 3.1 with additional EtOH/HCl.
- the resin is washed sequentially with excess MeOH, hot water, dioxane:water (1:1), dioxane, and CH 2 Cl 2 and used directly below.
- reaction tubes are submerged in reaction wells containing 3 mL of a solution of 0.08 M diisopropylethylamine, 0.16 M BOP
- reaction tubes are submerged in reaction wells containing a solution of 4 mL of sat.
- reaction tube array is drained and sparged as set forth in Example 1.
- reaction tube array is subjected to the standard wash cycle set forth in Example 1.
- reaction tubes are submerged in reaction wells containing a solution of 3 mL of 0.16 M phenyl isocyanate or ethyl isocyanate in dioxane with an internal standard (e.g., anthracene at 2-4 mg/mL).
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath for 6 hours, while maintaining a positive nitrogen flow through the manifold.
- the reaction progress is monitored by GC/ISTD as set forth in Example 1.
- the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tube array is subjected to the standard wash cycle set forth in Example 1.
- reaction tubes are submerged in reaction wells containing a solution of 3 mL of dry CH 2 Cl 2 at
- Example 1 and placed in an isopropanol/dry ice bath while maintaining a positive chilled nitrogen flow through the manifold.
- reaction tube array is drained and sparged as set forth in Example 1.
- Example 6 To isolate and purify the products, the reaction tubes are washed as set forth in Example 1, using 3 mL portions of methanol. The methanol extraction protocol is repeated until the filtrates are free of any organic components as determined by TLC (1-2 times). The appropriate HCl and methanol filtrates are then combined and concentrated on a Speed-Vac ® in tared vials to afford eight discrete keto-ureas.
- Example 6 To isolate and purify the products, the reaction tubes are washed as set forth in Example 1, using 3 mL portions of methanol. The methanol extraction protocol is repeated until the filtrates are free of any organic components as determined by TLC (1-2 times). The appropriate HCl and methanol filtrates are then combined and concentrated on a Speed-Vac ® in tared vials to afford eight discrete keto-ureas.
- Example 6 Example 6
- reaction tubes are submerged in reaction wells containing a solution of 4 mL of 25% piperidine in DMF (v/v) containing an internal standard (anthracene at 2-4 mg/mL).
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath while maintaining a positive nitrogen flow through the manifold.
- the reaction progress is monitored by removing a sample of the filtrate (e.g., 10-100 ⁇ L) and analyzing for the FMOC-piperidine adduct and dibenzofulvene by GC/ISTD calibration methods.
- the reaction tube array is drained and sparged as set forth in Example 1.
- the reaction tube array is subjected to the standard wash cycle set forth in Example 1.
- reaction tubes are submerged in reaction wells containing a solution of 4 mL of 0.10 to 0.30 M acetaldehyde or benzaldehyde in dioxane containing an internal standard (e.g., anthracene at 2-4 mg/mL).
- the apparatus is sealed and agitated in a sonic bath for 12 hours, while maintaining a positive nitrogen flow through the manifold.
- the reaction progress is monitored by GC/ISTD calibration methods as set forth in Example 1.
- the reaction tube array is drained and sparged as set forth in Example 1.
- the reaction tube array is subjected to the standard wash cycle set forth in Example 1.
- the appropriate reaction tubes are submerged in reaction wells containing a solution of 4 mL of 0.10-0.30 M sodium cyanoborohydride in methanol with an indicator (e.g., methyl orange at 2-4 mg/mL).
- the apparatus is sealed as set forth in Example l and agitated in a sonic bath while maintaining a positive nitrogen flow through the manifold.
- the reaction progress is monitored by visually observing the color of the filtrates.
- the pH is adjusted by injection of dilute aqueous HCl into the appropriate reaction tubes through the gasket at the top of the manifold. Stabilization of pH changes indicates completion of the reduction reaction.
- the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tube array is subjected to the standard wash cycle set forth in Example 1.
- reaction tubes are submerged in reaction wells containing a solution of 4 mL of 0.10-0.30 M trimethylsilyl isocyanate or allyl isocyanate in DMF containing an internal standard (e.g., anthracene at 2-4 mg/mL).
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath for 6 hours, while maintaining a positive nitrogen flow through the manifold.
- the reaction progress is monitored by removing a sample of the filtrate (10-100 ⁇ L), derivatization with an appropriate amine or alcohol, and analysis by GC/ISTD calibration methods as set forth in Example 1.
- the reaction tube array is drained and sparged as set forth in Example 1.
- the reaction tube array is subjected to the standard wash cycle set forth in Example 1.
- reaction tubes are submerged in reaction wells containing a solution of 4 mL of aqueous 6N HCl.
- the apparatus is sealed as set forth in Example 1, placed in an oil bath and heated at 95 to 100°C for 2 hours while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2.
- the reaction tube array is drained and sparged as set forth in Example 1.
- the reaction tubes are washed as set forth in Example 1 using 4 mL portions of methanol. The methanol extraction protocol is repeated until the filtrates are free of any organic components as determined by TLC (1-2 times).
- the appropriate HCl and methanol filtrates are then combined and concentrated on a Speed-Vac ® in tared vials to afford eight discrete hydantoins.
- reaction tubes gas dispersion tubes
- the apparatus is assembled, swelled with 3 mL of dioxane, and drained as set forth in Example 1.
- the reaction tubes are submerged in reaction wells containing a solution of tetrabutylammoniun fluoride (5 eq) in dioxane (3 mL) at room temperature.
- the apparatus is sealed as set forth in Example l and agitated at room temperature for 8 hours in a sonic bath as set forth in Example 5, while maintaining a positive nitrogen flow through the manifold.
- the reaction tube array is drained and sparged as set forth in Example 1.
- the reaction tubes are washed as set forth in
- Example 3 using 2 ⁇ 3 mL each of the following solutions, dioxane:H 2 O (1:1), dioxane and CH 2 Cl 2 .
- reaction tubes are submerged in reaction wells containing a solution of ethylchloroformate (3 eq) and triethylamine (3 eq) in dioxane (3 mL) at -10°C.
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at room temperature for 4 hours as set forth in Example 5, while maintaining a positive nitrogen flow through the manifold.
- the reaction tube array is allowed to warm to room temperature and then drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in
- Example 3 using 4 ⁇ 2 mL of anhydrous DMF. Because of the labile nature of the above formed acyl-carbonates, the reaction tubes are rapidly washed in order to minimize unwanted hydrolysis.
- reaction tubes are submerged in reaction wells containing a solution of 4 eq of either n-butylamine, cycloheptylamine,
- Example 1 8-azaspiro[4.5]decane, or dipentylamine in dioxane (4 mL) at -10°C.
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at -10°C as set forth in Example 5 for 1 hour and then 3 hours at room temperature, while maintaining a positive nitrogen flow through the manifold.
- the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in
- Example 3 using 2 ⁇ 3 mL each of the following solutions, dioxane:H 2 O (1:1), dioxane:1N HCl (1:1), dioxane:H 2 O (1:1), dioxane:0.1N NaOH (1:1), dioxane:H 2 O
- reaction tubes are submerged in reaction wells containing a solution of 20% piperidine in DMF at room temperature.
- the apparatus is sealed as set forth in Example 1 and agitated at room temperature in a sonic bath for 6 hours as set forth in Example 5, while maintaining a positive nitrogen flow through the manifold.
- the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 2 ⁇ 3 mL each of the following solutions, DMF, dioxane:H 2 O (1:1), dioxane and CH 2 Cl 2 .
- reaction tubes are submerged in reaction wells containing a solution of 2 eq of either benzoyl chloride, 3-methoxybenzoyl chloride, or 3-nitrobenzoyl chloride in pyridine (3 mL) at 0°C.
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at 0°C for 3 hours as set forth in Example 5, while maintaining a positive nitrogen flow through the manifold.
- the apparatus is allowed to warm to room temperature, and the reaction tubes are drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 3 x 2 mL each of the following solutions, dioxane, dioxane:H 2 O (1:1), and dioxane.
- reaction tubes are submerged in reaction wells containing 3 mL each of trifluoroacetic acid.
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at 0°C for 2 hours and then at room temperature for 4 hours as set forth in Example 5, while maintaining a positive nitrogen flow through the manifold. After 6 hours in a sonic bath, the apparatus is allowed to warm to room temperature, and the reaction tubes are drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 2 ⁇ 3 mL of methylene chloride.
- the filtrates are then combined and concentrated as set forth in Example 3.
- the crude products are then redissolved, transferred to tared vials, and reconcentrated to yield the final crude products.
- the apparatus is assembled, swelled with 3 mL of DMF, and drained as set forth in Example 1.
- the reaction tubes are submerged into wells containing a solution of 75.0 mg BOC 4-hydroxyproline cesium salt in 5 mL of DMF.
- the apparatus is assembled and sealed with clamps as set forth in Example 1, and placed into an oil bath over a magnetic stirring plate while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2 and reacted at 50 oC. After 24 hours, the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tube array is subjected to the standard wash cycle set forth in Example 1, ending however in CH 2 Cl 2 , to remove residual reagents and byproducts.
- reaction tubes are submerged in reaction wells containing a solution of 5 mL of 0.07 M acyl halide (either, benzoyl bromide, acetyl chloride, 4-biphenylcarbonyl chloride, p-anisoyl chloride, 4-chlorobenzoyl chloride, 4-nitrobenzoyl chloride, pivaloyl chloride, or trifluoroacetyl chloride) and 0.07 M triethylamine in CH 2 Cl 2 .
- the apparatus is sealed as set forth in Example 1 and agitated as above while maintaining a positive nitrogen flow through the manifold. After 72 hours, the reaction tube array is drained and sparged as set forth in Example 1, using DMF, methanol, and CH 2 Cl 2 .
- the reaction tubes are submerged in 5 mL of
- Three dispersion tubes are loaded each with 100 ⁇ 5 mg of hydroxymethyl polystyrene resin (1% cross-linked, 1.0 meq/g, loading) and placed in the holder block.
- the apparatus is assembled, swelled with 3 mL of acetonitrile, and drained as set forth in Example 1.
- the appropriate reaction tubes are submerged in reaction wells containing 2 mL of a solution of either 0.2 M acetic anhydride, propanoic anhydride, or 2-phenylacetic anhydride in acetonitrile, and 1.0 mL of a 0.4 M solution of triethylamine in CH 2 Cl 2 .
- the apparatus is sealed as set forth in Example 1, and agitated in a sonic bath while maintaining a positive nitrogen flow through the manifold for 12 hours.
- the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 10 ⁇ 4 mL of CH 2 Cl 2 .
- reaction tubes are submerged in reaction wells containing 3 mL of a solution of 0.2 M lithium diisopropylamide in THF and the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at room temperature as set forth in Example 5, while maintaining a positive nitrogen flow through the manifold for 4 hours.
- reaction tubes are washed as set forth in Example 3, using 10 ⁇ 4 mL of CH 2 Cl 2 .
- reaction tubes are submerged in reaction wells containing 2.0 mL of a 0.26 M THF solution of diethyl methoxy borane and the apparatus is sealed as set forth in Example 1.
- 1.0 mL of a 1.0 M THF solution of sodium borohydride is added to the top of the appropriate reaction tubes through the gasket at the top of the manifold and the apparatus is sonicated at room temperature for 4 hours as set forth in Example 5.
- the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 10 ⁇ 4 mL of CH 2 Cl 2 .
- the reaction tubes are submerged in reaction wells containing 3.0 mL of 3% hydrogen peroxide in 1:1 dioxane:water and the apparatus is assembled as set forth in Example 1, and sonicated at room temperature for 6 hours as set forth in Example 5 to affect boron oxidation.
- the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 10 ⁇ 3 mL of dioxane:water (1:1).
- the reaction tubes are submerged in reaction wells containing a solution of 0.1 M HCl in 1:1 dioxane:water (3 mL).
- the apparatus is assembled as set forth in Example 1, and sonicated at room temperature for 6 hours as set forth in Example 5 to affect hydrolysis/ring closure.
- the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in
- Example 3 using 3 ⁇ 3 mL of dioxane:water (1:1). The appropriate filtrates are then combined and concentrated as set forth in Example 3 to give the three individual expected lactone products.
- reaction tubes are submerged in reaction wells containing a solution of 0.09 M 4-chlorobutyric acid or 3-chloropropionic acid; and 0.09 M N,N'-diisopropylcarbodiimide and 0.09 M 4,4-dimethylaminopyridine in DMF (3 mL) at room temperature.
- the apparatus is sealed as set forth in Example l and agitated in a sonic bath for 2 hours, while maintaining a positive nitrogen flow through the manifold.
- the reaction tube array is drained and sparged as set forth in Example 1.
- the reaction tube array is subjected to the standard wash cycle set forth in Example 1.
- the appropriate reaction tubes are submerged in reaction wells containing a solution of 3 mL of either 0.09 M piperazine, phenylpiperazine, or 1-(2-pyridyl)piperazine; 0.18 M potassium carbonate; and 0.18 M potassium iodide in DMF.
- the apparatus is sealed as set forth in Example 1, placed in an oil bath, and heated at 95 to 100°C while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. After 6 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tube array is subjected to the standard wash cycle set forth in Example 1.
- the appropriate reaction tubes are submerged in reaction wells containing a solution of 3 mL of toluene-20% 1,2-dimethoxyethane at 0°C.
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at 0'C as set forth in Example 5, while maintaining a positive argon flow.
- THF 0.15 M trityllithium
- Example 5 After 15 minutes, 0.5 mL of 0.28 M acid chloride (either nicotinoyl chloride or naphthoyl chloride) in THF is added to the top of the appropriate reaction tubes through the gasket at the top of the manifold and sonicated at room temperature for 1 hour as set forth in Example 5. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
- 0.28 M acid chloride either nicotinoyl chloride or naphthoyl chloride
- the reaction tube array is subjected to the standard wash cycle set forth in Example 1.
- the reaction tubes are submerged in reaction wells containing a solution of 3 mL of dry HBr in TFA.
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath while maintaining a positive nitrogen flow through the manifold. After 1 hour, the reaction is stopped, and the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 1, using 3 mL portions of methanol.
- the methanol extraction protocol is repeated until the filtrates are free of any organic components as determined by TLC
- a modified Wolff-Kishner reduction is done on half of the amount of each of the isolated compounds.
- the compounds are placed in the appropriate reaction wells containing
- Example 1 3 mL of 0.09 M potassium hydroxide, and 0.09 M hydrazine hydrate in diethylene glycol.
- the reaction tubes are filled with 0.5 g sodium sulfate (to absorb water) and submerged in the reaction wells .
- the apparatus is sealed as set forth in Example 1, placed in an oil bath, and heated at 80°C while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. After 12 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1. Each product is isolated by adding
- Example 11 is a solution of 1:1 water:CH 2 Cl 2 . Each organic layer is separated, dried, and concentrated as set forth in Example 8 to yield another 12 desired products.
- Example 11
- reaction tubes 0.66 meq/g, 200-400 mesh
- the apparatus is assembled, swelled with 3 mL of dioxane and drained as set forth in Example 1.
- the appropriate reaction tubes are submerged in reaction wells containing a solution of 5 mL of either 0.2 M thiosalicylic acid, 5-chloro-thiosalicylic acid, or 2-mercaptonicotinic acid; and 0.4 M triethylamine in dioxane and magnetic stirring bars.
- the apparatus is sealed with clamps as set forth in Example 1 and placed over a magnetic stirring plate, while maintaining a positive nitrogen flow through the manifold. After 96 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 3 ⁇ 3 mL each of water, 1N HCl, 1N HCL:dioxane (1:1), and finally dioxane to remove residual reagents and byproducts.
- the reaction tubes are submerged in reaction wells containing a solution of 5 mL of 0.20 M carbonyldiimidazole in dioxane.
- the apparatus is assembled and agitated as above. After 5 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
- the reaction tubes are washed as set forth in Example 3, using 4 ⁇ 3 mL each of DMF then dioxane.
- the appropriate reaction tubes are submerged in reaction wells containing a solution of 5 mL of either 0.20 M 4-methoxyaniline, cyclohexylamine, or benzylamine in dioxane.
- the apparatus is assembled as set forth in Example 1, while maintaining a flow of cold nitrogen.
- the apparatus is placed in an oil bath over a magnetic stirring plate and the reactions are warmed to reflux and stirred as above. After 24 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
- the reaction tubes are washed as set forth in
- Example 3 using 4 ⁇ 3 mL each of DMF, methanol, CH 2 Cl 2 , and then dioxane.
- reaction tubes are submerged in reaction wells containing a solution of 5 mL of 0.13 M NaBrO 2 in dioxane/water (8:1).
- the apparatus is assembled as set forth in Example 1, while maintaining a flow of nitrogen.
- the apparatus is placed over a magnetic stirring plate and stirred at room temperature as above. After 1 hhur, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 4 ⁇ 3 mL each of dioxane, water, dioxane/water (1:1), methanol, and then CH 2 Cl 2 . Cyclization to the final product and thus cleavage from the resin is accomplished by addition of trichloroacetic anhydride to the sulfoxide and rearrangement as taught by Wright, et al, Tetrahedron Letters 1991; 33:153. Thus, reaction tubes are submerged in reaction wells containing a solution of 5 mL of CH 2 Cl 2 . The apparatus is assembled as set forth in Example 1, while maintaining a flow of nitrogen. The apparatus is then placed in a cold bath at 0°C and the reactions stirred as above.
- Trichloroacetic anhydride (0.18 mL) is then added to the top of each reaction tube through the gasket at the top of the manifold and the temperature of the reaction is allowed to warm to 25°C over 7 hours.
- the reaction tube array is drained and sparged as set forth in Example 1.
- Example 3 The reaction tubes are washed as set forth in Example 3, using 2 ⁇ 3 mL each of CH 2 Cl 2 , dioxane, MeOH, and CH 2 Cl 2 . The appropriate filtrates are then combined and concentrated as set forth in Example 3. These crude products are partitioned between CH 2 Cl 2 and 2N NaOH using a Tecan ® robot to deliver the necessary liquids and to remove the aqueous layer. The basic aqueous wash is repeated and the residual CH 2 Cl 2 layers are dried by passing the samples through a bed of MgSO 4 contained in standard SPE cartridges employing the vacuum SPE apparatus described above to yield the crude benzisothiazolones. Exmpte 12
- reaction tubes are submerged in reaction wells containing a solution of 5 mL of either 0.20 M 3-imino-1-oxoisoindoline, 6-chloro-3-imino-1-oxoisoindoline, or 6-phenyl-1-oxoisoindoline in diglyme with stirring magnetic bars.
- the 3-imino-1-oxoisoindoline employed are prepared by the method of Wrobel, et al, JOURNAL OF MEDICINAL CHEMISTRY 1992; 35:4613.
- the apparatus is sealed with clamps as set forth in Example 1, and placed in an oil bath over a magnetic stirring plate while maintaining a positive flow of cold nitrogen as set forth in Example 2.
- the reaction vessels are warmed to reflux, and after 2 hours the reaction is stopped, and the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 3 ⁇ 3 mL each of dioxane, CH 2 Cl 2 , and DMF.
- reaction tubes are submerged in reaction wells containing a solution of 0.20 M alkyl halide (either methyl iodide, benzyl bromide and 3-bromobenzyl bromide) and 1 mmol K 2 CO 3 in 5 mL of DMF.
- 0.20 M alkyl halide either methyl iodide, benzyl bromide and 3-bromobenzyl bromide
- 1 mmol K 2 CO 3 in 5 mL of DMF.
- reaction tubes are washed as set forth in Example 3, using 3 ⁇ 3 mL each of DMF, water, MeOH, dioxane, CH 2 Cl 2 , and DMSO.
- reaction tubes are submerged in reaction wells containing a solution of 5 mL of 0.20 M potassium cyanide in DMSO.
- the apparatus is assembled as set forth in Example 1 and agitated as above. After 24 hours at 25°C, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
- the reaction tubes are washed as set forth in Example 3, using 3 ⁇ 3 mL each of DMF, water, MeOH, water, and 10% aqueous HCl.
- the reaction tubes are submerged in reaction wells containing a solution of saturated dry HCl in MeOH.
- the apparatus is assembled as set forth in Example 1 and agitated as above. After 3 days at 25°C, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 3 ⁇ 3 mL each of MeOH, dioxane, and CH 2 Cl 2 .
- the appropriate filtrates are then combined and concentrated as set forth in Example 3.
- Example 1 The crude products are dissolved in glacial HOAc and a holder block with nine clean empty reactions tubes is attached.
- the apparatus is assembled as set forth in Example 1 and agitated as above. After 24 hours at 25°C, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 3 ⁇ 3 mL of MeOH.
- Example 13 The appropriate filtrates are then combined and concentrated as set forth in Example 3 to yield the crude spiro[1H-isoindole-1,3'-pyrolidine]-2',3,5'(2H))triones.
- Example 13
- FMOC-histidine methyl ester is coupled to the resin.
- the reaction tubes are submerged in reaction wells containing a solution of 0.2 M FMOC-histidine methyl ester and 0.4 M pyridine in 3 mL dry THF.
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath for 6 hours, while maintaining a positive nitrogen flow through the manifold.
- the reaction tube array is drained and sparged as set forth in Example 1.
- the reaction tube array is subjected to the standard wash cycle set forth in Example 1.
- reaction tubes are submerged in reaction wells containing 3 mL of a solution of 25% piperidine in DMF.
- the apparatus is sealed as set forth in Example 1 and placed in a sonic bath, while maintaining a positive nitrogen flow through the manifold.
- the reaction is stopped after 4 hours.
- the reaction tube array is drained and sparged as set forth in Example 1.
- the reaction tube array is subjected to the standard wash cycle set forth in Example 1.
- reaction tubes are submerged in reaction wells containing a solution of 0.2 M anhydride (either acetic anhydride or isobutyric anhydride) and 0.4 M triethylamine in 3 mL of dry THF.
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath for 12 hours, while maintaining a positive nitrogen flow through the manifold.
- the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tube array is subjected to the standard wash cycle set forth in Example 1.
- the apparatus is sealed as set forth in Example 1 while maintaining a positive nitrogen flow through the manifold.
- a solution of lithium aluminum hydride (LAH) in dry THF (0.1 M, 3 mL) is then added to the top of each reaction tube through the gasket at the top of the manifold.
- the apparatus is placed in an oil bath heated at 67°C for 8 hours, while maintaining a positive chilled nitrogen flow through the manifold (as set forth in Example 2).
- the apparatus is cooled to room temperature and 1 mL of water is added to the top of each reaction tube through the gasket at the top of the manifold, and the apparatus sonicated at room temperature for 30 minutes to neutralize any unreacted
- reaction tube array is drained and sparged as set forth in Example 1.
- reaction tube array is subjected to the standard wash cycle set forth in Example 1, except that a base wash cycle is added to remove the neutralized LAH salts.
- the cyclic carbamate is formed according to the method of Gonzalez, et al, TETRAHEDRON LETTERS 1989; 30: 2145.
- the reaction tubes are submerged in reaction wells containing a solution of 0.2 M diethyl carbonate and 0.4 M NaOMe in MeOH.
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath for 12 hours, while maintaining a positive nitrogen flow through the manifold.
- the reaction tube array is drained and sparged as set forth in Example 1.
- the reaction tube array is subjected to the standard wash cycle set forth in Example 1.
- the appropriate reaction tubes are submerged in reaction wells containing a solution of 0.2 M iodoalkane (either 1-iodohexane, or iodomethane) in 3 mL of CH 2 Cl 2 .
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath while maintaining a positive nitrogen flow through the manifold for 1 hour.
- the apparatus then placed in an oil bath heated at 37°C, while maintaining a positive chilled nitrogen flow through the manifold (as set forth in Example 2) for 6 hours.
- the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tube array is subjected to the standard wash cycle set forth in Example 1.
- reaction tubes are submerged in reaction wells containing a solution 3 mL each of MeOH.
- the apparatus is sealed as set forth in Example 1, placed in an oil bath and heated at 64°C while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2.
- the reaction tube array is allowed to cool and then drained and sparged as set forth in Example 1.
- Example 14 The reaction tubes are washed as set forth in Example 1, using 3 mL portions of methanol. The methanol extraction protocol is repeated until the filtrates are free of any organic components as determined by TLC (2 times). The appropriate methanol filtrates are then combined and concentrated on a Speed-Vac ® in tared vials to afford four discrete products.
- Example 14
- reaction tubes are submerged in reaction wells containing a solution of nBuLi (1 eq) in THF at 0°C.
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath (maintained at 0°C as set forth in Example 5), while maintaining a positive nitrogen flow through the manifold. After 1 hour, the bath is warmed to room temperature and sonicated for 3 hours more. The bath is then recooled to 0°C and a solution of either cyclohexyl- or phenyl- ethyleneoxide (2 eq) in THF (0.5 mL) is then added to the top of the appropriate reaction tube through the gasket at the top of the manifold.
- the bath is again warmed to room temperature and sonicated for 2 hours.
- the apparatus is then removed from the sonic bath, and 0.5 mL of THF:H 2 O (1:1) are added to the top of each reaction tube through the gasket at the top of the manifold as above, to quench any excess n-BuLi.
- the reaction tube array is drained and sparged as set forth in Example 1.
- the reaction tubes are washed as set forth in
- Example 3 using 3 ⁇ 3 mL each of dioxane: sat NH 4 Cl (1:1), dioxane:H 2 O (1:1), and dioxane.
- reaction tubes are submerged in reaction wells containing a solution of (2 eq) of either bromoacetaldehyde dimethyl acetal (4 reaction tubes) or [(formylamino)methyl]acetaldehyde dimethyl acetal (2 reaction tubes); and BF 3 OEt 2 (3 eq) in Et 2 O (3 mL) at 0°C.
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at room temperature for 24 hours, while maintaining a positive nitrogen flow through the manifold.
- the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 3 ⁇ 3 mL each of dioxane:H 2 O (1:1), dioxane:H 2 O 0.1N NaOH (1:1), dioxane:H 2 O (1:1), dioxane.
- the appropriate four reaction tubes are submerged in reaction wells containing a solution of either allylamine or benzylamine (2 eq) in dioxane (4 mL) at room temperature.
- reaction tubes (those which are reacted with [(formylamino)methyl]-acetaldehyde dimethyl acetal above) are submerged in wells containing a solution of dioxane:MeOH: 15% NaOH (2:2:1) 5 mL at room temperature.
- the apparatus is sealed as set forth in Example l and agitated in a sonic bath at 60°C as set forth in Example 5, while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. After 8 hours the reaction is stopped, the reaction tube array is allowed to cool, and then drained and sparged as set forth in Example 1.
- the reaction tubes are washed as set forth in
- Example 3 using 3 ⁇ 2 mL each of dioxane, dioxane:H 2 O (1:1), dioxane.
- reaction tubes are submerged in reaction wells containing a solution of 3 mL of 5 M HCl in dioxane: ethanol (1:1).
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at 80°C for 4 hours as set forth in Example 5, while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2.
- the reaction tube array is allowed to cool, and then drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 3 ⁇ 3 mL of dioxane:ethanol (1:1). The filtrates are then combined and concentrated as set forth in Example 3. The crude products are then redissolved, transferred to tared vials, and reconcentrated.
- the final crude products including, cis-1-(aminomethyl)-3-cyclohexyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride; cis- 1 -(aminomethyl)-3-phenyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride; cis-1-[(allylamino)methyl]-3-cyclohexyl-3,4-dihydro-5,6-dihydroxy-1H-2 -benzopyranhydrochloride; cis-1-[(allylamino)methyl]-3-phenyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyranhydrochloride; cis -1-[(benzylamino)methyl]-3-cyclohexyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyranhydrochloride; cis -1
- reaction tubes 95 to 105 mg of the acrylate ester resin prepared above is measured into each of eight gas dispersion tubes (reaction tubes).
- the reaction tubes are fitted into the holder block and swelled and drained as set forth in Example 1.
- reaction tubes are submerged in reaction wells containing a solution of either cyclohexylamine or n-hexylamine (1 eq) in 3 mL of DMF at room temperature.
- the apparatus is sealed as set forth in Example l and agitated in a sonic bath (maintained at room temperature as set forth in Example 5), while maintaining a positive nitrogen flow through the manifold.
- a solution of diethyl oxalate (1 eq) and Na 2 CO 3 (1 eq) in 1 mL of DMF is added to the top of the each reaction tube through the gasket at the top of the manifold.
- the bath is warmed to 60°C and sonicated for 2 hours.
- the reaction tube array is allowed to cool and then drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 3 ⁇ 2 mL each of dioxane: sat. NH 4 Cl (1:1), dioxane:1N HCl (1:1), dioxane:H 2 O (1:1), and dioxane.
- the appropriate reaction tubes are submerged in reaction wells containing a solution of (1 eq) of either 5-phenylpyrazol-3-amine or 5-(4-chlorophenyl)pyrazol-3-amine in HOAc (4 mL) at room temperature.
- Example 1 The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at 100°C for 2 hours as set forth in Example 5, while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. At the end of the reaction, the reaction tube array is allowed to cool and then drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 3 ⁇ 2 mL of dioxane:ethanol.
- the filtrates are then combined and concentrated as set forth in Example 3.
- the crude products are then redissolved, transferred to tared vials, and reconcentrated.
- a solution of either 2-chloroacetophenone (2 eq) and K 2 CO 3 (1.1 eq) in DMF (3 mL) or 1-bromo-5-hexene (2 eq) and K 2 CO 3 (1.1 eq) in DMSO (3 mL) is added to the appropriate reaction wells.
- a holder block with clean empty reaction tubes is added and the apparatus is sealed and agitated as set forth in Example 1 in a sonic bath at 40°C for 22 hours as set forth in Example 5, while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2.
- the reaction tube array is allowed to cool and then drained and sparged as set forth in Example 1
- the crude reaction mixtures are transferred to the corresponding tubes in the SPE apparatus equipped with 20 mL columns and 5 ⁇ m. filters. Each reaction mixture is diluted and mixed with 15 mL of H 2 O to precipitate the desired products. The suspensions are then filtered and washed with H 2 O and Et 2 O (3 ⁇ 2 mL, each). The resulting solids are then dissolved with CH 2 Cl 2 (3 ⁇ 2 mL washes) run through the filter and collected in clean tubes. These solutions are then concentrated as set forth in Example 3. The crude products are then redissolved, transferred to tared vials, and reconcentrated.
- the final crude products including, 6-Cyclohexyl-6,7-dihydro-4-(phenylmethyl)-2-phenyl-4H-pyrazolo[1,5a]pyrrolo[3,4-d]-pyrimidine- 5,8-dione; 6-Cyclohexyl-6,7-dihydro-4-(2-oxo- 2-phenylethyl)-2-phenyl-4H-pyrazolo[1,5-a]pyrrolo[3,4-d]-pyrimidine-5,8-dione; 6-Cyclohexyl-6,7-dihydro- 4-(phenylmethyl)-2-(4-chlorophenyl)-4H-pyrazolo[1,5-a]pyrrolo[3,4-d]-pyrimidine-5,8-dione; 6-Cyclohexyl- 6,7-dihydro-4-(2-oxo-2-phenylethyl)-2-(4-chlorophenyl)-4
- a solution (5 mL) of either 0.20 M 6-phenyl-4,6-dioxohexanoic acid, or 6-(4-chlorophenyl)-4,6-dioxohexanoic acid and 0.20 M carbonyldiimdazole in CH 2 Cl 2 are stirred for 6 hours at room temperature.
- the two6-aryl-4,6-dioxohexanoic acids employed are prepared by the method of Murray, et al, JOURNAL OF ORGANIC CHEMISTRY1990;55:3424.
- reaction tubes are submerged in the reaction wells above.
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath while maintaining a positive nitrogen flow through the manifold. After 12 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1. The reaction tubes are washed as set forth in
- Example 3 using 3 ⁇ 3 mm each of DMF, MeOH, dioxane, CH 2 Cl 2 , and MeOH.
- reaction tubes are submerged in reaction wells containing a solution of 5 mL of either 0.2 M 4-methoxyphenylhydrazine hydrochloride or 4-methylphenylhydrazine hydrochloride and 0.2 M triethylamine in MeOH.
- the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath, while maintaining a positive nitrogen flow through the manifold. After 12 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
- reaction tubes are washed as set forth in Example 3, using 3 x 3 mL each of DMF, MeOH, dioxane, and CH 2 Cl 2 .
- Cleavage is accomplished by aminolysis of the resin ester linkage.
- the appropriate reaction tubes are submerged in reaction wells containing a solution of 5 mL of either 0.20 M methylhydroxylamine hydrochloride or benzylhydroxylamine hydrochloride and 0.2 M triethylamine in CH 2 Cl 2 along with stirring bars.
- the apparatus is sealed with clamps as set forth in Example 1 and placed in an oil bath over a magnetic stirring plate while maintaining a positive flow of cold nitrogen as set forth in Example 2.
- the reaction vessels are warmed to reflux and stirred as above. After 24 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
- the reaction tubes are washed as set forth in
- Example 3 using 3 x 3 mL each of MeOH, dioxane, and CH 2 Cl 2 .
- Example 3 The appropriate filtrates are then combined and concentrated as set forth in Example 3. These crude products are partitioned between CH 2 Cl 2 and 1 M HCl using a Tecan ® robot to deliver the necessary liquids and to remove the aqueous layer. The acidic aqueous wash is repeated and the residual CH 2 Cl 2 layers are dried by passing the samples through a bed of MgSO 4 contained in standard SPE cartridges employing the vacuum SPE apparatus described above to yield tepoxalin and the expected tepoxalin derivatives.
- BB N represents the building blocks which are bifunctional to allow sequential attachment.
- the curved structure represents the solid support where the asterick is the functionality capable of covalently attaching the growing molecule to the solid support.
- Cleavage 1 represents the third building block attacking the solid support linkage to cleave the final molecule. This provides structural vaiation at the former site of attachment to the support.
- Cleavage 2 represents a distal functionality attacking the solid support linkage to cleave the final molecule as a cyclized product.
- Cleavage 3 represents a cleavage by an invariant agent. This provides a constant functional group at the former site of attachment to the support.
- the invention of the '483 patent describes the use of apparatus which facilitates the simultaneous introduction of multiple reagents to reaction or test wells.
- the invention described herein is applicable to a technique which permits the multistep, multireagents to obtain mixtures of unique reaction products.
- a 2-step reaction utilizing four building blocks for the manufacture of amides can be described below (Schemes 17 and 18 and Tables 17 and 18).
- P indicates polymeric support and the letters A, B, C, or D indicate reactants and the numbers 1, 2, 3, or 4 likewise indicate reactants.
- In the X and Y-plates there are four wells in each. The materials are prepared as follows with the reagents being placed in each of the wells as described. The individual materials made in each of the wells follows what is called a deconvolution technique. Convolute means to be coiled or wound together. Deconvolute therefore means the uncoiling or the unwinding of the mixture. In the present case, deconvolution means the ascertaining of the unique reaction product in the reaction or test wells containing the mixture of the products. Listed below (Scheme 19 and Table 17) is a proposed synthesis route and technique to deconvolute the products.
- a number of reaction vessels equal to the total number of wells to be synthesized by the array method are loaded with 1-1000 mg of the appropriate functionalized solid support, preferably 1-3% cross-linked polystyrene.
- the individual reaction vessels are charged with a volume, preferably 3-5 mL, of a solvent capable of swelling the polystyrene resin (such as, but not limited to, dichloromethane, chloroform, dimethylformamide (DMF), dioxane, toluene, tetrahydrofuran (THF)).
- a solvent capable of swelling the polystyrene resin such as, but not limited to, dichloromethane, chloroform, dimethylformamide (DMF), dioxane, toluene, tetrahydrofuran (THF)
- reaction vessels are emptied of solvent and the proper reactant solutions are dispensed into the reaction vessels at appropriate locations in the array. If the reactant is actually one of the building blocks that is to become covalently attached to the growing compound on the solid support, the quantity of reactant is usually 0.1-100 equivalents based on the meq/g loading of functionalized solid support (typically 0.1 - 1.0 meq/g for polystyrene resins) originally weighed into the reaction tube. If a mixture of reactants are charged to single resin-bound starting material or intermediate to generate a mixture of resin-bound or cleaved products, equimolar amounts of each reagent are preferable.
- each reactant should provide some quantity of each target compound in the final mixture , allowing for differing reaction kinetics of individual reactants. Additional equivalents of single or multiple reactants can be used if required to drive the reaction to completion in a reasonable time. Agitation is achieved by shaking, sonication, or magnetic stirring. The reaction is allowed to proceed for an amount of time deemed necessary from the preliminary validation experiments or monitored by removal and quantitative analysis of filtrate aliquots from selected wells by methods such as GC/ISTD (internal standard) or HPLC/ISTD.
- GC/ISTD internal standard
- HPLC/ISTD HPLC/ISTD
- the resin-bound intermediates within each reaction vessel are washed clean of excess retained reagents, solvents, and by-products by repetitive exposure to clean solvent (s).
- the washing procedure is repeated 1-50 times, monitoring the efficiency of reagent, solvent, and byproduct removal by methods such as TLC, GC, or visualization of the wash filtrates.
- Detachment of the final products from the solid support is achieved with a solution of a cleavage reagent (preferably 3-5 mL). Gas flow, temperature control, agitation, and reaction monitoring are implemented as above and as desired to affect the detachment reaction.
- the spent resin in the reaction vessels is then washed 2-5 times as above with 3-5 mL of an appropriate solvent to extract (wash out) as much of the detached products as possible.
- the final product solutions are combined, taking care to avoid cross-mixing.
- the individual solutions/extracts are then manipulated as needed to isolate the final compounds.
- Typical manipulations include, but are not limited to, evaporation, concentration, liquid/liquid extraction, acidification, basification, neutralization or additional reactions in solution.
- the apparatus was assembled, nitrogen atmosphere was initiated, and 10 mL of DMF was injected into each reaction tube.
- the appropriate carboxylic acids were injected as solutions into each reaction tube.
- a solution of the mixture of the carboxylic acids was made by combining 1.0 mL each of 0.52M 2-ethyl butyric acid in DMF, 0.52M 2-propyl pentanoic acid in DMF, 0.52M diphenylacetic acid in DMF, and 0.52M bis-(p-chlorophenyl)-acetic acid in DMF.
- the resultant mixture contained an equimolar concentration of each carboxylic acid.
- 1.0 mL of the dissolved acid mixture was dispensed into each reaction tube in plate Y (Y1-Y4) to provide 0.25 equivalents each of 2-ethyl butyric acid, 2-propyl pentanoic acid, diphenylacetic acid, and bis-(p-chlorophenyl)-acetic acid in each reaction tube, based upon indicated loading of commer cial resin.
- the apparatus was agitated at 20-25 oC in a sonic bath for 48 h, while maintaining a positive nitrogen flow through the manifold. At the end of the reaction, the reaction tube array was drained and sparged with nitrogen.
- reaction tubes were subjected to a series of wash cycles to remove residual solvents, reagents, and byproducts.
- a standard protocol included sequentially submerging the reaction tubes in 10-15 mL each of 2 ⁇ DMF, 2 ⁇ methanol, 2 ⁇ water, 2 ⁇ tetrahydrofuran (THF), and 2 ⁇ dichloromethane (DCM) followed by agitation by ultrasound for 10-15 minutes, and finally draining by gravity and nitrogen sparge.
- the apparatus was assembled, argon atmosphere was initiated, and 10 mL of anhydrous toluene was delivered into each reaction tube.
- a 1.0 mL solution of boron tribromide solution in DCM (1.0 m) was injected into each reaction tube.
- the apparatus was agitated in a sonic bath for 1.5 h, while maintaining a positive argon flow through the manifold.
- the appropriate amines were injected as solutions in toluene into each reaction tube.
- a solution mixture of the amines was made by combining 1.0 mL each of 0.52M benzylamine in toluene, 0.52M diethylamine in toluene, 0.52M aniline in toluene, and 0.52M cyclohexylamine in toluene.
- the resultant mixture contained an equimolar concentration of each amine.
- 1.0 mL of the dissolved amine mixture was dispensed into each reaction tube in plate Y (Y1-Y4) to provide 0.25 equivalents each of benzylamine, diethylamine, aniline, and cyclohexylamine in each reaction tube, based upon indicated loading of commercial resin.
- the apparatus was agitated at 20-25 oC in a sonic bath for 48 h, while maintaining a positive argon flow through the manifold. At the end of the reaction, the reaction tube array was drained and sparged with nitro- gen.
- reaction tubes were sequentially submerged in reaction wells containing 10 mL each of toluene and DCM.
- the apparatus was agitated in a sonic bath for 10-15 minutes to extract the amides from the resins then drained by gravity and nitrogen sparge.
- a second extraction protocol with 5 mL each of 1M HCl was executed to thoroughly remove ureacted amines.
- FIG. 1 Shown in Figure 1 are proposed combination statistics demonstrating the number of building blocks per step, namely, 4, 5 or 6 building blocks. Further indicated are the total number of reaction wells that may be utilized as well as the total number of compounds that may be produced. The small black box indicates the number of compounds per well.
- Table 18 shows the combinatorial statistics that may be obtained utilizing the techniques of the present invention, namely that combinations of mixtures of materials are synthesized and a rapid technique can be obtained for testing high numbers of different materials for biological or other activity.
- the screens can be used for determining a variety of biological activities as well as other utilities such as rust remover activity, ability to die textile materials, ability to clean substrates, ability to decompose in the presence of soil bacteria, ability to hybridize to a library of genes, ability to detect sunscreen activity, ability to detect immune response to mammals, ability to detect the presence or absence of a gene associated with a malady, ability to detect the activity of a gene associated with a biological response in mammals, ability to detect permeability of a membrane such as a cell, ability to detect signal transduction of a cell, ability to bind to a cell, ability to bind to an enzyme, ability to bind to an antibody, and the like.
- rust remover activity ability to die textile materials, ability to clean substrates, ability to decompose in the presence of soil bacteria, ability to hybridize to a library of genes, ability to detect sunscreen activity, ability to detect immune response to mammals, ability to detect the presence or absence of a gene associated with a malady, ability to detect the activity of
- the present invention is equally applicable to determining an optimized dosage or weight for active compounds.
- the present invention can assist in quantitatively determining active materials and their degree of activity. In this manner, identical or differential amounts of a compound(s) to be tested are placed in various unique well locations.
- each well corresponds to a unique building block used in forming the compounds.
- each compound to be analyzed is formed in N steps; in other words, each compound consists of N building blocks.
- Each of the building blocks can be represented by a variable B ij , where i is an index variable which indicates the step for which the building block B ij is employed in forming a compound.
- An index variable j is used to distinguish between m different building blocks which can be used for each step i.
- step 1 used in step 1 used in step 2 used in step N
- Each compound can be represented by a string formed by concatenating N building block variables, i.e., exactly one building block from each of the above groups. For example, ⁇ B 11 B 24 B 33 ... B N2 ⁇ represents one of the compounds.
- the current embodiment arranges the wells on separate plates as follows:
- plate 1 corresponds to the first building block
- plate 2 corresponds to the second building block
- plate N corresponds to the Nth building block.
- the method of deconvolution can be summarized as follows: using the observed hits, form all possible combinations of these observed hits using exactly one hit per plate. The potentially active components are then represented by these combinations.
- the potentially active compound is ⁇ B 11 B 21 B 32 ⁇ .
- the potentially active compounds are ⁇ B 11 B 21 B 32 ⁇ and ⁇ B 11 B 22 B 32 ⁇ .
- the method of the present invention allows the testing of m N different compounds using mN total wells.
- the resulting fraction of wells per compound is mN/m N , which simplifies to N/m N-1 .
- the number of compounds in each well is m N-1 .
- Using N plates to separate the wells results in m wells per plate. The above can be applied to the testing shown in Tables 20 and 21 as follows.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Described is a method of synthesizing a plurality of compounds in a plurality of wells comprising the steps of: (a) providing a plurality of test wells in a plurality of arrays of the wells; (b) reacting in at least a one step reaction a first reagent with a plurality of reagents called building blocks in the test well to obtain a unique product designed to be the same in each array; and (c) continuing to react reagents such that there are multiple reagents resulting in mixtures of multiple different products in each well.
Description
A METHOD FOR THE SYNTHESIS
OF MIXTURES OF COMPOUNDS
Technical Field
The invention relates to a method for the synthesis of mixtures of compounds and, in particular, the multiple simultaneous synthesis of compounds.
Background Art
It is well known in the art that peptides or oligonucleotides may be multiply and simultaneously synthesized. In a basic, single synthesis of a peptide, amino acids are sequentially coupled in solution or on a functionalized solid support. Several methods have been developed by which peptides or oligonucleotides may be multiply synthesized. One such methodology for peptide synthesis was disclosed in Geysen et al., International Publication No.g WO 90/09395. Geysen's method involves functionalizing the termini of polymeric rods and sequentially immersing the termini in solutions of individual amino acids. A second method of peptide or oligonucleotide synthesis was developed by Affymax Technologies N.V. and disclosed in U.S. Patent No. 5,143,854. The Affymax method involves sequentially using light for illuminating a plurality of polymer sequences on a substrate and delivering reaction fluids to said substrate.
A further method and device for producing peptides or oligonucleotides is disclosed in Houghton, European Patent No. 196174. Houghton' s apparatus is a
polypropylene mesh container, similar to a tea-bag, which encloses reactive particles.
Combinatorial strategies for the synthesis of oligonucleotide mixtures are described in the paper by David J. Ecker, Timothy A. Vickers, Ronnie Hanecak, Vickie Driver and Kevin Anderson, entitled "Rational Screening of Oligonucleotide Combinatorial Libraries for Drug Discovery", NUCLEIC ACIDS RESEARCH, 1993, Vol. 21, No. 8, 1853-1856. The reference describes a technique known as synthetic unrandomization of randomized fragments which is based on repetitive synthesis and screening of increasingly simplified sets of oligonucleotide analogue pools. The technique is limited to oligonucleotides.
Another similarly limited approach is de- scribed in a paper by Colette T. Dooley and Richard A. Houghten, entitled "The Use of Positional Scanning Synthetic Peptide Combinatorial Libraries for the Rapid Determination of Opioid Receptor Ligands", LIFE SCIENCES, Vol. 52, pp. 1509-1517. This technique requires the resynthesis of potentially active individual components of the mixtures. Furthermore, this technique is limited to the sequentially constructed compounds such as peptides.
U.S. Patent No. 5,281,540 teaches a test array for performing assays. A semi-automated biological sample analyzer is described for simultaneously performing a plurality of enzyme immunoassays for human IgE class antibodies specific to a panel of preselected allergens in each of a plurality of biological samples. The technique, while having multiple biological samples in a well, uses a coating of an elongated cellulosic body such as a strip of paper which will contact the
multiple samples to ascertain which antibodies are specific for the coated allergens and which will then, in turn, bind to the appropriate bands or islands. The bands or islands are then analyzed for the presence of labeled antibodies. The technique describes testing done in a seriatim basis, namely, a number of samples, one after the other, even though multiple samples are present in a reaction vessel. The use of antibodies which bind to a specific sample is required for the system to be effective. The samples may be detected by use of optical reading capabilities.
Other patents that test multiple compounds in a seriatim fashion utilizing automated equipment are described in U.S. Patent Nos. 4,039,286 and 4,166,095. In the journal, INTERNATIONAL JOURNAL OF PEPTIDE
PROTEIN RESEARCH, 37, 1991, 487-493 entitled "General Method for Rapid Synthesis of Multicomponent Peptide Mixtures", A. Furka et al., a method is suggested for the synthesis of multicomponent peptide mixtures. The method is a solid phase synthesis modified in order to give a closely equimolar mixture of peptides with predetermined sequences. The main point of modification is that before every coupling cycle, the resin is divided into equal parts and each portion is coupled with a different amino acid. Then, the portions are mixed and before the next coupling cycle, the resin is again distributed into equal portions.
Another method is described in the journal,
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE, U.S.A., Vol .12 , pp. 5131-5135, August 1985, Immunology. The paper by
R.A. Houghton is entitled "General Method for the Rapid
Solid-Phase Synthesis of Large Numbers of Peptides:
Specificity of Antigen-Antibody Interaction at the Level of Individual Amino Acids". The paper indicates that 248 different 1,3-residue peptides representing single amino acid variance of a segment of the hemoglobulin hemaglutinin (HAI) protein were prepared and characterized in approximately 4 weeks. Through examination of the binding of these analogs to monoclonal antibodies raised against residues of HA1, it was found that a single amino acid, aspartic acid at position 101, is of unique importance to the interaction.
Publication No. WO91/17823, published November 28, 1991, describes a method and apparatus for synthesizing biopolymers such as polypeptides and polynucleotides. The apparatus includes plural reaction vessels in which subunit coupling to biopolymers in a particle suspension is carried out. The vessels are connected to common valving structure for use in mixing the suspension and removing suspension liquid.
"Encoded combinatorial chemistry" by S. Brenner et al., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, U.S.A., Vol. 89, pp. 5381-5383, June 1992, describes a method for drug screening. A process of alternating parallel combinatorial syntheses was used to encode individual members of a large library of chemicals with unique nucleotide sequences. After the chemical entity is bound to a target, the genetic tag can be amplified by replication and utilized for enrichment of the bound molecules by serial hybridization to a subset of the library. The nature of the chemical structure bound to the receptor is decoded by sequencing the nucleotide tag.
International Published Patent Application No. WO 9408711 A 1 (Warner Lambert Company) discloses an apparatus and method for multiple simultaneous synthesis. The patent indicates at column 14 that the final product solutions are combined, taking care to avoid cross-mixing. The individual solutions/extracts are then manipulated as needed to isolate the final compounds which compounds are individually tested for biologic activity. The problem that has arisen in the previous prior art techniques generally requires that the materials be physically separated or resynthesized for subsequent testing. Frequently, to ascertain the identification of active ingredients of testing requires a resynthesis of the original mixture.
It is an object of the present invention to accommodate multiple simultaneous synthesis of general organic compounds including, but not limited to, non-peptide or non-nucleotide compounds. It is another object of the present invention to synthesize mixtures of compounds, especially organic compounds. These mixtures may then be tested for activity, preferably biological activity without physical separation or resynthesis of unique products. It is also an object of the present invention after synthesis of unique compounds to be able to identify the precise unique compound that is prepared from the numerous compounds that are simultaneously prepared.
It is a further object of the present invention to describe a method for synthesizing a plurality of compounds utilizing a plurality of arrays of reaction wells or test zones and to be able to ascertain the unique products produced in each test zone without separating the mixture.
Summary Of The Invention
Described is a method of synthesizing and analyzing a plurality of compounds in a plurality of wells comprising the steps of: (a) providing a plurality of test wells in a plurality of arrays of the wells, (b) reacting in at least a one step reaction a first reagent with a plurality of reagents called building blocks in the test well to obtain a unique product designed to uniquely occur in each array, (c) continuing to react the same or different reagents such that there are multiple reagents resulting in multiple different products in each well. Preferably, the synthesis is by solid phase or traditional solution phase methods. Brief Description Of The Drawings
FIGURE 1 shows the combinatorial statistics for 4, 5 or 6 building blocks (reagents) and the number of compounds that may be synthesized per well.
Description OfPreferred Embodiments
The present invention is directed to a method which will provide a means to synthesize, analyze, and ascertain the individual components of the mixtures of organic compounds as they are synthesized. Additionally, the synthesis of inorganic compounds, organo metallic compounds, as well as other compounds, are within the scope of this invention.
Central to the demonstration of this technique is the need to devise a "general" method for synthesis, analysis, identification, and quantitiation of individual components of compound mixtures. The compounds may be synthesized simultaneously or sequentially and compatible with standard techniques of organic synthesis. Traditional solution phase or solid-phase techniques (commonly used in peptide or oligonucleotide synthesis) enable achievement of this criteria.
Typical solid supports (resins) include cross-linked divinylbenzene-styrene (polystyrene), controlled pore glass (CPG), polyacrylamides, poly (ethylene glycol) monomethyl ether and poly (ethylene glycol) (PEG), silica gel, cellulose, acrylic acid grafted polypropylene, and the like. Additionally, the solid support contains a reactive moiety. Thus, a functionalized solid support is an insoluble material containing an accessible reactive moiety such as, for example, a carboxylic acid, alcohol, amine, halomethyl, and the like which is used to covalently attach an incoming building block.
The approach described herein greatly increases the flexibility and diversity of structures that can be produced by a parallel, solid phase synthesis tech
nology. Since neither the building blocks nor the methods for connecting them are in any way limited, the chemistries compatible with this method are very broad, encompassing nearly all organic reactions. In particular, the steps to synthesize permits one to construct orthogonally overlapped compound mixtures such that each unique product within a mixture of compounds is synthesized in "n" unique mixtures, where "n" represents the number of reaction steps in a synthetic group.
The steps utilized to synthesize mixtures of compounds are: 1) development of a synthetic route that will be feasible in solution or on a solid support, 2) utilize the "mixed resin" or subequimolar reagent approach to generate mixtures of products or intermediates, and 3) construct orthogonally overlapped compound mixtures such that each unique product within a mixture of compounds is synthesized in n unique mixtures, where n represents the number of reaction steps in a synthetic route. The steps possible to analyze mixtures of compounds are: 1) construction of a compound mixture which contain products each with unique molecular weights, 2) qualitative analysis of each mixture by mass spectrometry technique to confirm the presence of each unique product, 3) analysis of each mixture by 1H NMR (nuclear magnetic resonance) or other analytical methods and comparison of spectra of different mixtures of compounds (computationally by addition or subtraction of spectra) to identify and confirm the presence of each desired product, and 4) quantitate the concentration of each unique product in the compound mixture utilizing a standard in combination with the 1H NMR.
The method involves the sequential coupling of building blocks to form soluble or resin-bound intermediates.
Reference is made to U.S. Patent No. 5,324,483 for the broad scheme outline for multiple simultaneous synthesis. This patent is incorporated by reference herein. The patent indicates a very detailed description of the synthesis of various materials described below. General Description Of Experimental Procedure
U.S. 5,324,483 description taught the synthesis of individual reaction products on a solid support. Extension of this method to the synthesis of mixtures would involve the simultaneous addition of multiple reagents at one or more steps during the synthesis. The reagents may be soluble or attached to a solid support.
As described in U.S. Patent No. 5,324,483, a number of reaction tubes equal to the total number of compounds to be synthesized by the array method are loaded with 1 to 1000 mg, preferably 100 mg, of the appropriate functionalized solid support, preferably 1 to 3% cross-linked polystyrene. The individual reaction tubes are inserted into a holder block. The reaction tubes, in combination with the holder block and a manifold, are inserted into the reservoir block so that each reaction tube is submerged in a volume, preferably 3 to 5 mL, of a solvent capable of swelling the polystyrene resin (such as, but not limited to, dichloromethane, chloroform, dimethylformamide (DMF), dioxane, toluene, tetrahydrofuran (THF), ethanol and the like). The polystyrene resin within the reaction tubes
is preferably agitated for 15 to 30 minutes to affect swelling. Swelling times of 5 to 600 minutes, with or without agitation are also within the scope of the invention. The reaction tubes, in combination with the holder block and manifold, are removed from the reservoir block and the excess solvent within the reaction tubes is allowed to drain, preferably by gravity, although gas pressure applied to the manifold inlet (while closing the outlet) can be used to expel the solvent, if desired.
The reaction wells are emptied of solvent and the proper reactant solutions are dispensed into the new or clean reaction wells at appropriate locations in the reservoir block. If the reactant is actually one of the building blocks that is to become covalently attached to the growing compound on the solid support, the quantity of reactant is usually 1 to 100 equivalents based on the milliequivalents per gram (meq/g) loading of functionalized solid support (typically 0.1 to 1.0 meq/g for polystyrene resins) originally weighed into the reaction tube. Additional equivalents of reactants can be used if required to drive the reaction to completion in a reasonable time. The reaction tubes, in combination with the holder block and manifold, are reinserted into the reservoir block and the apparatus is fastened together. Gas flow through the manifold is initiated to provide a controlled environment, for example, nitrogen, argon, air, and the like. The gas flow may also be heated or chilled prior to flow through the manifold. Heating or cooling of the reaction wells is achieved by immersing the reservoir block in water baths, oil baths, isopropanol/dry ice baths, sand baths, and the like to perform synthetic reactions. Agitation is achieved by shaking, sonication (preferred), or magnetic stirring
(within the reaction well or within the reaction tube). Reflux is achieved by circulating chilled gas through the manifold while heating the reaction wells in the reservoir block. Reactants may be injected directly into the reaction tubes through an injectable gasket on the top of the manifold. The reaction is allowed to proceed for an amount of time deemed necessary from the preliminary validation experiments or monitored by removal and quantitative analysis of filtrate aliquots from selected wells by methods such as GC/ISTD (internal standard) or HPLC/ISTD. If necessary, the complete assembly is allowed to return to ambient temperature, then the holder block and manifold, in combination with the reaction tubes, are detached from and raised above the reservoir block and the excess reagent solution is drained by gravity followed by gas pressure applied to the manifold inlet (while closing the outlet) to expel the excess reagents, solvents, and by-products. The resin-bound intermediate within each reaction tube is washed clean of excess retained reagents, solvents, and by-products by repetitive exposure to clean solvent (s) by one of two methods: 1) the reaction wells are filled with solvent (preferably 1-5 mL), the reaction tubes, in combination with the holder block and manifold, are immersed and agitated for 5 to 300 minutes, preferably 15 minutes, and drained by gravity followed by gas pressure applied through the manifold inlet (while closing the outlet) to expel the solvent; 2) the manifold is removed from the holder block, aliquots of solvent (preferably 5 mL) are dispensed through the top of the reaction tubes and drained by gravity through the filter into a receiving vessel such as a test tube or vial. Both of the above washing procedures are repeated 1 to 50 times (preferably 10 times), monitoring the efficiency of reagent, solvent, and byproduct removal by
methods such as TLC, GC, or visualization of the wash filtrates.
The above described procedure of reacting the resin-bound compound with reagents within the reaction wells followed by removal of excess reagents, byproducts, and solvents is repeated with each successive transformation until the final or penultimate resin-bound compound is prepared.
Detachment of the final product from the solid support is achieved by immersion of the reaction tubes, in combination with the holder block and manifold, in reaction wells containing a solution of the cleavage reagent (preferably 3-5 mL). Gas flow, temperature control, agitation, and reaction monitoring are implemented as above and as desired to affect the detachment reaction. The reaction tubes, in combination with the holder block and manifold, are disassembled from the reservoir block and raised above the solution level but below the upper lip of the reaction wells and gas pressure is applied through the manifold inlet (while closing the outlet) to efficiently expel the final product solution into the reservoir wells. The spent resin in the reaction tubes is then washed 2 to 5 times as above with 3 to 5 mL of an appropriate solvent to extract (wash out) as much of the detached product as possible. The final product solutions are combined, taking care to avoid cross-mixing. The individual solutions/extracts are then manipulated as needed to isolate the final compounds. Typical manipulations include, but are not limited to, evaporation, concentration, liquid/liquid extraction, acidification, basification, neutralization or additional reactions in solution.
The final compounds are individually tested for biological activity once they are isolated. For example, the method of Sweetnam, et al, Molecular Pharmacology 1986;29:299 employing bovine cortical membranes as a receptor source and a radiolabeled benzodiazepine, such as Flunitrazepam, to determine competitive ligand binding to the benzodiazepine receptor (central [brain] localized) and some quantitative measure of relative binding potency such as KD or IC50 values. Performing this type of assay serves two purposes: 1) to discover new compounds with biological activity in a given biological screening assay and 2) the development of a relationship between the structural variations contained within the series and biolog- ical potency. This second utility is known as development of a structure activity relationship (SAR). This type of assay can be done using the compounds isolated from the array synthesis for any receptor binding screen or assay (screening for receptor agonists or antagonists), enzyme functional assays (measuring competitive or noncompetitive inhibition of the catalyzed reaction), and the like.
This strategy may be used to screen for pharmaceutical agents, veterinary agents, agricultural agents, diagnostic reagents, and the like.
Typical compounds and pharmaceutical applications include: (l) nitrogen containing heterocyclic compounds; imidazopyridines having antiulcer or anxioly- tic activities, dihydropyridines having calcium antagonist activity, nucleoside and nucleoside analogs having antiviral activity, indazoles having 5HT3 antagonist activity, piperidines having antidopamine, antiserotonin, antidepressant, or antihistamine
activities, benzazepines having antiparkinsonism and antidopamine activities, indoles and condensed indoles with 5HT antagonist activities, quinolines and isoquinolines having anti-infective and antiulcer activities, pyrrolidines having anti-infective and antihypertensive activities, aminopyrimidines having antihypertensive activities, pyrrolizidines having antiarrhythmic activities, guanidines having anticancer activities, tetrazoles having antiallergenic; (2) oxygen containing heterocycles; benzopyrans having potassium agonist and antagonist activities, coumarins having antiplatelet aggregating and antithrombotic activities, prostaglandins and prostacyclins having antiplatelet, antiulcer, labor inducing activities, psoralens having antipsoriasis activities, tetrahydrofurans and pyrans having antidiabetic activity; (3) nitrogen and sulfur containing compounds; beta-lactams and cephalosporins having anti- infective activities; (4) carbocyclic compounds; tocopherol analogs having antipsoriasis activities, vitamin D analogs having antipsoriasis activities, steroids having anti-inflammatory, bronchiodilating, antihyperplasia and antifertility activities, naphthalenes having antifungal activities, anthracene analogs having anticancer activities; (5) alicyclic compounds; polyunsaturated alkenes having antithrombotic activities, hydroxypropanolamines having adrenergic blocking activities, benzofused bicyclic amines having analgesic activities, aryl amides having anesthetic, gastroprokinetic, antidepressant, and anti- inflammatory activities; and (6) cyclic peptides and cyclic nucleotide having anti-infective and antiautoimmune activities; and the like.
In alternative uses, the apparatus and methods may be implemented without using a solid support, for
example, standard solution techniques. An additional alternative use of the apparatus is for the optimization of chemical reactions, for example, reaction yields or reaction times, on solid supports or in solution. This use is accomplished by performing the same reaction in all reaction well locations but systematically determining and varying dependent reaction variables across the array. For example, the reagent concentration and/or reagent equivalency (mole percentage) can be varied from near zero to the maximum achievable with an undiluted reagent. Typically, one varies this variable from 0.001 to 25 mol. Reaction times can be varied within the array by withdrawal of the contents of the reaction well, followed by for example workup, and/or isolation, and/or purification, and/or quantitation of the final solution. Statistical experimental design strategies or quantitative structure activity relationship (QSAR) strategies may also be implemented to select a subset of locations within the original array which will provide the necessary information for final analysis and conclusions, therefore reducing the number of reactions necessary in the final array.
Synthesis of Dipeptides In the operation of the present invention, the synthesis of dipeptides is achieved using the apparatus and applying 9-fluorenylmethyloxycarbonyl (FMOC) strategy, as taught in Meienhofer, et al, INTERNATIONAL JOURNAL PEPTIDE PROTEIN RESEARCH 1979; 13: 35 and Atherton, et al, BIOORGANIC CHEMISTRY, 1979; 8:351 on a variety of commercially available polystyrene resins (see Table 1). For peptide acids the p-benzyloxy benzyl alcohol cross-linked divinylbenzene-styrene (WANG) resin, as taught in
Wang, JOURNAL AMERICAN CHEMISTRY SOCIETY 1973; 95:1328, is utilized. Eight FMOC amino acid resins including phenylalanine, glycine, alanine, isoleucine, leucine, proline, valine, and tryptophan are deprotected, reacted with either FMOC alanine or FMOC isoleucine, deprotected again, then cleaved from the resin to generate 16 discrete dipeptides. A total of 3 to 20 mg (28-85%) of each crude dipeptide is isolated as the trifluoroacetic acid (TFA) salt and analyzed by HPLC, mass spectroscopy (MS), and proton nuclear magnetic resonance spectroscopy (1H NMR) (see Table 1).
Synthesis of Hydantoins
The synthesis of an array of 40 hydantoins, including phenytoin, is achieved using the apparatus described herein. Five samples of eight FMOC or BOC protected amino acid resins (phenylalanine, glycine, isoleucine, leucine, alanine, valine, tryptophan, and 2,2-diphenylglycine) are deprotected then separately reacted with five isocyanates (trimethylsilyl, n-butyl, allyl, 2-trifluorotolyl, or 4-methoxyphenyl isocyanate) followed by treatment with aqueous 6N hydrochloric acid (HCl) to generate 40 discrete hydantoins (see Scheme 2 and Table 2).
The synthesis of 40 hydantoins in an array illustrates a standard protocol for a typical parallel array synthesis. In this example, a robotic sample processor (Tecan® 5032) is used for every liquid sample handling step. Some of the key features which demonstrate the strengths, flexibility and scope of the method and apparatus are highlighted below. Forty BOC or FMOC protected resin-bound amino acids are weighed into the reaction tubes, assembled in the apparatus, and
simultaneously deprotected employing GC/ISTD calibration methods to determine the completion of the FMOC deprotection reactions. The ability to simultaneously perform different reactions with vastly different reagents (for example, piperidine, DMF and TFA) further demonstrates the flexibility of the apparatus. Residual solvents, reactants, or byproducts are removed by wash cycles which include submersion and sonication of the reaction tubes in a series of solvents, followed by robotic spotting of the filtrates on a TLC plate and observation of the results under ultraviolet (UV) light to insure the thoroughness of the wash cycles. Following the wash cycles, the resin-bound amines are reacted with the desired isocyanates in DMF. Again, GC/ISTD calibration methods are used to quantitatively monitor the uptake of the isocyanates. After washing, the resin-bound ureas are cyclized by heating in aqueous 6N HCl to produce the desired hydantoins. Following the HCl treatment, the spent resins in the reaction tubes are washed with methanol to completely extract the hydantoins from the resins. All filtrates are combined, concentrated on a commercial centrifugal vacuum system
(SpeedVac®), weighed, and analyzed to yield the expected hydantoins, in all but one example (see Table 2). A total of 0 to 11.5 mg corresponding to 0 to 81% yield of each crude hydantoin is isolated and analyzed by TLC, MS, and 1H NMR.
Synthesis of Benzodiazepines and Biological Testing
The investigation of an array synthesis of benzodiazepines as potential targets was prompted by a brief communication by Camps, et al, ANALES DE QUIMICA
1974; 70: 848 who reported a one-step synthesis of several benzodiazepines starting with a resin-bound amino acid.
A two-step route is outlined in Scheme 3. The first step in the sequence is the formation of an imine between a resin-bound amino acid and a 2-amino-benzophenone. Initially, a number of condensation methods were explored, but all proved unsatisfactory. Replacement of the imine condensation with a transimination reaction, as taught by O'Donnell and Polt, JOURNAL ORGANIC CHEMISTRY 1982 ,-47:2663, to form a mixture of E and Z imine isomers proved satisfactory. The resin-bound amino acid imines are then converted to the corresponding benzodiazepines by heating in TFA.
The synthesis of 40 benzodiazepines in the array is similar to that outlined for the dipeptides and hydantoins with several modifications, which demonstrate the flexibility of both the method and the apparatus (see Scheme 3 and Table 3). Five amino acid Merrifield resins (alanine, glycine, 2-bromobenzyloxycarbonyltyrosine, tryptophan, and valine) as their TFA salts are separately reacted with eight 2-aminobenzophenone imines. The reactions are not monitored, but are reacted long enough to accommodate the slowest example (valine resin with N-isopropyl 2 -amino-4-methylbenzophenone imine) based on previous validation studies. Following wash cycles to extract the unreacted imine, the resin bound imines are heated in TFA for a time sufficient to ensure cyclization of the slowest examples (imines of N-methyl 2-amino-5-nitro-benzophenone), while minimizing decomposition of the tryptophan derived benzodiazepines. When the reaction is complete, the spent resins in the reaction tubes are washed and the combined filtrates concentrated to dryness. In this case, an aqueous bicarbonate work-up is implemented (utilizing the Tecan® 5032 robotic sample processor) to remove residual TFA. For each reaction
tube the corresponding organic extracts are combined, dried, and concentrated to yield the expected benzodiazepines in all but one example (see Table 3). The 40 (39 desired) products are characterized by TLC, 1H-NMR, and MS. The crude yields range from 7 to >100% and the estimated purities from NMR and TLC are greater than 60% in most cases.
To verify that the compounds produced could be used directly in a biological assay, the crude benzodiazepines are tested for activity in a benzodiazepine receptor binding assay without further purification. (The assay was performed using the commercially available NovaScreen® assay system contracted by Scios-Nova Pharmaceutical Corp., Baltimore, MD, whereby bovine cortical membrane preparations were used as the source of receptor and the radioligand employed was [3H] Flunitrazipam while the positive control was Clonazepam.) The calculated IC50's from three concentrations (average of two determinations) for the individual compounds are shown in Table 3.
The following nonlimiting examples are offered by way of illustration and are not intended to limit the invention in any manner. Example 1
Synthesis of Dipeptides
The synthesis of 16 dipeptides is summarized in Table 1.
101 to 153 mg each of eight FMOC protected amino acids (phenylalanine, glycine, alanine, isoleucine, leucine, proline, valine, and tryptophan) on a commercially available WANG resin (loading = 0.37-0.60 meq/g, 200-400 mesh) was measured into each of 16 gas dispersion tubes (reaction tubes). The reaction tubes were fitted into the holder block with two gaskets, one above and one below the holder block. The array of reaction tubes was fitted into a matching array of reaction wells in an appropriate reservoir block, in this case a test tube rack, and 3 mL of DMF was dispensed through the aperture at the top of the reaction tubes to wash any residual resin to the bottom of the glass frit. The manifold was fitted over the holder block and a nitrogen atmosphere was initiated through the ports on the manifold. The apparatus was then agitated in a sonic bath for 15 minutes to swell the resin support in preparation for the first reaction. Following swelling of the resin, the holder block and the manifold, in combination with the reaction tubes, were raised above the reservoir block and the reaction tubes were allowed to drain by gravity.
To deprotect the FMOC amino acids, the reaction tubes were submerged in reaction wells containing 2 mL of a solution of 22% piperidine in DMF
(v/v) with an internal standard (e.g., anthracene at
1.97 mg/mL). The apparatus was fastened together with clamps and agitated in a sonic bath for 2 hours, while maintaining a positive nitrogen flow through the manifold. The reaction progress was monitored by removing a sample of the filtrate (10-100 μl ) and analyzing for the FMOC-piperidine adduct and dibenzofulvene by GC/ISTD calibration methods. At the end of the reaction, the holder block and the manifold,
in combination with the reaction tubes, were raised above the reservoir block and the reaction tubes were allowed to drain by gravity, then sparged with nitrogen. The reaction tubes were sparged by introducing nitrogen into one port of the manifold and closing off the second port.
The reaction tubes were subjected to a series of wash cycles to remove residual solvents, reagents, and byproducts. A standard protocol included sequentially submerging the reaction tubes in 2 to 5 mL each of 2 x DMF, 2 × methanol, 2 × water, 2 x water:dioxane
(1:1), 2 × dioxane, and 2 × DMF, followed by agitation by sonication for 10 to 15 minutes, and finally draining by gravity and nitrogen sparge. The efficiency of the wash cycles was monitored by TLC or GC/ISTD of the wash filtrates.
In order to couple the FMOC amino acids, the following DMF solutions were sequentially admixed in two 8-unit reservoir blocks, to generate the activated esters: 1.0 mL of 0.46 M FMOC alanine or FMOC isoleucine , 0 .5 mL of 1. 02 M Benzotriazol - 1 -yloxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP), 1.0 mL of 1.02 M N-Hydroxybenzotriazole (HOBT), and 0.5 mL of 1.84 M N-methylmorpholine. The apparatus was assembled as above and agitated on a rotational platform shaker for 18 hours, while maintaining a positive nitrogen flow through the manifold. The reaction progress was monitored by removing a sample of the resin following the wash cycles and colorometrically analyzing for primary amines (Bromophenol blue or Kaiser/Ninhydrin). At the end of the reaction, the holder block and the manifold, in combination with the reaction tubes, were raised above the reservoir block
and the reaction tubes were allowed to drain by gravity then sparged with nitrogen.
The reaction tubes were subjected to the same series of wash cycles as previously set forth. The deprotection of the above formed FMOC protected dipeptides was repeated following the same procedure as previously set forth.
The reaction tubes were again subjected to the same series of wash cycles as previously set forth. In order to cleave the product from the solid support, the reaction tubes were submerged in reaction wells containing 3 mL of a solution of anisole:TFA
(5:95). The apparatus was sealed with clamps and agitated in a sonic bath, while maintaining a positive nitrogen flow through the manifold. After 3 hours, the holder block and the manifold, in combination with the reaction tubes, were raised above the reservoir block and the reaction tubes were allowed to drain by gravity then sparged with nitrogen. To isolate and purify the products, a holder block was fitted with disposable glass pipets which were submerged in the TFA filtrates. The filtrates were concentrated in a well-ventilated hood or glove box fitted with a scrubber by initiating and maintaining a positive, subsurface nitrogen flow through the manifold. The TFA salt was dissolved in 2 mL of water and extracted with 2 mL of ethyl acetate. The reaction reservoirs were vortexed to affect efficient extraction and the upper organic layer was withdrawn via syringe. The extraction cycle was repeated until the organic
layer contained no residues as determined by TLC or GC/ISTD (3 times). The aqueous layers were concentrated on a Speed-Vac® in tared vials. The dipeptides generated in the apparatus including, alanylphenylalanine; alanylglycine; alanylisoleucine; alanylleucine; alanylalanine; alanylproline; alanylvaline; alanyltryptophan; isoleucylphenylalanine; isoleucylglycine; isoleucylisoleucine; isoleucylleucine; isoleucylalanine; isoleucylproline; isoleucylvaline; and isoleucyltryptophan, are set forth in Table 1.
Example 2 Synthesis of Hydantoins
The synthesis of 40 hydantoins is summarized in Scheme 2 and Table 2. 95 to 105 mg each of seven FMOC protected amino acids (phenylalanine, glycine, isoleucine, leucine, alanine, valine, and tryptophan) on a commercially available WANG resin (loading = 0.37 to 0.60 meq/g, 200 to 400 mesh) and 95 to 105 mg of BOC protected diphenylglycine loaded on a commercially available cross-linked hydroxymethyl divinylbenzene-styrene resin (loading = 1.04 meq/g, 200-400 mesh) was measured into 40 reaction tubes. The apparatus was assembled, swelled with 4 mL of DMF, and drained as set forth in Example 1.
To deprotect the FMOC amino acids, the appropriate reaction tubes were submerged in reaction wells containing 3 mL of a solution of 25% piperidine in
DMF (v/v) with an internal standard (anthracene at 1.74 mg/mL). To deprotect the BOC amino acids the
appropriate reaction tubes are submerged in wells containing 3 mL of 50% TFA/DMF. The apparatus was assembled as set forth in Example 1 and agitated in a sonic bath while maintaining a positive nitrogen flow through the manifold. The reaction progress was monitored by removing a sample of the filtrate (e.g. 10-100 μl) and analyzing for the FMOC-piperidine adduct and dibenzofulvene by GC/ISTD calibration methods. The reaction was complete after 6 hours in a sonic bath. At the end of the reaction, the reaction tube array was drained and sparged as set forth in Example 1.
The reaction tubes were subjected to the standard wash cycle set forth in Example 1.
To facilitate urea formation, the appropriate reaction tubes were submerged in reaction wells containing 3 mL of a solution of 0.19 to 0.23 M isocyanate (trimethylsilyl isocyanate, butyl isocyanate, allyl isocyanate, trifluoro-o-tolyl isocyanate, and 4-methoxyphenyl isocyanate) in DMF, containing an internal standard (e.g., anthracene at 1.89-2.00 mg/mL). The apparatus was sealed as set forth in Example 1 and agitated in a sonic bath for 6 hours, while maintaining a positive nitrogen flow through the manifold. The reaction progress was monitored by removing a sample of the filtrate (10-100 μl ) , derivatization with an appropriate amine or alcohol, and analysis by GC/ISTD calibration methods. At the end of the reaction, the reaction tube array was drained and sparged as set forth in Example 1. The reaction tubes were subjected to the standard wash cycle set forth in Example 1.
To facilitate cleavage of the final product from the solid support, the reaction tubes, in combination with the holder block and manifold, were submerged in reaction wells containing 3 mL each of 6N HCl. The apparatus was sealed with clamps and submerged in an oil bath (at 105°C) and heated at 85 to 100°C while maintaining a positive chilled nitrogen flow through the manifold. (The chilled nitrogen flow through the manifold was affected by submersion of the nitrogen inlet tubing in an isopropanol/dry ice bath.) After 2 hours, the reaction tube array was cooled, drained and sparged as set forth in Example 1.
To isolate and purify the products, the reaction tubes, in combination with the holder block and manifold, were submerged in reaction wells containing 3 mL each of methanol . The apparatus was agitated in a sonic bath for 10 to 15 minutes to extract the hydantoins from the resins then drained by gravity and nitrogen sparge. The methanol extraction protocol was repeated until the filtrates were free of any organic components as determined by TLC (4 times). The HCl and methanol filtrates were concentrated on a Speed-Vac® in tared vials to afford 39 of the 40 desired hydantoins. The hydantoins generated in the apparatus, including: 5-methyl-2,4-imidazolidinedione; 5-(phenylmethyl)-2,4-imidazolidinedione; 2,4-imidazolidinedione; 5- (1-methylpropyl)-2,4-imidazolidinedione; 5- (2-methylpropyl) -2,4-imidazolidinedione; 5-(1-methylethyl)-2,4-imidazolidinedione; 5-(1H-indol-2-ylmethyl)-2,4-imidazolidinedione; 5,5-diphenyl-2,4-imidazolidinedione; 3-butyl-5-methyl-2,4-imidazolidinedione; 3-butyl-5-(phenylmethyl)-2,4-imidazolidinedione; 3-butyl-2,4-imidazolidinedione, 3-butyl-5-(1-methylpropyl)-2,4-imidazolidinedione;
3-butyl-5-(2-methylpropyl)-2,4-imidazolidinedione; 3-butyl-5-(1-methylethyl)-2,4-imidazolidinedione; 3-butyl-5-(1H-indol-2-ylmethyl)-2,4-imidazolidinedione; 3-butyl-5,5-diphenyl-2,4-imidazolidinedione; 5-methyl-3-(2-propenyl)-2,4-imidazolidinedione; 5-(phenylmethyl)- 3-(2-propenyl)-2,4-imidazolidinedione; 3-(2-propenyl)-2,4-imidazolidinedione; 5-(1-methylpropyl)-3-(2-propenyl)-2,4-imidazolidinedione; 5-(2-methyl-propyl)-3-(2-propenyl)-2,4-imidazolidinedione; 5-(1-methylethyl)-3-(2-propenyl)-2,4-imidazolidinedione;
5- (1H-indol-2-ylmethyl) -3- (2-propenyl) -2,4-imidazolidinedione; 5,5-diphenyl-3-(2-propenyl)- 2,4-imidazolidinedione; 5-methyl-3-[2-(trifluoromethyl)-phenyl]-2,4-imidazolidinedione; 5-(phenylmethyl)-3-[2-(trifluoromethyl)phenyl]-2,4-imidazolidinedione;
3-[2-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; 5-(1-methylpropyl)-3-[2-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; 5-(2-methylpropyl)-3-[2-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; 5-(1-methylethyl)-3-[2-(trifluoromethyl)phenyl]- 2,4-imidazolidinedione; 5-(1H-indol-2-ylmethyl)- 3-[2-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; 5,5-diphenyl-3- [2-(trifluoromethyl)phenyl] -2,4-imidazolidinedione; 3-(4-methoxyphenyl)-5-methyl-2,4-imidazolidinedione; 3-(4-methoxyphenyl)- 5- (phenylmethyl) -2,4-imidazolidinedione; 3- (4-methoxyphenyl)-2,4-imidazolidinedione; 3-(4-methoxyphenyl)-5-(1-methylpropyl)-2,4-imidazolidinedione; 3-(4-methoxyphenyl)-5-(2-methylpropyl)-2,4-imidazolidinedione; 3-(4-methoxyphenyl)-5-(1-methyl¬ethyl)-2,4-imidazolidinedione; 5-(1H-indol-2-ylmethyl)-3- (4-methoxyphenyl)-2,4-imidazolidinedione; 3-(4-methoxyphenyl)-5,5-diphenyl-2,4-imidazolidinedione; are set forth in Table 2.
Example 3
Synthesis of Benzodiazepines
The synthesis of 40 benzodiazepines is summarized in Scheme 3 and Table 3. Five commercially available BOC amino acid
Merrifield resins (alanine, glycine, 2-bromobenzyloxy carbonyl- tyrosine, tryptophan, and valine; 0.57-0.89 meq/g, 200-400 mesh) were deprotected in bulk (1-5 g) instead of within the apparatus, using TFA:CH2Cl2 (1:1) at room temperature overnight. After washing with dioxane and CH2Cl2, the resins were dried under vacuum and used directly.
99 to 107 mg of each amino acid resin prepared above, as its TFA salt, was loaded into 40 reaction tubes. The apparatus was assembled, swelled with 3 mL of CH2Cl2, and drained as set forth in Example 1. The appropriate reaction tubes are submerged in reaction wells containing a solution of the appropriate 2-aminobenzophenoneimines (3-6 eq) in 3 mL of dichloroethane (see Scheme 2). The apparatus was sealed as set forth in Example 1 and heated at 60°C (oil bath temp.), while maintaining a positive chilled nitrogen flow through the manifold. In this case the reactions were not monitored, but were reacted for sufficient time (24 hours) to drive the slowest reaction (valine resin with N-isopropyl 2-amino-4-methyl benzophenone imine) to completion based on earlier validation studies. The reaction tube array was allowed to cool and then drained and sparged as set forth in Example 1.
In this example, the reaction tubes were washed by adding 4 mL portions of CH2Cl2 through the top of each reaction tube repeatedly (12 times) until the washes were no longer colored (indicating the absence of 2 -amino benzophenone imine or its corresponding ketone from hydrolysis).
The reaction tube array was then sparged as set forth in Example 1 and the reaction tubes are submerged in reaction wells containing 3 mL of 100% TFA. The apparatus is sealed as set forth in Example 1 and heated at 60°C (oil bath temp.) for 20 hours, while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. Again, the reactions were not monitored, but were allowed to react for a time sufficient to ensure conversion of the slowest reactions (N-methyl2-amino-5-nitro benzophenone imine), while minimizing decomposition of the tryptophan derived benzodiazepines. The reaction tube array was allowed to cool and then drained as set forth in Example 1.
The reaction tubes are then washed as above with 3 × 2 mL portions of CH2Cl2.
The appropriate washes are then combined and evaporated under a stream of nitrogen as set forth in Example 1, except in this case the pipet tips were maintained above the surface of the liquid. A simple extraction procedure was implemented using the Tecan® robot. The residues from evaporation were dissolved in 3 mL CH2Cl2 and mixed with 3 mL saturated sodium bicarbonate. The organic phase was withdrawn and the aqueous layer was extracted twice more with 1.5 mL of CH2Cl2. The combined organic extracts were dried
with MgSO4, filtered, and concentrated as before to yield the expected benzodiazepines in all but one example (see Table 3). The 40 (39 desired) products were characterized by TLC, 1H-NMR, and MS. The crude yields range from 4 to >100% and the estimated purities from
NMR and TLC are greater than 60% in most cases. The desired products including: 1, 3-dihydro-3-methyl- 5-phenyl-2H-1,4-benzodiazepin-2-one; 7-chloro- 1,3-dihydro-3-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-5-(4-methoxyphenyl)-3-methyl-2H- 1,4-benzodiazepin-2-one; 1,3-dihydro-3-methyl-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-dihydro- 1-isopropyl-3,6-dimethyl-2H-1,4-benzodiazepin-2-one; 7-nitro-1,3-dihydro-1,3-dimethyl-5-phenyl-2H-1,4-benzodiazepin-2-one; 5-cyclohexyl-1,3-dihydro- 3-methyl-2H-1,4-benzodiazepin-2-one; 1,3-dihydro- 3-methyl-5-(2-thienyl)-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-5-(4-methoxyphenyl)-2H- 1,4-benzodiazepin-2-one; 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-1-isopropyl-6-methyl-2H-1,4-benzodiazepin-2-one; 7-nitro- 1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; 5-cyclohexyl-1,3-dihydro-2H-1,4-benzodiazepin- 2-one; 1,3-dihydro-5-(2-thienyl)-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-3-(4-hydroxyphenyl)-5-phenyl-2H- 1,4-benzodiazepin-2-one; 7-chloro-1,3-dihydro- 3-(4-hydroxyphenyl)-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-5-(4-methoxyphenyl)-3-(4-hydroxyphenyl)-2H- 1,4-benzodiazepin-2-one; 1,3-dihydro-7-nitro- 3-(4-hydroxyphenyl)-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-1-isopropyl-6-methyl-3-(4-hydroxyphenyl)-2H-1,4-benzodiazepin-2-one; 7-nitro-1,3-dihydro-1-methyl-3-(4-hydroxyphenyl)-5-phenyl-2H-1,4-benzodiazepin-2-one;
5-cyclohexyl-1,3-dihydro-3-(4-hydroxyphenyl)-2H-1,4-benzodiazepin-2-one; 1,3-dihydro- 3-(4-hydroxyphenyl)-5-(2-thienyl)-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-3-(1H-indol-2-ylmethyl)-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-chloro-1,3-dihydro-3-(1H-indol-2-ylmethyl)-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-3-(1H-indol-2-ylmethyl)-5-(4-methoxyphenyl)-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-3-(1H-indol- 2-ylmethyl)-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-3-(1H-indol-2-ylmethyl)-1-isopropyl- 6-methyl-2H-1,4-benzodiazepin-2-one; 7-nitro- 1,3-dihydro-3-(1H-indol-2-ylmethyl)-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; 5-cyclohexyl-1,3-dihydro-3-(1H-indol-2-ylmethyl)-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-3-(1H-indol-2-ylmethyl)-5-(2-thienyl)-2H- 1,4-benzodiazepin-2-one; 1,3-dihydro-3-(1-methylethyl)-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-chloro- 1,3-dihydro-3- (1-methylethyl) -5-phenyl-2H-1,4-benzodiazepin-2-one; 1, 3-dihydro- 5- (4-methoxyphenyl) -3- (1-methylethyl) -2H- 1,4-benzodiazepin-2-one; 1,3-dihydro-3-(1-methylethyl)-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-1-isopropyl-6-methyl-3-(1-methylethyl)-2H-1,4-benzodiazepin-2-one; 7-nitro-1,3-dihydro-1-methyl-3-(1-methylethyl)-5-phenyl-2H-1,4-benzodiazepin-2-one;
5-cyclohexyl-1,3-dihydro-3-(1-methylethyl)-2H-1,4-benzodiazepin-2-one; 1,3-dihydro-3-(1-methylethyl)-5-(2-thienyl)-2H-1,4-benzodiazepin-2-one; are set forth in Table 3.
Example 4
Synthesis of Quinolones
The synthesis of 36 quinolones is summarized in Scheme 4 and Table 4. Thirty-six gas dispersion tubes are loaded each with 100 ± 5 mg of hydroxymethyl polystyrene resin (1% cross-linked, 1.0 meq/g, loading) and placed in the holder block. The apparatus is assembled, swelled with 3 mL of CH2Cl2, and drained as set forth in Example 1.
To three sets of 12 reaction wells within the array is added 2 mL of a 0.2 M CH2Cl2 solution of either 3-(2,4,5-trifluorophenyl)-3-oxo-1-propanoic acid, 3-(2,3,4,5-tetrafluorophenyl)-3-oxo-1-propanoic acid, or 3-(2,4-dichloro-5-fluoropyridyl)-3-oxo-3-propanoic acid. An additional 1 mL of a CH2Cl2 stock solution containing 0.4 M dicyclohexylcarbodiimide and 0.4 M 1-hydroxybenzotriazole is added to all 36 reaction wells of the array and the appropriate reaction tubes are submerged in the corresponding reaction wells. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath for 12 hours, while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tube array is then washed using CH2Cl2 (10 times) as set forth in Example 3.
Into every well of the array is added 3 mL of a solution of acetic anhydride/triethyl orthoformate (1:1 v/v) and the apparatus is sealed as set forth in
Example 1. The apparatus is then heated at 150°C (oil bath temp.) for 3 hours, while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using CH2Cl2 (10 times, 3 mL.)
To three sets of 12 reaction wells within the array is added 3 mL of a t-butanol solution 0.13 M in both ethyl amine and t-butoxide, or cyclopropyl amine and t-butoxide, or 2,4-difluoroaniline and t-butoxide. The apparatus is reassembled as set forth in Example 1, immersed in an oil bath (60°C) and heated for 12 hours as set forth in Example 3. At the end of the reaction, the reaction tube array is allowed to cool and then drained and sparged as set forth in Example 1.
The reaction tubes are then washed as set forth in Example 3, using CH2Cl2 (12 times, 3 mL.) To four sets of nine reaction wells within the array is added 3 mL of a 0.26 M acetonitrile solution of either piperazine, piperidine, N-methyl piperazine, or 3- (ethylaminomethyl) pyrrolidine. The apparatus is assembled as set forth in Example 1, and heated in an oil bath (80°C) for 4 hours as set forth in Example 3. At the end of the reaction, the reaction tube array is allowed to cool and then drained and sparged as set forth in Example 1.
The reaction tubes are then washed as set forth in Example 3, using CH2Cl2 (12 times, 3 mL.)
The reaction tubes are submerged in reaction wells containing 3 mL of 2N NaOH in 1:1 dioxane :water. The apparatus is assembled as set forth in Example 1, and allowed to stand at room temperature for 6 hours to affect ester hydrolysis. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are then washed as set forth in Example 3, using 3 x 3 mL of 0.1N NaOH in dioxane:water (1:1). The filtrates are then combined and the dioxane is removed by evaporation as set forth in Example 3. The resulting aqueous solutions are acidified with 5 N HCl solution and evaporated to give the 36 individual expected crude quinolones. Example 5
Synthesis of Keto-ureas
The synthesis of eight keto-ureas is summarized in Scheme 5 and Table 5.
100 g of Merrifield' s chloromethyl polystyrene resin (1-3% cross-linked, loading = 0.78 meq/g, 200-400 mesh) is heated for 20 hours at 150-155°C in 500 mL of DMSO with 5 eq of NaHCO3 to form the resin-bound benzaldehyde. The resin is filtered and washed sequentially with excess DMSO, hot water, dioxane:water (2:1), water, dioxane, acetone, ethanol, CH2Cl2, and benzene. The dried aldehyde resin is then reacted with O-methylhydroxylamine hydrochloride (7.5 eq) and pyridine (7.8 eq) in refluxing ethanol to form the resin-bound oxime, which is washed with excess MeOH and CH2Cl2, and then directly reduced with sodium
cyanoborohydride (10 eq) in EtOH saturated with HCl at room temperature for 3 hours using methyl orange as an indicator and adjusting the pH to 3.1 with additional EtOH/HCl. The resin is washed sequentially with excess MeOH, hot water, dioxane:water (1:1), dioxane, and CH2Cl2 and used directly below.
100 mg of O-Methyl hydroxylamine resin from above is measured into each of the eight gas dispersion tubes (reaction tubes). The apparatus is assembled, swelled with 3 mL of CH2Cl2, and drained as set forth in Example 1.
To facilitate coupling of the Boc-amino benzoic acids, the appropriate reaction tubes are submerged in reaction wells containing 3 mL of a solution of 0.08 M diisopropylethylamine, 0.16 M BOP
(Benzotriazol-1-yloxy-tris-(dimethylamino)-phosphonium hexafluorophosphate), and 0.08 M Boc-amino benzoic acid
(either 3-amino-4-chlorobenzoic acid or 4-amino-
3-hydroxybenzoic acid) in CH2Cl2. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath for 8 hours while maintaining a positive nitrogen flow through the manifold. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1. The reaction tube array is subjected to the standard wash cycle set forth in Example 1.
The appropriate reaction tubes are submerged in reaction wells containing a solution of 4 mL of sat.
HCl-Ether:dioxane (2:1). The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath for
2 hours, while maintaining a positive nitrogen flow
through the manifold. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tube array is subjected to the standard wash cycle set forth in Example 1.
The appropriate reaction tubes are submerged in reaction wells containing a solution of 3 mL of 0.16 M phenyl isocyanate or ethyl isocyanate in dioxane with an internal standard (e.g., anthracene at 2-4 mg/mL). The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath for 6 hours, while maintaining a positive nitrogen flow through the manifold. The reaction progress is monitored by GC/ISTD as set forth in Example 1. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tube array is subjected to the standard wash cycle set forth in Example 1.
In order to cleave the product from the solid support, the reaction tubes are submerged in reaction wells containing a solution of 3 mL of dry CH2Cl2 at
-78°C. The apparatus is sealed as set forth in
Example 1 and placed in an isopropanol/dry ice bath while maintaining a positive chilled nitrogen flow through the manifold. A solution of either methylmagnesium bromide 1.4 M in toluene/tetrahydrofuran or phenylmagnesium bromide 1.0 M in tetrahydrofuran
(0.2 mL) is added to the top of the appropriate reaction tubes through the gasket at the top of the manifold and the apparatus is sonicated at -78°C (maintained at -10°C by circulating chilled fluid through the sonic bath).
After 2 hours, 10% HCl (0.5 mL) is added to each reaction tube through the gasket at the top of the manifold and the apparatus is allowed to warm to room temperature. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
To isolate and purify the products, the reaction tubes are washed as set forth in Example 1, using 3 mL portions of methanol. The methanol extraction protocol is repeated until the filtrates are free of any organic components as determined by TLC (1-2 times). The appropriate HCl and methanol filtrates are then combined and concentrated on a Speed-Vac® in tared vials to afford eight discrete keto-ureas. Example 6
Synthesis of N2-Substituted Hydantoins
The synthesis of eight N2-substituted hydantoins is summarized in Scheme 6 and Table 6.
100 mg each of the commercially available FMOC- protected amino acids on WANG resins (FMOC-Alanine and FMOC-Phenylalanine, loading = 0.37-0.60 meq/g, 200-400 mesh) are measured into two sets of four gas dispersion tubes (reaction tubes). The apparatus is assembled, swelled with 3 mL of DMF, and drained as set forth in Example 1.
To deprotect the FMOC amino acids, the appropriate reaction tubes are submerged in reaction wells containing a solution of 4 mL of 25% piperidine in DMF (v/v) containing an internal standard (anthracene at
2-4 mg/mL). The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath while maintaining a positive nitrogen flow through the manifold. The reaction progress is monitored by removing a sample of the filtrate (e.g., 10-100 μL) and analyzing for the FMOC-piperidine adduct and dibenzofulvene by GC/ISTD calibration methods. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1. The reaction tube array is subjected to the standard wash cycle set forth in Example 1.
The appropriate reaction tubes are submerged in reaction wells containing a solution of 4 mL of 0.10 to 0.30 M acetaldehyde or benzaldehyde in dioxane containing an internal standard (e.g., anthracene at 2-4 mg/mL). The apparatus is sealed and agitated in a sonic bath for 12 hours, while maintaining a positive nitrogen flow through the manifold. The reaction progress is monitored by GC/ISTD calibration methods as set forth in Example 1. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tube array is subjected to the standard wash cycle set forth in Example 1. The appropriate reaction tubes are submerged in reaction wells containing a solution of 4 mL of 0.10-0.30 M sodium cyanoborohydride in methanol with an indicator (e.g., methyl orange at 2-4 mg/mL). The apparatus is sealed as set forth in Example l and agitated in a sonic bath while maintaining a positive nitrogen flow through the manifold. The reaction
progress is monitored by visually observing the color of the filtrates. When neutral or basic conditions are observed, the pH is adjusted by injection of dilute aqueous HCl into the appropriate reaction tubes through the gasket at the top of the manifold. Stabilization of pH changes indicates completion of the reduction reaction. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tube array is subjected to the standard wash cycle set forth in Example 1.
The appropriate reaction tubes are submerged in reaction wells containing a solution of 4 mL of 0.10-0.30 M trimethylsilyl isocyanate or allyl isocyanate in DMF containing an internal standard (e.g., anthracene at 2-4 mg/mL). The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath for 6 hours, while maintaining a positive nitrogen flow through the manifold. The reaction progress is monitored by removing a sample of the filtrate (10-100 μL), derivatization with an appropriate amine or alcohol, and analysis by GC/ISTD calibration methods as set forth in Example 1. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1. The reaction tube array is subjected to the standard wash cycle set forth in Example 1.
In order to cleave the product from the solid support, the reaction tubes are submerged in reaction wells containing a solution of 4 mL of aqueous 6N HCl. The apparatus is sealed as set forth in Example 1, placed in an oil bath and heated at 95 to 100°C for
2 hours while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1. To isolate and purify the products, the reaction tubes are washed as set forth in Example 1 using 4 mL portions of methanol. The methanol extraction protocol is repeated until the filtrates are free of any organic components as determined by TLC (1-2 times). The appropriate HCl and methanol filtrates are then combined and concentrated on a Speed-Vac® in tared vials to afford eight discrete hydantoins.
Example 7
Synthesis of (R)-4-Benzamido-5-oxopentanoic Acids The synthesis of 12 oxopentanoic acids is summarized in Scheme 7 and Table 7.
5 g of α-2-Trimethysilylethyl-N-BOC-glutamic acid is linked through the γ-carboxyl group to commercially available p-benzyloxybenzyl alcohol resin (loading = 1.2 meq/g, 200-400 mesh) using
N,N'-diisopropylcarbodiimide (4 eq) and HOBT (2 eq) in
3 mL of DMF for 24 hours. The resulting resin is then washed with excess MeOH and CH2Cl2 and used directly below. 95 to 105 mg of the above formed resin is measured into each of 12 gas dispersion tubes (reaction tubes). The apparatus is assembled, swelled with 3 mL of dioxane, and drained as set forth in Example 1.
The reaction tubes are submerged in reaction wells containing a solution of tetrabutylammoniun fluoride (5 eq) in dioxane (3 mL) at room temperature. The apparatus is sealed as set forth in Example l and agitated at room temperature for 8 hours in a sonic bath as set forth in Example 5, while maintaining a positive nitrogen flow through the manifold. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1. The reaction tubes are washed as set forth in
Example 3, using 2 × 3 mL each of the following solutions, dioxane:H2O (1:1), dioxane and CH2Cl2.
The reaction tubes are submerged in reaction wells containing a solution of ethylchloroformate (3 eq) and triethylamine (3 eq) in dioxane (3 mL) at -10°C. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at room temperature for 4 hours as set forth in Example 5, while maintaining a positive nitrogen flow through the manifold. At the end of the reaction, the reaction tube array is allowed to warm to room temperature and then drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in
Example 3, using 4 × 2 mL of anhydrous DMF. Because of the labile nature of the above formed acyl-carbonates, the reaction tubes are rapidly washed in order to minimize unwanted hydrolysis.
The appropriate reaction tubes are submerged in reaction wells containing a solution of 4 eq of either n-butylamine, cycloheptylamine,
8-azaspiro[4.5]decane, or dipentylamine in dioxane
(4 mL) at -10°C. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at -10°C as set forth in Example 5 for 1 hour and then 3 hours at room temperature, while maintaining a positive nitrogen flow through the manifold. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in
Example 3, using 2 × 3 mL each of the following solutions, dioxane:H2O (1:1), dioxane:1N HCl (1:1), dioxane:H2O (1:1), dioxane:0.1N NaOH (1:1), dioxane:H2O
(1:1), and dioxane.
The reaction tubes are submerged in reaction wells containing a solution of 20% piperidine in DMF at room temperature. The apparatus is sealed as set forth in Example 1 and agitated at room temperature in a sonic bath for 6 hours as set forth in Example 5, while maintaining a positive nitrogen flow through the manifold. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 2 × 3 mL each of the following solutions, DMF, dioxane:H2O (1:1), dioxane and CH2Cl2.
The appropriate reaction tubes are submerged in reaction wells containing a solution of 2 eq of either benzoyl chloride, 3-methoxybenzoyl chloride, or 3-nitrobenzoyl chloride in pyridine (3 mL) at 0°C. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at 0°C for 3 hours as set forth in Example 5, while maintaining a positive nitrogen flow through the manifold. At the end of the reaction, the
apparatus is allowed to warm to room temperature, and the reaction tubes are drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 3 x 2 mL each of the following solutions, dioxane, dioxane:H2O (1:1), and dioxane.
In order to cleave the product from the solid support, the reaction tubes are submerged in reaction wells containing 3 mL each of trifluoroacetic acid. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at 0°C for 2 hours and then at room temperature for 4 hours as set forth in Example 5, while maintaining a positive nitrogen flow through the manifold. After 6 hours in a sonic bath, the apparatus is allowed to warm to room temperature, and the reaction tubes are drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 2 × 3 mL of methylene chloride. The filtrates are then combined and concentrated as set forth in Example 3. The crude products are then redissolved, transferred to tared vials, and reconcentrated to yield the final crude products.
Example 8
Synthesis of Diketopiperazines The synthesis of 40 diketopiperazines is summarized in Scheme 8 and Table 8.
95 to 105 mg of Merrifield' s resin (loading = 0.66 meq/g, 200-400 mesh) is measured into each of
40 gas dispersion tubes (reaction tubes) containing a magnetic stirring bar. The apparatus is assembled, swelled with 3 mL of DMF, and drained as set forth in Example 1. The reaction tubes are submerged into wells containing a solution of 75.0 mg BOC 4-hydroxyproline cesium salt in 5 mL of DMF. The apparatus is assembled and sealed with clamps as set forth in Example 1, and placed into an oil bath over a magnetic stirring plate while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2 and reacted at 50 ºC. After 24 hours, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tube array is subjected to the standard wash cycle set forth in Example 1, ending however in CH2Cl2, to remove residual reagents and byproducts.
The appropriate reaction tubes are submerged in reaction wells containing a solution of 5 mL of 0.07 M acyl halide (either, benzoyl bromide, acetyl chloride, 4-biphenylcarbonyl chloride, p-anisoyl chloride, 4-chlorobenzoyl chloride, 4-nitrobenzoyl chloride, pivaloyl chloride, or trifluoroacetyl chloride) and 0.07 M triethylamine in CH2Cl2. The apparatus is sealed as set forth in Example 1 and agitated as above while maintaining a positive nitrogen flow through the manifold. After 72 hours, the reaction tube array is drained and sparged as set forth in Example 1, using DMF, methanol, and CH2Cl2. The reaction tubes are submerged in 5 mL of
0.08 M TFA in CH2Cl2 to remove the BOC protecting group
from N1. The apparatus is assembled and the reactions stirred as above. After 72 hours, the reaction tubes are drained and washed with DMF, methanol, 1.0 M TFA in CH2Cl2, and CH2Cl2 as set forth in Example 1. A solution (5 mL) of 0.07 M BOC amino acid,
0.07 M diisopropylcarbodiimide and 0.07 M TFA in CH2Cl2 are stirred for 3 hours at room temperature. The appropriate reaction tubes are then submerged in the above reaction wells, and the apparatus is assembled as set forth in Example 1. Five BOC amino acids are employed, BOC-glycine, BOC-alanine, BOC-valine, BOC-phenylalanine, and BOC-diphenylglycine. After 72 hours, the reaction tube array is drained and sparged as set forth in Example 1. The reaction tube array is subjected to the standard wash cycle set forth in Example 1, ending however in CH2Cl2.
Cyclization to the final product and thus cleavage from the resin is accomplished by removal of the BOC (t-butyloxycarbony) group of the amino acid. The reaction tubes are submerged in reaction wells containing a solution of 5 mL of saturated HCl in CH2Cl2. The apparatus is assembled as set forth in Example 1 and the reactions stirred as above at room temperature. After 24 hours, the reaction tube array is drained and sparged as set forth in Example 1. The contents in the reaction wells are concentrated to dryness using a stream of nitrogen as set forth in Example 3.
A solution of 5 mL of 1.0 M triethylamine in CH2Cl2 is added to each reaction well and the reaction tubes are then submerged in these wells. The apparatus
is assembled as set forth in Example 1, and the reactions stirred as above. After 24 hours, the reaction tube array is drained and sparged as set forth in Example 1. The contents in the reaction wells are concentrated to dryness using a stream of nitrogen as set forth in Example 3. These crude products are partitioned between CH2Cl2 and a saturated solution of NaHCO3 using a Tecan® robot to deliver the necessary liquids and to remove the aqueous layer. The basic aqueous wash is repeated and the residual CH2Cl2 layers are dried by passing the samples through a bed of MgSO4 contained in standard SPE cartridges employing the vacuum SPE apparatus described above, giving the crude diketopiperazines.
Example 9
Synthesis of Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1yI)
ethyl]-2H-pyran-2-ones
The synthesis of three 2H-pyranones is summarized in Scheme 9 and Table 9.
Three dispersion tubes are loaded each with 100 ± 5 mg of hydroxymethyl polystyrene resin (1% cross-linked, 1.0 meq/g, loading) and placed in the holder block. The apparatus is assembled, swelled with 3 mL of acetonitrile, and drained as set forth in Example 1. The appropriate reaction tubes are submerged in reaction wells containing 2 mL of a solution of either 0.2 M acetic anhydride, propanoic anhydride, or 2-phenylacetic anhydride in acetonitrile, and 1.0 mL of a 0.4 M
solution of triethylamine in CH2Cl2. The apparatus is sealed as set forth in Example 1, and agitated in a sonic bath while maintaining a positive nitrogen flow through the manifold for 12 hours. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 10 × 4 mL of CH2Cl2.
The reaction tubes are submerged in reaction wells containing 3 mL of a solution of 0.2 M lithium diisopropylamide in THF and the apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at room temperature as set forth in Example 5, while maintaining a positive nitrogen flow through the manifold for 4 hours.
1 mm of a solution (in THF) of either 1.0 M 5-[2-(4-fluorophenyl)-3-phenyl-4-carboxamidophenyl-5-isopropyl-1-pyrrololyl]-3-oxo-1-pentanoic acid methyl ester (to wells #1 and #2), or 1.0 M 5- [2,3,4-triphenyl-5-methyl-1-pyrroloyl]-3-oxo-1-pentanoic acid methyl ester (to well #3) is added to the top of the appropriate reaction tubes through the gasket at the top of the manifold and sonicated at room temperature for 12 hours as set forth in Example 5. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 10 × 4 mL of CH2Cl2.
The reaction tubes are submerged in reaction wells containing 2.0 mL of a 0.26 M THF solution of diethyl methoxy borane and the apparatus is sealed as
set forth in Example 1. 1.0 mL of a 1.0 M THF solution of sodium borohydride is added to the top of the appropriate reaction tubes through the gasket at the top of the manifold and the apparatus is sonicated at room temperature for 4 hours as set forth in Example 5. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 10 × 4 mL of CH2Cl2. The reaction tubes are submerged in reaction wells containing 3.0 mL of 3% hydrogen peroxide in 1:1 dioxane:water and the apparatus is assembled as set forth in Example 1, and sonicated at room temperature for 6 hours as set forth in Example 5 to affect boron oxidation. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 10 × 3 mL of dioxane:water (1:1). The reaction tubes are submerged in reaction wells containing a solution of 0.1 M HCl in 1:1 dioxane:water (3 mL). The apparatus is assembled as set forth in Example 1, and sonicated at room temperature for 6 hours as set forth in Example 5 to affect hydrolysis/ring closure. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in
Example 3, using 3 × 3 mL of dioxane:water (1:1). The appropriate filtrates are then combined and concentrated
as set forth in Example 3 to give the three individual expected lactone products.
Example 10
Synthesis of N-Arylpiperazines The synthesis of 12 N-arylpiperazines is summarized in Scheme 10 and Table 10.
100 mg of hydroxymethyl polystyrene (2% cross- linked, 1.2 meq/g, loading) resin is measured into each of 12 gas dispersion tubes (reaction tubes) . The apparatus is assembled, swelled with 3 mL of DMF, and drained as set forth in Example 1.
To facilitate coupling of the acid, the appropriate reaction tubes are submerged in reaction wells containing a solution of 0.09 M 4-chlorobutyric acid or 3-chloropropionic acid; and 0.09 M N,N'-diisopropylcarbodiimide and 0.09 M 4,4-dimethylaminopyridine in DMF (3 mL) at room temperature. The apparatus is sealed as set forth in Example l and agitated in a sonic bath for 2 hours, while maintaining a positive nitrogen flow through the manifold. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tube array is subjected to the standard wash cycle set forth in Example 1. The appropriate reaction tubes are submerged in reaction wells containing a solution of 3 mL of either 0.09 M piperazine, phenylpiperazine, or 1-(2-pyridyl)piperazine; 0.18 M potassium carbonate; and
0.18 M potassium iodide in DMF. The apparatus is sealed as set forth in Example 1, placed in an oil bath, and heated at 95 to 100°C while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. After 6 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tube array is subjected to the standard wash cycle set forth in Example 1. The appropriate reaction tubes are submerged in reaction wells containing a solution of 3 mL of toluene-20% 1,2-dimethoxyethane at 0°C. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at 0'C as set forth in Example 5, while maintaining a positive argon flow.
To form the enolate, 0.5 mL of a solution (in
THF) of 0.15 M trityllithium is added to the top of the appropriate reaction tubes through the gasket at the top of the manifold and sonicated at 0°C for 15 minutes as set forth in Example 5.
After 15 minutes, 0.5 mL of 0.28 M acid chloride (either nicotinoyl chloride or naphthoyl chloride) in THF is added to the top of the appropriate reaction tubes through the gasket at the top of the manifold and sonicated at room temperature for 1 hour as set forth in Example 5. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tube array is subjected to the standard wash cycle set forth in Example 1.
In order to cleave the product from the solid support, the reaction tubes are submerged in reaction wells containing a solution of 3 mL of dry HBr in TFA. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath while maintaining a positive nitrogen flow through the manifold. After 1 hour, the reaction is stopped, and the reaction tube array is drained and sparged as set forth in Example 1.
To isolate and purify the products, the reaction tubes are washed as set forth in Example 1, using 3 mL portions of methanol. The methanol extraction protocol is repeated until the filtrates are free of any organic components as determined by TLC
(1-2 times) . The appropriate HCl and methanol filtrates are then combined and concentrated on a Speed-Vac® in tared vials to afford 12 discrete products.
In an example of a post-cleavage reaction, a modified Wolff-Kishner reduction is done on half of the amount of each of the isolated compounds. The compounds are placed in the appropriate reaction wells containing
3 mL of 0.09 M potassium hydroxide, and 0.09 M hydrazine hydrate in diethylene glycol. The reaction tubes are filled with 0.5 g sodium sulfate (to absorb water) and submerged in the reaction wells . The apparatus is sealed as set forth in Example 1, placed in an oil bath, and heated at 80°C while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. After 12 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1. Each product is isolated by adding
4 mL of a solution of 1:1 water:CH2Cl2. Each organic layer is separated, dried, and concentrated as set forth in Example 8 to yield another 12 desired products.
Example 11
Synthesis of Benzisothiazolones
The synthesis of nine benzisothiazolones is summarized in Scheme 11 and Table 11. 95 to 105 mg of Merrifield's resin (loading =
0.66 meq/g, 200-400 mesh) is measured into each of nine gas dispersion tubes (reaction tubes). The apparatus is assembled, swelled with 3 mL of dioxane and drained as set forth in Example 1. The appropriate reaction tubes are submerged in reaction wells containing a solution of 5 mL of either 0.2 M thiosalicylic acid, 5-chloro-thiosalicylic acid, or 2-mercaptonicotinic acid; and 0.4 M triethylamine in dioxane and magnetic stirring bars. The apparatus is sealed with clamps as set forth in Example 1 and placed over a magnetic stirring plate, while maintaining a positive nitrogen flow through the manifold. After 96 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 3 × 3 mL each of water, 1N HCl, 1N HCL:dioxane (1:1), and finally dioxane to remove residual reagents and byproducts. The reaction tubes are submerged in reaction wells containing a solution of 5 mL of 0.20 M carbonyldiimidazole in dioxane. The apparatus is assembled and agitated as above. After 5 hours, the
reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 4 × 3 mL each of DMF then dioxane. The appropriate reaction tubes are submerged in reaction wells containing a solution of 5 mL of either 0.20 M 4-methoxyaniline, cyclohexylamine, or benzylamine in dioxane. The apparatus is assembled as set forth in Example 1, while maintaining a flow of cold nitrogen. The apparatus is placed in an oil bath over a magnetic stirring plate and the reactions are warmed to reflux and stirred as above. After 24 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1. The reaction tubes are washed as set forth in
Example 3, using 4 × 3 mL each of DMF, methanol, CH2Cl2, and then dioxane.
The reaction tubes are submerged in reaction wells containing a solution of 5 mL of 0.13 M NaBrO2 in dioxane/water (8:1). The apparatus is assembled as set forth in Example 1, while maintaining a flow of nitrogen. The apparatus is placed over a magnetic stirring plate and stirred at room temperature as above. After 1 hhur, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 4 × 3 mL each of dioxane, water, dioxane/water (1:1), methanol, and then CH2Cl2.
Cyclization to the final product and thus cleavage from the resin is accomplished by addition of trichloroacetic anhydride to the sulfoxide and rearrangement as taught by Wright, et al, Tetrahedron Letters 1991; 33:153. Thus, reaction tubes are submerged in reaction wells containing a solution of 5 mL of CH2Cl2. The apparatus is assembled as set forth in Example 1, while maintaining a flow of nitrogen. The apparatus is then placed in a cold bath at 0°C and the reactions stirred as above. Trichloroacetic anhydride (0.18 mL) is then added to the top of each reaction tube through the gasket at the top of the manifold and the temperature of the reaction is allowed to warm to 25°C over 7 hours. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 2 × 3 mL each of CH2Cl2, dioxane, MeOH, and CH2Cl2. The appropriate filtrates are then combined and concentrated as set forth in Example 3. These crude products are partitioned between CH2Cl2 and 2N NaOH using a Tecan® robot to deliver the necessary liquids and to remove the aqueous layer. The basic aqueous wash is repeated and the residual CH2Cl2 layers are dried by passing the samples through a bed of MgSO4 contained in standard SPE cartridges employing the vacuum SPE apparatus described above to yield the crude benzisothiazolones.
Exmpte 12
Synthesis of Isoindolone-Based Spirosuccinimdes
The synthesis of nine spirosuccinimides is summarized in Scheme 12 and Table 12. A solution of 0.10 mol cyanoacetic acid and
0.10 mol carbonyldiimidazole are combined in 500 mL of dioxane. After 5 hours, 10 g of benzylhydroxy polystyrene resin (loading = 1.08 meq/g, 200 400 mesh) is added. The reaction is refluxed for 8 hours, cooled to room temperature, filtered, and washed with DMF, methanol, dioxane, and finally CH2Cl2. The product resin, benzyl cyanoacetate polystyrene resin, is used directly in the next step.
95 of 105 mg of the resin prepared above (loading = 1.08 meq/g, 200-400 mesh) is measured into each of nine gas dispersion tubes (reaction tubes). The apparatus is assembled, swelled with 3 mL of DMF and drained as set forth in Example 1.
The appropriate reaction tubes are submerged in reaction wells containing a solution of 5 mL of either 0.20 M 3-imino-1-oxoisoindoline, 6-chloro-3-imino-1-oxoisoindoline, or 6-phenyl-1-oxoisoindoline in diglyme with stirring magnetic bars. The 3-imino-1-oxoisoindoline employed are prepared by the method of Wrobel, et al, JOURNAL OF MEDICINAL CHEMISTRY 1992; 35:4613. The apparatus is sealed with clamps as set forth in Example 1, and placed in an oil bath over a magnetic stirring plate while maintaining a positive flow of cold nitrogen as set forth in Example 2. The reaction vessels are warmed to reflux, and after 2 hours the
reaction is stopped, and the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 3 × 3 mL each of dioxane, CH2Cl2, and DMF.
The appropriate reaction tubes are submerged in reaction wells containing a solution of 0.20 M alkyl halide (either methyl iodide, benzyl bromide and 3-bromobenzyl bromide) and 1 mmol K2CO3 in 5 mL of DMF. The apparatus is assembled as set forth in Example 1, while maintaining a positive flow of cold nitrogen as set forth in Example 2. The oil bath is then warmed to 100°C and agitated as above. After 24 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 3 × 3 mL each of DMF, water, MeOH, dioxane, CH2Cl2, and DMSO.
The reaction tubes are submerged in reaction wells containing a solution of 5 mL of 0.20 M potassium cyanide in DMSO. The apparatus is assembled as set forth in Example 1 and agitated as above. After 24 hours at 25°C, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 3 × 3 mL each of DMF, water, MeOH, water, and 10% aqueous HCl.
The reaction tubes are submerged in reaction wells containing a solution of saturated dry HCl in MeOH. The apparatus is assembled as set forth in Example 1 and agitated as above. After 3 days at 25°C, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 3 × 3 mL each of MeOH, dioxane, and CH2Cl2. The appropriate filtrates are then combined and concentrated as set forth in Example 3.
The crude products are dissolved in glacial HOAc and a holder block with nine clean empty reactions tubes is attached. The apparatus is assembled as set forth in Example 1 and agitated as above. After 24 hours at 25°C, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 3 × 3 mL of MeOH.
The appropriate filtrates are then combined and concentrated as set forth in Example 3 to yield the crude spiro[1H-isoindole-1,3'-pyrolidine]-2',3,5'(2H))triones.
Example 13
Synthesis of Pilocarpine Analogs
The synthesis of four pilocarpine analogs is summarized in Scheme 13 and Table 13. 95 to 105 mg of 2-Chloro-triphenylmethyl resin as taught by Barlos, et al, TETRAHEDRON LETTERS 1989 ,-30:3947 is measured into each of four gas dispersion tubes (reaction tubes). The apparatus is assembled, swelled with 3 mL of DMF, and drained as set forth in Example 1.
FMOC-histidine methyl ester is coupled to the resin. The reaction tubes are submerged in reaction wells containing a solution of 0.2 M FMOC-histidine methyl ester and 0.4 M pyridine in 3 mL dry THF. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath for 6 hours, while maintaining a positive nitrogen flow through the manifold. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1. The reaction tube array is subjected to the standard wash cycle set forth in Example 1.
To deprotect the FMOC amino acids, reaction tubes are submerged in reaction wells containing 3 mL of a solution of 25% piperidine in DMF. The apparatus is sealed as set forth in Example 1 and placed in a sonic bath, while maintaining a positive nitrogen flow through the manifold. The reaction is stopped after 4 hours. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tube array is subjected to the standard wash cycle set forth in Example 1.
The appropriate reaction tubes are submerged in reaction wells containing a solution of 0.2 M anhydride (either acetic anhydride or isobutyric anhydride) and 0.4 M triethylamine in 3 mL of dry THF. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath for 12 hours, while maintaining a positive nitrogen flow through the manifold. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tube array is subjected to the standard wash cycle set forth in Example 1.
The apparatus is sealed as set forth in Example 1 while maintaining a positive nitrogen flow through the manifold. A solution of lithium aluminum hydride (LAH) in dry THF (0.1 M, 3 mL) is then added to the top of each reaction tube through the gasket at the top of the manifold. The apparatus is placed in an oil bath heated at 67°C for 8 hours, while maintaining a positive chilled nitrogen flow through the manifold (as set forth in Example 2). The apparatus is cooled to room temperature and 1 mL of water is added to the top of each reaction tube through the gasket at the top of the manifold, and the apparatus sonicated at room temperature for 30 minutes to neutralize any unreacted
LAH. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tube array is subjected to the standard wash cycle set forth in Example 1, except that
a base wash cycle is added to remove the neutralized LAH salts.
The cyclic carbamate is formed according to the method of Gonzalez, et al, TETRAHEDRON LETTERS 1989; 30: 2145. The reaction tubes are submerged in reaction wells containing a solution of 0.2 M diethyl carbonate and 0.4 M NaOMe in MeOH. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath for 12 hours, while maintaining a positive nitrogen flow through the manifold. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tube array is subjected to the standard wash cycle set forth in Example 1. The appropriate reaction tubes are submerged in reaction wells containing a solution of 0.2 M iodoalkane (either 1-iodohexane, or iodomethane) in 3 mL of CH2Cl2. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath while maintaining a positive nitrogen flow through the manifold for 1 hour. The apparatus then placed in an oil bath heated at 37°C, while maintaining a positive chilled nitrogen flow through the manifold (as set forth in Example 2) for 6 hours. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tube array is subjected to the standard wash cycle set forth in Example 1.
To isolate and purify the products, the reaction tubes are submerged in reaction wells
containing a solution 3 mL each of MeOH. The apparatus is sealed as set forth in Example 1, placed in an oil bath and heated at 64°C while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. At the end of the reaction, the reaction tube array is allowed to cool and then drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 1, using 3 mL portions of methanol. The methanol extraction protocol is repeated until the filtrates are free of any organic components as determined by TLC (2 times). The appropriate methanol filtrates are then combined and concentrated on a Speed-Vac® in tared vials to afford four discrete products. Example 14
3-Substituted-(Aminomethyl)-3.4-dihydro-5.6-dihydroxy-1H-2-benzopyrans
The synthesis of six benzopyrans is summarized in Scheme 14 and Table 14.
10 g of Merrifield' s chloromethyl polystyrene resin (2% cross-linked, loading = 1.2 meq/g,
200-400 mesh) is reacted with excess sodium ethyl acetoacetate (10 eq) in DMF at 80°C for 16 hours. After washing with DMF and dioxane the crude beta-keto ester is hydrolyzed and decarboxylated 4N HCl: dioxane (1:1) at 60°C to give the phenethyl ketone resin, after washing with dioxane. This is further reacted with excess catechol and cat. p-TsOH in toluene at 90°C for
30 hours. The resin is thoroughly washed with toluene, dioxane, and CH2Cl2 to remove all catechol. The crude resin is then used directly below.
95 to 105 mg of the catechol ketal resin prepared above is measured into each of six gas dispersion tubes (reaction tubes). The reaction tubes are fitted into the appropriate holder block and swelled and drained as set forth in Example 1.
The appropriate reaction tubes are submerged in reaction wells containing a solution of nBuLi (1 eq) in THF at 0°C. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath (maintained at 0°C as set forth in Example 5), while maintaining a positive nitrogen flow through the manifold. After 1 hour, the bath is warmed to room temperature and sonicated for 3 hours more. The bath is then recooled to 0°C and a solution of either cyclohexyl- or phenyl- ethyleneoxide (2 eq) in THF (0.5 mL) is then added to the top of the appropriate reaction tube through the gasket at the top of the manifold. The bath is again warmed to room temperature and sonicated for 2 hours. The apparatus is then removed from the sonic bath, and 0.5 mL of THF:H2O (1:1) are added to the top of each reaction tube through the gasket at the top of the manifold as above, to quench any excess n-BuLi. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1. The reaction tubes are washed as set forth in
Example 3, using 3 × 3 mL each of dioxane: sat NH4Cl (1:1), dioxane:H2O (1:1), and dioxane.
The appropriate reaction tubes are submerged in reaction wells containing a solution of (2 eq) of either bromoacetaldehyde dimethyl acetal (4 reaction tubes) or [(formylamino)methyl]acetaldehyde dimethyl acetal (2 reaction tubes); and BF3OEt2 (3 eq) in Et2O
(3 mL) at 0°C. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at room temperature for 24 hours, while maintaining a positive nitrogen flow through the manifold. At the end of the reaction, the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 3 × 3 mL each of dioxane:H2O (1:1), dioxane:H2O 0.1N NaOH (1:1), dioxane:H2O (1:1), dioxane. The appropriate four reaction tubes are submerged in reaction wells containing a solution of either allylamine or benzylamine (2 eq) in dioxane (4 mL) at room temperature. The other two reaction tubes (those which are reacted with [(formylamino)methyl]-acetaldehyde dimethyl acetal above) are submerged in wells containing a solution of dioxane:MeOH: 15% NaOH (2:2:1) 5 mL at room temperature. The apparatus is sealed as set forth in Example l and agitated in a sonic bath at 60°C as set forth in Example 5, while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. After 8 hours the reaction is stopped, the reaction tube array is allowed to cool, and then drained and sparged as set forth in Example 1. The reaction tubes are washed as set forth in
Example 3, using 3 × 2 mL each of dioxane, dioxane:H2O (1:1), dioxane.
In order to cleave the products from the solid support, the reaction tubes are submerged in reaction wells containing a solution of 3 mL of 5 M HCl in dioxane: ethanol (1:1). The apparatus is sealed as set
forth in Example 1 and agitated in a sonic bath at 80°C for 4 hours as set forth in Example 5, while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. After 4 hours the reaction is stopped, the reaction tube array is allowed to cool, and then drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 3 × 3 mL of dioxane:ethanol (1:1). The filtrates are then combined and concentrated as set forth in Example 3. The crude products are then redissolved, transferred to tared vials, and reconcentrated. The final crude products including, cis-1-(aminomethyl)-3-cyclohexyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride; cis- 1 -(aminomethyl)-3-phenyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride; cis-1-[(allylamino)methyl]-3-cyclohexyl-3,4-dihydro-5,6-dihydroxy-1H-2 -benzopyranhydrochloride; cis-1-[(allylamino)methyl]-3-phenyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyranhydrochloride; cis -1-[(benzylamino)methyl]-3-cyclohexyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride; cis-1-[(benzylamino)methyl]-3-phenyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride; are set forth in Table 14. Example 15
6,7-Dihydro-4H-pyrazolo-1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-diones
The synthesis of eight pyrimidinediones is summarized in Scheme 15 and Table 15.
15 g of Merrifield' s chloromethyl polystyrene resin (2% cross-linked, loading = 0.7 meq/g,
200-400 mesh) is reacted with excess cesium acrylate (10 eq) and Nal (0.1 eq) in DMF at 80°C for 14 hours to yield the desired ester. The resin is thoroughly washed with DMF, dioxane:H2O (1:1), dioxane, and CH2Cl2 to remove excess reagents. The crude resin is then used directly below.
95 to 105 mg of the acrylate ester resin prepared above is measured into each of eight gas dispersion tubes (reaction tubes). The reaction tubes are fitted into the holder block and swelled and drained as set forth in Example 1.
The appropriate reaction tubes are submerged in reaction wells containing a solution of either cyclohexylamine or n-hexylamine (1 eq) in 3 mL of DMF at room temperature. The apparatus is sealed as set forth in Example l and agitated in a sonic bath (maintained at room temperature as set forth in Example 5), while maintaining a positive nitrogen flow through the manifold. After 24 hours, a solution of diethyl oxalate (1 eq) and Na2CO3 (1 eq) in 1 mL of DMF is added to the top of the each reaction tube through the gasket at the top of the manifold. The bath is warmed to 60°C and sonicated for 2 hours. At the end of the reaction, the reaction tube array is allowed to cool and then drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 3 × 2 mL each of dioxane: sat. NH4Cl (1:1), dioxane:1N HCl (1:1), dioxane:H2O (1:1), and dioxane. In order to cleave the products from the solid support, the appropriate reaction tubes are submerged in
reaction wells containing a solution of (1 eq) of either 5-phenylpyrazol-3-amine or 5-(4-chlorophenyl)pyrazol-3-amine in HOAc (4 mL) at room temperature. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath at 100°C for 2 hours as set forth in Example 5, while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. At the end of the reaction, the reaction tube array is allowed to cool and then drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 3 × 2 mL of dioxane:ethanol. The filtrates are then combined and concentrated as set forth in Example 3. The crude products are then redissolved, transferred to tared vials, and reconcentrated.
In an example of a post-cleavage reaction, a solution of either 2-chloroacetophenone (2 eq) and K2CO3 (1.1 eq) in DMF (3 mL) or 1-bromo-5-hexene (2 eq) and K2CO3 (1.1 eq) in DMSO (3 mL) is added to the appropriate reaction wells. A holder block with clean empty reaction tubes is added and the apparatus is sealed and agitated as set forth in Example 1 in a sonic bath at 40°C for 22 hours as set forth in Example 5, while maintaining a positive chilled nitrogen flow through the manifold as set forth in Example 2. At the end of the reaction, the reaction tube array is allowed to cool and then drained and sparged as set forth in Example 1
The crude reaction mixtures are transferred to the corresponding tubes in the SPE apparatus equipped with 20 mL columns and 5 μm. filters. Each reaction mixture is diluted and mixed with 15 mL of H2O to
precipitate the desired products. The suspensions are then filtered and washed with H2O and Et2O (3 × 2 mL, each). The resulting solids are then dissolved with CH2Cl2 (3 × 2 mL washes) run through the filter and collected in clean tubes. These solutions are then concentrated as set forth in Example 3. The crude products are then redissolved, transferred to tared vials, and reconcentrated. The final crude products including, 6-Cyclohexyl-6,7-dihydro-4-(phenylmethyl)-2-phenyl-4H-pyrazolo[1,5a]pyrrolo[3,4-d]-pyrimidine- 5,8-dione; 6-Cyclohexyl-6,7-dihydro-4-(2-oxo- 2-phenylethyl)-2-phenyl-4H-pyrazolo[1,5-a]pyrrolo[3,4-d]-pyrimidine-5,8-dione; 6-Cyclohexyl-6,7-dihydro- 4-(phenylmethyl)-2-(4-chlorophenyl)-4H-pyrazolo[1,5-a]pyrrolo[3,4-d]-pyrimidine-5,8-dione; 6-Cyclohexyl- 6,7-dihydro-4-(2-oxo-2-phenylethyl)-2-(4-chlorophenyl)-4H-pyrazolo[1,5-a]pyrrolo[3,4-d]-pyrimidine-5,8-dione;6-Hexyl-6,7-dihydro-4-(phenylmethyl)-2-phenyl-4H-pyrazolo[1,5-a]pyrrolo[3,4-d]-pyrimidine-5,8-dione; 6-Hexyl-6,7-dihydro-4-(2-oxo-2-phenylethyl)-2-phenyl-4H-pyrazolo[1,5-a]-pyrrolo[3,4-d]-pyrimidine-5,8-dione; 6-Hexyl-6,7-dihydro-4-(phenylmethyl)-2-(4-chlorophenyl)-4H-pyrazolo[1,5-a]pyrrolo[3,4-d]-pyrimidine-5,8-dione; 6-Hexyl-6,7-dihydro-4-(2-oxo-2-phenylethyl)-2- (4-chlorophenyl)-4H-pyrazolo[1,5-a]pyrrolo[3,4-d]-pyrimidine-5,8-dione are set forth in Table 15.
Example 16
Synthesis of Tenoxalin Derivatives
The synthesis of eight tepoxalin derivatives is summarized in Scheme 16 and Table 16.
95 to 105 mg of benzylhydroxy polystyrene resin (loading = 1.08 meq/g, 200-400 mesh) is measured into each of eight gas dispersion tubes (reaction tubes). The apparatus is assembled, swelled with 3 mL of DMF, and drained as set forth in Example 1.
A solution (5 mL) of either 0.20 M 6-phenyl-4,6-dioxohexanoic acid, or 6-(4-chlorophenyl)-4,6-dioxohexanoic acid and 0.20 M carbonyldiimdazole in CH2Cl2 are stirred for 6 hours at room temperature. The two6-aryl-4,6-dioxohexanoic acids employed are prepared by the method of Murray, et al, JOURNAL OF ORGANIC CHEMISTRY1990;55:3424.
The appropriate reaction tubes are submerged in the reaction wells above. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath while maintaining a positive nitrogen flow through the manifold. After 12 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1. The reaction tubes are washed as set forth in
Example 3, using 3 × 3 mm each of DMF, MeOH, dioxane, CH2Cl2, and MeOH.
The appropriate reaction tubes are submerged in reaction wells containing a solution of 5 mL of either 0.2 M 4-methoxyphenylhydrazine hydrochloride or 4-methylphenylhydrazine hydrochloride and 0.2 M triethylamine in MeOH. The apparatus is sealed as set forth in Example 1 and agitated in a sonic bath, while maintaining a positive nitrogen flow through the manifold. After 12 hours, the reaction is stopped and
the reaction tube array is drained and sparged as set forth in Example 1.
The reaction tubes are washed as set forth in Example 3, using 3 x 3 mL each of DMF, MeOH, dioxane, and CH2Cl2.
Cleavage is accomplished by aminolysis of the resin ester linkage. Thus, the appropriate reaction tubes are submerged in reaction wells containing a solution of 5 mL of either 0.20 M methylhydroxylamine hydrochloride or benzylhydroxylamine hydrochloride and 0.2 M triethylamine in CH2Cl2 along with stirring bars. The apparatus is sealed with clamps as set forth in Example 1 and placed in an oil bath over a magnetic stirring plate while maintaining a positive flow of cold nitrogen as set forth in Example 2. The reaction vessels are warmed to reflux and stirred as above. After 24 hours, the reaction is stopped and the reaction tube array is drained and sparged as set forth in Example 1. The reaction tubes are washed as set forth in
Example 3, using 3 x 3 mL each of MeOH, dioxane, and CH2Cl2.
The appropriate filtrates are then combined and concentrated as set forth in Example 3. These crude products are partitioned between CH2Cl2 and 1 M HCl using a Tecan® robot to deliver the necessary liquids and to remove the aqueous layer. The acidic aqueous wash is repeated and the residual CH2Cl2 layers are dried by passing the samples through a bed of MgSO4 contained in standard SPE cartridges employing the vacuum SPE
apparatus described above to yield tepoxalin and the expected tepoxalin derivatives.
BBN represents the building blocks which are bifunctional to allow sequential attachment. The curved structure represents the solid support where the asterick is the functionality capable of covalently attaching the growing molecule to the solid support.
The three possible cleavage modes are illustrated. Cleavage 1 represents the third building block attacking the solid support linkage to cleave the final molecule. This provides structural vaiation at the former site of attachment to the support. Cleavage 2 represents a distal functionality attacking the solid support linkage to cleave the final molecule as a cyclized product. Cleavage 3 represents a cleavage by an invariant agent. This provides a constant functional group at the former site of attachment to the support.
I
The invention of the '483 patent describes the use of apparatus which facilitates the simultaneous introduction of multiple reagents to reaction or test wells. The invention described herein is applicable to a technique which permits the multistep, multireagents to obtain mixtures of unique reaction products.
Combinatorial Mixtures
For The Synthesis Of Amides
A 2-step reaction utilizing four building blocks for the manufacture of amides can be described below (Schemes 17 and 18 and Tables 17 and 18). P indicates polymeric support and the letters A, B, C, or D indicate reactants and the numbers 1, 2, 3, or 4 likewise indicate reactants. In the X and Y-plates, there are four wells in each. The materials are prepared as follows with the reagents being placed in each of the wells as described. The individual materials made in each of the wells follows what is called a deconvolution technique. Convolute means to be coiled or wound together. Deconvolute therefore means the uncoiling or the unwinding of the mixture. In the present case, deconvolution means the ascertaining of the unique reaction product in the reaction or test wells containing the mixture of the products. Listed below (Scheme 19 and Table 17) is a proposed synthesis route and technique to deconvolute the products.
3-Step Reaction Utilizing Three Building Blocks
Following a similar technique as outlined above for the 2-step reaction with four building blocks, listed below in Schemes 20 and 21 and Table 19 is a 3-step reaction using three building blocks. The letters A, B and C, X, Y and Z are reactants and the numbers 1, 2 and 3 are likewise reactants. The reaction procedure can be outlined below:
3-Step Reaction Utilizing Four Building Blocks
Following the technique outlined above, listed below in Schemes 22 and 23 and Table 20 is a technique for a 3-step reaction utilizing four building blocks where the letters A, B, C, and D, W, X, Y and Z are reactants and the numbers 1, 2, 3, and 4 further designate reactants.
General Description of Experimental Procedure Utilizing A Solid Support
A number of reaction vessels equal to the total number of wells to be synthesized by the array method are loaded with 1-1000 mg of the appropriate functionalized solid support, preferably 1-3% cross-linked polystyrene. The individual reaction vessels are charged with a volume, preferably 3-5 mL, of a solvent capable of swelling the polystyrene resin (such as, but not limited to, dichloromethane, chloroform, dimethylformamide (DMF), dioxane, toluene, tetrahydrofuran (THF)).
The reaction vessels are emptied of solvent and the proper reactant solutions are dispensed into the reaction vessels at appropriate locations in the array. If the reactant is actually one of the building blocks that is to become covalently attached to the growing compound on the solid support, the quantity of reactant is usually 0.1-100 equivalents based on the meq/g loading of functionalized solid support (typically 0.1 - 1.0 meq/g for polystyrene resins) originally weighed into the reaction tube. If a mixture of reactants are charged to single resin-bound starting material or intermediate to generate a mixture of resin-bound or cleaved products, equimolar amounts of each reagent are preferable. For example, if four reactants are charged to a single resin-bound intermediate, 0.25 equivalents of each reactant should provide some quantity of each target compound in the final mixture , allowing for differing reaction kinetics of individual reactants. Additional equivalents of single or multiple reactants can be used if required to drive the reaction to completion in a reasonable time. Agitation is achieved by shaking, sonication, or magnetic stirring. The
reaction is allowed to proceed for an amount of time deemed necessary from the preliminary validation experiments or monitored by removal and quantitative analysis of filtrate aliquots from selected wells by methods such as GC/ISTD (internal standard) or HPLC/ISTD. The resin-bound intermediates within each reaction vessel are washed clean of excess retained reagents, solvents, and by-products by repetitive exposure to clean solvent (s). The washing procedure is repeated 1-50 times, monitoring the efficiency of reagent, solvent, and byproduct removal by methods such as TLC, GC, or visualization of the wash filtrates.
The above described procedure of reacting the resin-bound compounds with reagents within the reaction vessels followed by removal of excess reagents, byproducts, and solvents is repeated with each successive transformation until the final or penultimate resin-bound compounds are prepared.
Detachment of the final products from the solid support is achieved with a solution of a cleavage reagent (preferably 3-5 mL). Gas flow, temperature control, agitation, and reaction monitoring are implemented as above and as desired to affect the detachment reaction. The spent resin in the reaction vessels is then washed 2-5 times as above with 3-5 mL of an appropriate solvent to extract (wash out) as much of the detached products as possible. The final product solutions are combined, taking care to avoid cross-mixing. The individual solutions/extracts are then manipulated as needed to isolate the final compounds.
Typical manipulations include, but are not limited to, evaporation, concentration, liquid/liquid extraction,
acidification, basification, neutralization or additional reactions in solution.
Example 17 Synthesis of Substituted Amides Approximately 800 mg of commercially available cross-linked hydroxymethyl divinylbenzene-styrene resin
(loading = 0.65 meq/g, 200-400 mesh, 1% Divinylbenzene
Crosslinked) was weighed into each of 8 reaction tubes.
The apparatus was assembled, nitrogen atmosphere was initiated, and 10 mL of DMF was injected into each reaction tube. A 1.0 mL solution of diisopropylcarbodiimide (DIC, 263 mg, 2.08 mmol, 4 eq) and N,N-dimethylaminopyridine (DMAP, 6.25 mg, 0.053 mmol, 0.1 eq) in DMF was delivered to each reaction tube. The appropriate carboxylic acids were injected as solutions into each reaction tube. 1.0 mL each of 0.52M 2-ethyl butyric acid in DMF (1 eq), 0.52M 2-propyl pentanoic acid in DMF (1 eq), 0.52M diphenylacetic acid in DMF (1 eq), and 0.52M bis-(p-chlorophenyl)-acetic acid in DMF 1 eq) were delivered to reaction tubes 1, 2, 3, and 4 of plate X respectively (X1-X4). A solution of the mixture of the carboxylic acids was made by combining 1.0 mL each of 0.52M 2-ethyl butyric acid in DMF, 0.52M 2-propyl pentanoic acid in DMF, 0.52M diphenylacetic acid in DMF, and 0.52M bis-(p-chlorophenyl)-acetic acid in DMF. The resultant mixture contained an equimolar concentration of each carboxylic acid. 1.0 mL of the dissolved acid mixture was dispensed into each reaction tube in plate Y (Y1-Y4) to provide 0.25 equivalents each of 2-ethyl butyric acid, 2-propyl pentanoic acid, diphenylacetic acid, and bis-(p-chlorophenyl)-acetic acid in each reaction tube, based upon indicated loading of commer
cial resin. The apparatus was agitated at 20-25 ºC in a sonic bath for 48 h, while maintaining a positive nitrogen flow through the manifold. At the end of the reaction, the reaction tube array was drained and sparged with nitrogen.
The reaction tubes were subjected to a series of wash cycles to remove residual solvents, reagents, and byproducts. A standard protocol included sequentially submerging the reaction tubes in 10-15 mL each of 2 × DMF, 2 × methanol, 2 × water, 2 × tetrahydrofuran (THF), and 2 × dichloromethane (DCM) followed by agitation by ultrasound for 10-15 minutes, and finally draining by gravity and nitrogen sparge.
To facilitate cleavage and amide formation, the apparatus was assembled, argon atmosphere was initiated, and 10 mL of anhydrous toluene was delivered into each reaction tube. A 1.0 mL solution of boron tribromide solution in DCM (1.0 m) was injected into each reaction tube. The apparatus was agitated in a sonic bath for 1.5 h, while maintaining a positive argon flow through the manifold. Following activation of the resin-bound ester with boron tribromide, the appropriate amines were injected as solutions in toluene into each reaction tube. A solution mixture of the amines was made by combining 1.0 mL each of 0.52M benzylamine in toluene, 0.52M diethylamine in toluene, 0.52M aniline in toluene, and 0.52M cyclohexylamine in toluene. The resultant mixture contained an equimolar concentration of each amine. 1.0 mL of the dissolved amine mixture was dispensed into each reaction tube in plate Y (Y1-Y4) to provide 0.25 equivalents each of benzylamine, diethylamine, aniline, and cyclohexylamine in each reaction tube, based upon indicated loading of commercial resin.
The apparatus was agitated at 20-25 ºC in a sonic bath for 48 h, while maintaining a positive argon flow through the manifold. At the end of the reaction, the reaction tube array was drained and sparged with nitro- gen.
To isolate and purify the products, the reaction tubes, were sequentially submerged in reaction wells containing 10 mL each of toluene and DCM. The apparatus was agitated in a sonic bath for 10-15 minutes to extract the amides from the resins then drained by gravity and nitrogen sparge. A second extraction protocol with 5 mL each of 1M HCl was executed to thoroughly remove ureacted amines.
The filtrates were combined and the upper organic layer was separated. The combined organic extracts were washed with 1M HCl (2 × 10 mL), 1M NaOH (1 × 10 mL), and saturated NaCl (1 × 10 mL), dried with MgSO4, filtered, and concentrated to yield the expected mixtures of substituted amides. The 8 unique mixtures were characterized by 1H-NMR, and MS. The crude yields range from 6 to 23%. See Table 21.
Shown in Figure 1 are proposed combination statistics demonstrating the number of building blocks per step, namely, 4, 5 or 6 building blocks. Further indicated are the total number of reaction wells that may be utilized as well as the total number of compounds that may be produced. The small black box indicates the number of compounds per well. Table 18 shows the combinatorial statistics that may be obtained utilizing the techniques of the present invention, namely that combinations of mixtures of materials are synthesized and a rapid technique can be obtained for testing high numbers of different materials for biological or other activity.
In copending application Serial No.
(Case # PD 5137-01) filed concurrently herewith, entitled "Method and Apparatus for Simultaneously Testing a Plurality of Compounds to Detect Their Activity", commonly assigned to the assignee of the present invention, there is a discussion as to a large number of activities or biological assays that compounds can be tested for. Because the technique as described herein for the synthesis of mixtures of compounds are likewise useful for a rapid screening technique, the present invention is equally applicable toward the screens or activities as described therein. In other words, through the synthesis of mixture of compounds described herein, the mixtures may be tested without separating the materials. The screens can be used for determining a variety of biological activities as well as other utilities such as rust remover activity, ability to die textile materials, ability to clean substrates, ability to decompose in the presence of soil bacteria, ability to hybridize to a library of genes, ability to detect sunscreen activity, ability to detect immune response to
mammals, ability to detect the presence or absence of a gene associated with a malady, ability to detect the activity of a gene associated with a biological response in mammals, ability to detect permeability of a membrane such as a cell, ability to detect signal transduction of a cell, ability to bind to a cell, ability to bind to an enzyme, ability to bind to an antibody, and the like. For a more detailed listing of screens or assays, see the aforementioned S.N.
, filed concurrently.
The present invention is equally applicable to determining an optimized dosage or weight for active compounds. In other words, the present invention can assist in quantitatively determining active materials and their degree of activity. In this manner, identical or differential amounts of a compound(s) to be tested are placed in various unique well locations.
Further, by the present invention, one may ascertain from the mixture of different compounds with unique molecular weights in the wells which materials were synthesized and are particularly active. One could therefore confirm and select for appropriate target molecules by the present invention. For example, as part of an analysis by mass spectrometry of a mixture of products in the wells one could confirm the synthesis of individual components within a matrix. The particular desired synthetic compounds would be uniquely designed and identified.
Further, by utilizing NMR techniques one could quantitate activities for individual materials within each matrix. At the end of the synthesis and NMR analysis, one would be able to quantify the desirable
materials made, the desirable target molecular weights (in combination with mass spectrometry) and the concentration of the desired products. NMR, in combination with internal or external standards, could be used to quantitate the amounts of each individual compound in a synthetic mixture of products. Following synthesis, analysis, and testing, identification of potency by quantitative deconvolution would be achieved.
A general way of reviewing the ascertainment of compounds that are biologically active after the mixture has been detected to have biologic activity is described below. This is utilization of the concept "deconvolution", namely, the ascertainment of an individual compound that is reactive in a mixture. The key concept behind the method of deconvolution is that each well corresponds to a unique building block used in forming the compounds. Suppose each compound to be analyzed is formed in N steps; in other words, each compound consists of N building blocks. Each of the building blocks can be represented by a variable Bij, where i is an index variable which indicates the step for which the building block Bij is employed in forming a compound. An index variable j is used to distinguish between m different building blocks which can be used for each step i.
In order to further clarify the definition of Bij, the different building blocks used at each step are grouped as follows:
All building blocks All building blocks All building blocks
used in step 1 used in step 2 used in step N
B 11, B11, ..., B1m B21, B22. . .. B2m . . . BN1, BN2, ..., BNm
Each compound can be represented by a string formed by concatenating N building block variables, i.e., exactly one building block from each of the above groups. For example, {B11 B24 B33 ... BN2} represents one of the compounds.
In the step of creating the plates, each building block Bij is assigned to a corresponding well Wij. More specifically, the well Wij contains all possible compounds formed using building block Bij. This is illustrated by the following example using N=3 steps and m=2 building blocks per step.
Example (N = 3 , m = 2 )
Hence, plate 1 corresponds to the first building block, plate 2 corresponds to the second building block, and plate N corresponds to the Nth building block.
If a "hit" (or positive cavity) occurs for well Wij, it can be concluded that there exists an active compound having a Bij as a building block. Hence, one active compound will result in N hits, with each plate having one hit.
The method of deconvolution can be summarized as follows: using the observed hits, form all possible combinations of these observed hits using exactly one hit per plate. The potentially active components are then represented by these combinations.
Example (N = 3, m = 2):
Suppose the hits are in wells W11, W21, and W32. The potentially active compound is {B11 B21 B32}.
Next, suppose the hits are in wells Wu, W2J, W22, and W32. The potentially active compounds are {B11 B21 B32} and {B11 B22 B32}.
In general, the method of the present invention allows the testing of mN different compounds using mN total wells. The resulting fraction of wells per compound is mN/mN, which simplifies to N/mN-1. The number of compounds in each well is mN-1. Using N plates to separate the wells results in m wells per plate.
The above can be applied to the testing shown in Tables 20 and 21 as follows.
Plate Creation
A. Make up N "plates", numbers P=l to N.
B. Each plate has Bmax wells, numbered W=l to Bmax.
C. Into well "W" of plate "P", put exactly one copy of each string (compound) being Building Block Bij = Brø. If max (By) for each step i = Bmax, there will be (Bmax)N-1 such strings. For any string of length N, with j building blocks at step i = Bij, max (Bij) ≡ Bmax. Note: Each string (compound) will occur exactly once on each plate in this scenario.
Plate Deconvolution A. Let the property be binary (1= Hit, 0= No Hit), contain no missing data.
C. Matrix of Hits
If exactly one string is a hit and since each string occurs exactly once on each plate, then each row of the matrix W^ will have values = 0 except for a single "1" in the well containing the active string. Similarly, each column will have only one value = 1. Therefore, the non-zero entries of Wij matrix = Wij hit. For plate 1 = row 1 = Wij hit, the hit occurs in column = j corresponding to well,
, corresponding to building block
Therefore, for each row (plate) i of Wij,
For each column (well) j of Wij;
If Wij =∅, ignore it
otherwise (i.e., Wij = 1).
End: otherwise,
next j
Each well :
(See Table 20)
If "231" is the hit, then:
where = plate X (1)
plate Y (2)
plate Z (3)
Application of Algorithm:
For row 1
For column 2 (hit), position 1 of string - B12 For row 2
For column 3 (hit), position 2 of string = B23=2
For row 3
For column 1 (hit), position 3 of string = B31=X So string = B2X
Multiple Hits; Quantitative Deconvolution
A. Qualitative Hits: Uncertainty of Deconvolution
The basic algorithm breaks down and any of the following could produce this result:
B2X + C2Y
B2X + C2Y + C2X
B2Y + B2X + C2X + C2Y
B2Y + C2X + C2Y
B2Y + C2X
compatible with all 27 possible strings.
B. Quantitative Hits (Based on Analytical Calibration)
Suppose B2X has hit value = 3
& C2Y has hit value = 2
Therefore, "5" is clearly a sum, since its a single value in rows that generally have 2 values. However, B2X with hit value = 2
& C2Y with hit value = 2
Ambiguous because hits could also be:
Other alternative combinations may be possible.
While the forms of the invention herein disclosed constitute presently preferred embodiments, others may be possible. It is not intended herein to mention all of the possible equivalent forms or ramifications of the invention. It is understood that terms used herein are merely descriptive rather than limited, and that various changes may be made without departing from the spirit or scope of the invention.
Claims
1. A method of synthesizing a plurality of compounds in a plurality of wells comprising the steps of:
(a) providing a plurality of test wells in a plurality of arrays of the wells;
(b) reacting in at least a one step reaction a first reagent with a plurality of reagents called building blocks in the test well to obtain a unique product designed to be the same in each array; and
(c) continuing to react the same or additional reagents such that there are multiple reagents resulting in mixtures of multiple different products in each well.
2. The method of claim 1 wherein there are at least two steps to the reaction scheme.
3. The method of claim 1 wherein there are at least three steps to the reaction scheme.
4. The method of claim 1 wherein there are at least three building blocks for each step.
5. The method of claim 1 wherein there are at least four building blocks for each step.
6. The method of claim 1 wherein there are at least two arrays of test wells.
7. The method of claim 1 wherein there are at least three arrays of test wells.
8. The method of claim 1 wherein there are at least four arrays of test wells.
9. The method of claim 1 wherein the compounds synthesized are dipeptides.
10. The method of claim 1 wherein the compounds synthesized are hydantoins.
11. The method of claim 1 wherein the compounds synthesized are benzodiazepines.
12. The method of claim 1 wherein the com- pounds synthesized are quinolones.
13. The method of claim 1 wherein the compounds synthesized are keto-ureas.
14. The method of claim 1 wherein the compounds synthesized are N2-substituted hydantoins.
15. The method of claim 1 wherein the compounds synthesized are (R)-4-benzamido-5-oxopentanoic acids.
16. The method of claim 1 wherein the compounds synthesized are diketopiperazines.
17. The method of claim 1 wherein the compounds synthesized are tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-lyl)ethyl]-2H-pyran-2-ones.
18. The method of claim 1 wherein the compounds synthesized are N-arylpiperazines.
19. The method of claim 1 wherein the compounds synthesized are benzisothiazolones.
20. The method of claim 1 wherein the compounds synthesized are isoindolone-based spirosuccinimdes.
21. The method of claim 1 wherein the compounds synthesized are pilocarpine analogs.
22. The method of claim 1 wherein the compounds synthesized are 3substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans.
23. The method of claim l wherein the compounds synthesized are 6,7-dihydro-4H-pyrazolo[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-diones.
24. The method of claim 1 wherein the compounds synthesized are tepoxalin derivatives.
25. The method of claim 1 further comprising analyzing the mixtures of reaction products to identify the unique products produced.
26. The method of claim 25 wherein the analysis is performed by nuclear magnetic resonance.
27. The method of claim 25 wherein the analysis is performed by mass spectroscopy.
28. The method of claim 25 wherein the analysis of the mixtures is performed by comparing the spectra of different mixtures of known compounds to confirm the presence or absence of desired products.
29. A method of simultaneously testing a plurality of compounds for activity comprising the steps of:
(a) providing a plurality of test wells in a plurality of arrays of the wells;
(b) reacting in at least a one step reaction a first reagent with a plurality of reagents called building blocks in the test well to obtain a unique product designed to be the same in each array;
(c) continuing to react reagents such that there are multiple reagents resulting in mixtures of multiple different products in each well;
(d) determining the location of each compound in each test well;
(e) subjecting the arrays of mixtures of products to a testing screen; and
(f) ascertaining those compounds that had a positive response to the testing screen.
30. The method of claim 29 further comprising ascertaining quantitative data from the testing screen.
31. The method of claim 29 wherein there are at least two steps to the reaction scheme.
32. The method of claim 29 wherein there are at least three steps to the reaction scheme.
33. The method of claim 29 wherein there are at least three building blocks for each step.
34. The method of claim 29 wherein there are at least four building blocks for each step.
35. The method of claim 29 wherein there are at least two arrays of test wells.
36. The method of claim 29 wherein there are at least three arrays of test wells.
37. The method of claim 29 wherein there are at least four arrays of test wells.
38. The method of claim 29 further comprising analyzing the mixtures of reaction products to identify the unique products produced.
39. The method of claim 38 wherein the analysis is performed by nuclear magnetic resonance.
40. The method of claim 38 wherein the analysis is performed by mass spectroscopy.
41. The method of claim 39 wherein the analysis of the mixtures is performed by comparing the spectra of different mixtures of known compounds to confirm the presence or absence of desired products.
42. The method of claim 40 further comprising designing molecular weights of products and analyzing the mixtures to confirm those compounds which were synthetically achieved.
43. The method of claim 41 further comprising utilizing quantitative methods in combination with NMR for the compounds synthesized and ascertaining individual product yields and concentrations.
44. The method of claim 43 wherein the product mixtures are tested to ascertain quantitative activity for individual components.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU44244/96A AU4424496A (en) | 1995-03-27 | 1995-12-08 | A method for the synthesis of mixtures of compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41104095A | 1995-03-27 | 1995-03-27 | |
US08/411,040 | 1995-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996030393A1 true WO1996030393A1 (en) | 1996-10-03 |
Family
ID=23627317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/016332 WO1996030393A1 (en) | 1995-03-27 | 1995-12-08 | A method for the synthesis of mixtures of compounds |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4424496A (en) |
WO (1) | WO1996030393A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998015532A1 (en) * | 1996-10-09 | 1998-04-16 | Novartis Ag | Solid phase synthesis of heterocyclic compounds |
EP1959255A3 (en) * | 1997-04-04 | 2008-09-24 | Caliper Life Sciences, Inc. | Closed-loop biochemical analyzers |
US7491743B2 (en) | 2003-08-29 | 2009-02-17 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis |
US7932213B2 (en) | 1999-05-11 | 2011-04-26 | President And Fellows Of Harvard College | Small molecule printing |
US8697362B2 (en) | 2002-12-20 | 2014-04-15 | Caliper Life Sciences, Inc. | Methods of detecting low copy nucleic acids |
US9499521B2 (en) | 2014-12-11 | 2016-11-22 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis and related methods |
US9586880B2 (en) | 2008-12-23 | 2017-03-07 | President And Fellows Of Harvard College | Small molecule inhibitors of necroptosis |
US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0355582A2 (en) * | 1988-08-23 | 1990-02-28 | Boehringer Ingelheim Kg | Process and apparatus to simultaneously synthesize several polypeptides in a fully automated way |
WO1990002605A1 (en) * | 1988-09-02 | 1990-03-22 | Meldal Morten | An apparatus and a method for the synthesis of peptides |
WO1992002303A1 (en) * | 1990-08-07 | 1992-02-20 | Pharmacia Lkb Biotechnology Ab | Apparatus for carrying out biochemical reactions |
EP0542422A1 (en) * | 1991-11-12 | 1993-05-19 | General Atomics | Multi-well microtiter plate |
WO1993009668A1 (en) * | 1991-11-22 | 1993-05-27 | Affymax Technology N.V. | Combinatorial strategies for polymer synthesis |
WO1994005394A1 (en) * | 1992-09-02 | 1994-03-17 | Arris Pharmaceutical Corporation | Specification method and apparatus for peptide synthesis and screening |
WO1994008711A1 (en) * | 1992-10-08 | 1994-04-28 | Warner-Lambert Company | Apparatus and method for multiple simultaneous synthesis |
WO1994024314A1 (en) * | 1993-04-19 | 1994-10-27 | Kauffman Stuart A | Random chemistry for the generation of new compounds |
WO1995011262A1 (en) * | 1993-10-22 | 1995-04-27 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and method for polymer synthesis using arrays |
-
1995
- 1995-12-08 WO PCT/US1995/016332 patent/WO1996030393A1/en active Search and Examination
- 1995-12-08 AU AU44244/96A patent/AU4424496A/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0355582A2 (en) * | 1988-08-23 | 1990-02-28 | Boehringer Ingelheim Kg | Process and apparatus to simultaneously synthesize several polypeptides in a fully automated way |
WO1990002605A1 (en) * | 1988-09-02 | 1990-03-22 | Meldal Morten | An apparatus and a method for the synthesis of peptides |
WO1992002303A1 (en) * | 1990-08-07 | 1992-02-20 | Pharmacia Lkb Biotechnology Ab | Apparatus for carrying out biochemical reactions |
EP0542422A1 (en) * | 1991-11-12 | 1993-05-19 | General Atomics | Multi-well microtiter plate |
WO1993009668A1 (en) * | 1991-11-22 | 1993-05-27 | Affymax Technology N.V. | Combinatorial strategies for polymer synthesis |
WO1994005394A1 (en) * | 1992-09-02 | 1994-03-17 | Arris Pharmaceutical Corporation | Specification method and apparatus for peptide synthesis and screening |
WO1994008711A1 (en) * | 1992-10-08 | 1994-04-28 | Warner-Lambert Company | Apparatus and method for multiple simultaneous synthesis |
WO1994024314A1 (en) * | 1993-04-19 | 1994-10-27 | Kauffman Stuart A | Random chemistry for the generation of new compounds |
WO1995011262A1 (en) * | 1993-10-22 | 1995-04-27 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and method for polymer synthesis using arrays |
Non-Patent Citations (2)
Title |
---|
M.MELDAL ET AL.: "Multiple Column Peptide Synthesis Part 2 (1,2)", INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, vol. 41, no. 3, COPENHAGEN, pages 250 - 260 * |
R.N.ZUCKERMANN ET AL.: "Design, Construction and Application of a Fully Automated Equimolar Peptide Mixture Synthesizer.", INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, vol. 40, no. 6, COPENHAGEN, pages 497 - 506 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998015532A1 (en) * | 1996-10-09 | 1998-04-16 | Novartis Ag | Solid phase synthesis of heterocyclic compounds |
EP1959255A3 (en) * | 1997-04-04 | 2008-09-24 | Caliper Life Sciences, Inc. | Closed-loop biochemical analyzers |
US7932213B2 (en) | 1999-05-11 | 2011-04-26 | President And Fellows Of Harvard College | Small molecule printing |
US8697362B2 (en) | 2002-12-20 | 2014-04-15 | Caliper Life Sciences, Inc. | Methods of detecting low copy nucleic acids |
US10428377B2 (en) | 2002-12-20 | 2019-10-01 | Caliper Life Sciences, Inc. | Methods of detecting low copy nucleic acids |
US8741942B2 (en) | 2003-08-29 | 2014-06-03 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis |
US8143300B2 (en) | 2003-08-29 | 2012-03-27 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis |
US7491743B2 (en) | 2003-08-29 | 2009-02-17 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis |
US9586880B2 (en) | 2008-12-23 | 2017-03-07 | President And Fellows Of Harvard College | Small molecule inhibitors of necroptosis |
US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
US9499521B2 (en) | 2014-12-11 | 2016-11-22 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis and related methods |
US9944628B2 (en) | 2014-12-11 | 2018-04-17 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis and related methods |
US10508102B2 (en) | 2014-12-11 | 2019-12-17 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis and related methods |
Also Published As
Publication number | Publication date |
---|---|
AU4424496A (en) | 1996-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5324483A (en) | Apparatus for multiple simultaneous synthesis | |
US5714127A (en) | System for multiple simultaneous synthesis | |
US5968736A (en) | Methods for recording the reaction history of a solid support | |
Jacobs et al. | Combinatorial chemistry—applications of light-directed chemical synthesis | |
US6001579A (en) | Supports and combinatorial chemical libraries thereof encoded by non-sequencable tags | |
US5864010A (en) | Peptide nucleic acid combinatorial libraries | |
US5770455A (en) | Methods and apparatus for synthesizing labeled combinatorial chemistrylibraries | |
AU686579B2 (en) | Complex combinatorial chemical libraries encoded with tags | |
US5976894A (en) | Combinatorial amide alcohol libraries | |
Backes et al. | Solid support linker strategies | |
Merritt | Solution phase combinatorial chemistry | |
US5891737A (en) | Combinatorial non-peptide libraries | |
US5702672A (en) | Apparatus and method for multiple simultaneous synthesis | |
Golebiowski et al. | Solid supported high-throughput organic synthesis of peptide β-turn mimetics via tandem Petasis reaction/diketopiperazine formation | |
US5567391A (en) | Apparatus for multiple simultaneous synthesis | |
AU2537397A (en) | Methods for spatially-dispersed positionally-encoded combinatorial library synthesis | |
Desai et al. | Recent advances in the generation of chemical diversity libraries | |
Sanchez-Martin et al. | The impact of combinatorial methodologies on medicinal chemistry | |
WO1996030393A1 (en) | A method for the synthesis of mixtures of compounds | |
Pandeya | Combinatorial chemistry: A novel method in drug discovery and its application | |
Bertels et al. | Synergistic use of combinatorial and natural product chemistry | |
Ambre et al. | Combinatorial Chemistry: Role in Lead Discovery | |
NANDAN et al. | PREMLATA K. AMBRE, ANISH N. GOMATAM | |
Kumar et al. | An overview on Combinatorial Chemistry | |
AU705844B2 (en) | Combinatorial 1,4-benzodiazepin-2, 5-dione library |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BG BY CA CN CZ EE FI GE HU JP KG KR KZ LT LV MD MX NO NZ PL RO RU SG SI SK TJ UA UZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |